Suchergebnisse

Publisher's version (útgefin grein). ; Quantifying the genetic correlation between cancers can provide important insights into the mechanisms driving cancer etiology. Using genome-wide association study summary statistics across six cancer types based on a total of 296,215 cases and 301,319 controls of European ancestry, here we estimate the pair-wise genetic correlations between breast, colorectal, head/neck, lung, ovary and prostate cancer, and between cancers and 38 other diseases. We observed statistically significant genetic correlations between lung and head/neck cancer (rg = 0.57, p = 4.6 × 10−8), breast and ovarian cancer (rg = 0.24, p = 7 × 10−5), breast and lung cancer (rg = 0.18, p =1.5 × 10−6) and breast and colorectal cancer (rg = 0.15, p = 1.1 × 10−4). We also found that multiple cancers are genetically correlated with non-cancer traits including smoking, psychiatric diseases and metabolic characteristics. Functional enrichment analysis revealed a significant excess contribution of conserved and regulatory regions to cancer heritability. Our comprehensive analysis of cross-cancer heritability suggests that solid tumors arising across tissues share in part a common germline genetic basis. ; The authors in this manuscript were working on behalf of BCAC, CCFR, CIMBA, CORECT, GECCO, OCAC, PRACTICAL, CRUK, BPC3, CAPS, PEGASUS, TRICL-ILCCO, ABCTB, APCB, BCFR, CONSIT TEAM, EMBRACE, GC-HBOC, GEMO, HEBON, kConFab/AOCS Mod SQuaD, and SWE-BRCA. The breast cancer genome-wide association analyses: BCAC is funded by Cancer Research UK [C1287/A16563, C1287/A10118], the European Union's Horizon 2020 Research and Innovation Programme (grant numbers 634935 and 633784 for BRIDGES and B-CAST, respectively), and by the European Community's Seventh Framework Programme under grant agreement number 223175 (grant number HEALTH-F2-2009-223175) (COGS). The EU Horizon 2020 Research and Innovation Programme funding source had no role in study design, data collection, data analysis, data interpretation, or writing of the report. Genotyping of the OncoArray was funded by the NIH Grant U19 CA148065, and Cancer UK Grant C1287/A16563 and the PERSPECTIVE project supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research (grant GPH-129344) and, the Ministère de l'Économie, Science et Innovation du Québec through Genome Québec and the PSR-SIIRI-701 grant, and the Quebec Breast Cancer Foundation. Funding for the iCOGS infrastructure came from: the European Community's Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978), and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065, and 1U19 CA148112—the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, and Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund. The DRIVE Consortium was funded by U19 CA148065. The Australian Breast Cancer Family Study (ABCFS) was supported by grant UM1 CA164920 from the National Cancer Institute (USA). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the USA Government or the BCFR. The ABCFS was also supported by the National Health and Medical Research Council of Australia, the New South Wales Cancer Council, the Victorian Health Promotion Foundation (Australia), and the Victorian Breast Cancer Research Consortium. J.L.H. is a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellow. M.C.S. is a NHMRC Senior Research Fellow. The ABCS study was supported by the Dutch Cancer Society [grants NKI 2007-3839; 2009 4363]. The Australian Breast Cancer Tissue Bank (ABCTB) is generously supported by the National Health and Medical Research Council of Australia, The Cancer Institute NSW and the National Breast Cancer Foundation. The ACP study is funded by the Breast Cancer Research Trust, UK. The AHS study is supported by the intramural research program of the National Institutes of Health, the National Cancer Institute (grant number Z01-CP010119), and the National Institute of Environmental Health Sciences (grant number Z01-ES049030). The work of the BBCC was partly funded by ELAN-Fond of the University Hospital of Erlangen. The BBCS is funded by Cancer Research UK and Breast Cancer Now and acknowledges NHS funding to the NIHR Biomedical Research Centre, and the National Cancer Research Network (NCRN). The BCEES was funded by the National Health and Medical Research Council, Australia and the Cancer Council Western Australia and acknowledges funding from the National Breast Cancer Foundation (JS). For the BCFR-NY, BCFR-PA, and BCFR-UT this work was supported by grant UM1 CA164920 from the National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the BCFR. For BIGGS, ES is supported by NIHR Comprehensive Biomedical Research Centre, Guy's & St. Thomas' NHS Foundation Trust in partnership with King's College London, United Kingdom. IT is supported by the Oxford Biomedical Research Centre. BOCS is supported by funds from Cancer Research UK (C8620/A8372/A15106) and the Institute of Cancer Research (UK). BOCS acknowledges NHS funding to the Royal Marsden/Institute of Cancer Research NIHR Specialist Cancer Biomedical Research Centre. The BREast Oncology GAlician Network (BREOGAN) is funded by Acción Estratégica de Salud del Instituto de Salud Carlos III FIS PI12/02125/Cofinanciado FEDER; Acción Estratégica de Salud del Instituto de Salud Carlos III FIS Intrasalud (PI13/01136); Programa Grupos Emergentes, Cancer Genetics Unit, Instituto de Investigacion Biomedica Galicia Sur. Xerencia de Xestion Integrada de Vigo-SERGAS, Instituto de Salud Carlos III, Spain; Grant 10CSA012E, Consellería de Industria Programa Sectorial de Investigación Aplicada, PEME I + D e I + D Suma del Plan Gallego de Investigación, Desarrollo e Innovación Tecnológica de la Consellería de Industria de la Xunta de Galicia, Spain; Grant EC11-192. Fomento de la Investigación Clínica Independiente, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain; and Grant FEDER-Innterconecta. Ministerio de Economia y Competitividad, Xunta de Galicia, Spain. The BSUCH study was supported by the Dietmar-Hopp Foundation, the Helmholtz Society and the German Cancer Research Center (DKFZ). The CAMA study was funded by Consejo Nacional de Ciencia y Tecnología (CONACyT) (SALUD-2002-C01-7462). Sample collection and processing was funded in part by grants from the National Cancer Institute (NCI R01CA120120 and K24CA169004). CBCS is funded by the Canadian Cancer Society (grant # 313404) and the Canadian Institutes of Health Research. CCGP is supported by funding from the University of Crete. The CECILE study was supported by Fondation de France, Institut National du Cancer (INCa), Ligue Nationale contre le Cancer, Agence Nationale de Sécurité Sanitaire, de l'Alimentation, de l'Environnement et du Travail (ANSES), Agence Nationale de la Recherche (ANR). The CGPS was supported by the Chief Physician Johan Boserup and Lise Boserup Fund, the Danish Medical Research Council, and Herlev and Gentofte Hospital. The CNIO-BCS was supported by the Instituto de Salud Carlos III, the Red Temática de Investigación Cooperativa en Cáncer and grants from the Asociación Española Contra el Cáncer and the Fondo de Investigación Sanitario (PI11/00923 and PI12/00070). COLBCCC is supported by the German Cancer Research Center (DKFZ), Heidelberg, Germany. D.T. was in part supported by a postdoctoral fellowship from the Alexander von Humboldt Foundation. The American Cancer Society funds the creation, maintenance, and updating of the CPS-II cohort. The CTS was initially supported by the California Breast Cancer Act of 1993 and the California Breast Cancer Research Fund (contract 97-10500) and is currently funded through the National Institutes of Health (R01 CA77398, UM1 CA164917, and U01 CA199277). Collection of cancer incidence data was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885. H.A.C eceives support from the Lon V Smith Foundation (LVS39420). The University of Westminster curates the DietCompLyf database funded by Against Breast Cancer Registered Charity No. 1121258 and the NCRN. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by: Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF) (Germany); the Hellenic Health Foundation, the Stavros Niarchos Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC (RD06/0020) (Spain); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom). The ESTHER study was supported by a grant from the Baden Württemberg Ministry of Science, Research and Arts. Additional cases were recruited in the context of the VERDI study, which was supported by a grant from the German Cancer Aid (Deutsche Krebshilfe). FHRISK is funded from NIHR grant PGfAR 0707-10031. The GC-HBOC (German Consortium of Hereditary Breast and Ovarian Cancer) is supported by the German Cancer Aid (grant no 110837, coordinator: Rita K. Schmutzler, Cologne). This work was also funded by the European Regional Development Fund and Free State of Saxony, Germany (LIFE - Leipzig Research Centre for Civilization Diseases, project numbers 713-241202, 713-241202, 14505/2470, and 14575/2470). The GENICA was funded by the Federal Ministry of Education and Research (BMBF) Germany grants 01KW9975/5, 01KW9976/8, 01KW9977/0, and 01KW0114, the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, the Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, as well as the Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany. The GEPARSIXTO study was conducted by the German Breast Group GmbH. The GESBC was supported by the Deutsche Krebshilfe e. V. [70492] and the German Cancer Research Center (DKFZ). GLACIER was supported by Breast Cancer Now, CRUK and Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London. The HABCS study was supported by the Claudia von Schilling Foundation for Breast Cancer Research, by the Lower Saxonian Cancer Society, and by the Rudolf-Bartling Foundation. The HEBCS was financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (266528), the Finnish Cancer Society, and the Sigrid Juselius Foundation. The HERPACC was supported by MEXT Kakenhi (No. 170150181 and 26253041) from the Ministry of Education, Science, Sports, Culture and Technology of Japan, by a Grant-in-Aid for the Third Term Comprehensive 10-Year Strategy for Cancer Control from Ministry Health, Labour and Welfare of Japan, by Health and Labour Sciences Research Grants for Research on Applying Health Technology from Ministry Health, Labour and Welfare of Japan, by National Cancer Center Research and Development Fund, and "Practical Research for Innovative Cancer Control (15ck0106177h0001)" from Japan Agency for Medical Research and development, AMED, and Cancer Bio Bank Aichi. The HMBCS was supported by a grant from the Friends of Hannover Medical School and by the Rudolf Bartling Foundation. The HUBCS was supported by a grant from the German Federal Ministry of Research and Education (RUS08/017), and by the Russian Foundation for Basic Research and the Federal Agency for Scientific Organizations for support the Bioresource collections and RFBR grants 14-04-97088, 17-29-06014, and 17-44-020498. ICICLE was supported by Breast Cancer Now, CRUK, and Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London. Financial support for KARBAC was provided through the regional agreement on medical training and clinical research (A.L.F.) between Stockholm County Council and Karolinska Institutet, the Swedish Cancer Society, The Gustav V Jubilee foundation and Bert von Kantzows foundation. The KARMA study was supported by Märit and Hans Rausings Initiative Against Breast Cancer. The KBCP was financially supported by the special Government Funding (E.V.O.) of Kuopio University Hospital grants, Cancer Fund of North Savo, the Finnish Cancer Organizations, and by the strategic funding of the University of Eastern Finland. kConFab is supported by a grant from the National Breast Cancer Foundation, and previously by the National Health and Medical Research Council (NHMRC), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. Financial support for the AOCS was provided by the United States Army Medical Research and Materiel Command [DAMD17-01-1-0729], Cancer Council Victoria, Queensland Cancer Fund, Cancer Council New South Wales, Cancer Council South Australia, The Cancer Foundation of Western Australia, Cancer Council Tasmania and the National Health and Medical Research Council of Australia (NHMRC; 400413, 400281, 199600). G.C.-T. and P.W. are supported by the NHMRC. RB was a Cancer Institute NSW Clinical Research Fellow. The KOHBRA study was partially supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), and the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (HI16C1127; 1020350; 1420190). LAABC is supported by grants (1RB-0287, 3PB-0102, 5PB-0018, 10PB-0098) from the California Breast Cancer Research Program. Incident breast cancer cases were collected by the USC Cancer Surveillance Program (CSP) which is supported under subcontract by the California Department of Health. The CSP is also part of the National Cancer Institute's Division of Cancer Prevention and Control Surveillance, Epidemiology, and End Results Program, under contract number N01CN25403. L.M.B.C. is supported by the 'Stichting tegen Kanker'. D.L. is supported by the FWO. The MABCS study is funded by the Research Centre for Genetic Engineering and Biotechnology "Georgi D. Efremov" and supported by the German Academic Exchange Program, DAAD. The MARIE study was supported by the Deutsche Krebshilfe e.V. [70-2892-BR I, 106332, 108253, 108419, 110826, 110828], the Hamburg Cancer Society, the German Cancer Research Center (DKFZ) and the Federal Ministry of Education and Research (BMBF) Germany [01KH0402]. MBCSG is supported by grants from the Italian Association for Cancer Research (AIRC) and by funds from the Italian citizens who allocated the 5/1000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects "5 × 1000"). The MCBCS was supported by the NIH grants CA192393, CA116167, CA176785 an NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer [CA116201], and the Breast Cancer Research Foundation and a generous gift from the David F. and Margaret T. Grohne Family Foundation. MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants 209057 and 396414, and by infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry (VCR) and the Australian Institute of Health and Welfare (AIHW), including the National Death Index and the Australian Cancer Database. The MEC was support by NIH grants CA63464, CA54281, CA098758, CA132839, and CA164973. The MISS study is supported by funding from ERC-2011-294576 Advanced grant, Swedish Cancer Society, Swedish Research Council, Local hospital funds, Berta Kamprad Foundation, Gunnar Nilsson. The MMHS study was supported by NIH grants CA97396, CA128931, CA116201, CA140286, and CA177150. MSKCC is supported by grants from the Breast Cancer Research Foundation and Robert and Kate Niehaus Clinical Cancer Genetics Initiative. The work of MTLGEBCS was supported by the Quebec Breast Cancer Foundation, the Canadian Institutes of Health Research for the "CIHR Team in Familial Risks of Breast Cancer" program – grant # CRN-87521 and the Ministry of Economic Development, Innovation and Export Trade – grant # PSR-SIIRI-701. MYBRCA is funded by research grants from the Malaysian Ministry of Higher Education (UM.C/HlR/MOHE/06) and Cancer Research Malaysia. MYMAMMO is supported by research grants from Yayasan Sime Darby LPGA Tournament and Malaysian Ministry of Higher Education (RP046B-15HTM). The NBCS has been supported by the Research Council of Norway grant 193387/V50 (to A.-L. Børresen-Dale and V.N. Kristensen) and grant 193387/H10 (to A.-L. Børresen-Dale and V.N. Kristensen), South Eastern Norway Health Authority (grant 39346 to A.-L. Børresen-Dale and 27208 to V.N. Kristensen) and the Norwegian Cancer Society (to A.-L. Børresen-Dale and 419616 - 71248 - PR-2006-0282 to V.N. Kristensen). It has received funding from the K.G. Jebsen Centre for Breast Cancer Research (2012-2015). The NBHS was supported by NIH grant R01CA100374. Biological sample preparation was conducted the Survey and Biospecimen Shared Resource, which is supported by P30 CA68485. The Northern California Breast Cancer Family Registry (NC-BCFR) and Ontario Familial Breast Cancer Registry (OFBCR) were supported by grant UM1 CA164920 from the National Cancer Institute (USA). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the USA Government or the BCFR. The Carolina Breast Cancer Study was funded by Komen Foundation, the National Cancer Institute (P50 CA058223, U54 CA156733, and U01 CA179715), and the North Carolina University Cancer Research Fund. The NGOBCS was supported by Grants-in-Aid for the Third Term Comprehensive Ten-Year Strategy for Cancer Control from the Ministry of Health, Labor and Welfare of Japan, and for Scientific Research on Priority Areas, 17015049 and for Scientific Research on Innovative Areas, 221S0001, from the Ministry of Education, Culture, Sports, Science, and Technology of Japan. The NHS was supported by NIH grants P01 CA87969, UM1 CA186107, and U19 CA148065. The NHS2 was supported by NIH grants UM1 CA176726 and U19 CA148065. The OBCS was supported by research grants from the Finnish Cancer Foundation, the Academy of Finland (grant number 250083, 122715 and Center of Excellence grant number 251314), the Finnish Cancer Foundation, the Sigrid Juselius Foundation, the University of Oulu, the University of Oulu Support Foundation, and the special Governmental EVO funds for Oulu University Hospital-based research activities. The ORIGO study was supported by the Dutch Cancer Society (RUL 1997-1505) and the Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-NL CP16). The PBCS was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. Genotyping for PLCO was supported by the Intramural Research Program of the National Institutes of Health, NCI, Division of Cancer Epidemiology and Genetics. The PLCO is supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics and supported by contracts from the Division of Cancer Prevention, National Cancer Institute, National Institutes of Health. The POSH study is funded by Cancer Research UK (grants C1275/A11699, C1275/C22524, C1275/A19187, C1275/A15956, and Breast Cancer Campaign 2010PR62, 2013PR044. PROCAS is funded from NIHR grant PGfAR 0707-10031. The RBCS was funded by the Dutch Cancer Society (DDHK 2004-3124, DDHK 2009-4318). The SASBAC study was supported by funding from the Agency for Science, Technology and Research of Singapore (A*STAR), the US National Institute of Health (NIH) and the Susan G. Komen Breast Cancer Foundation. The SBCGS was supported primarily by NIH grants R01CA64277, R01CA148667, UMCA182910, and R37CA70867. Biological sample preparation was conducted the Survey and Biospecimen Shared Resource, which is supported by P30 CA68485. The scientific development and funding of this project were, in part, supported by the Genetic Associations and Mechanisms in Oncology (GAME-ON) Network U19 CA148065. The SBCS was supported by Sheffield Experimental Cancer Medicine Centre and Breast Cancer Now Tissue Bank. The SCCS is supported by a grant from the National Institutes of Health (R01 CA092447). Data on SCCS cancer cases used in this publication were provided by the Alabama Statewide Cancer Registry; Kentucky Cancer Registry, Lexington, KY; Tennessee Department of Health, Office of Cancer Surveillance; Florida Cancer Data System; North Carolina Central Cancer Registry, North Carolina Division of Public Health; Georgia Comprehensive Cancer Registry; Louisiana Tumor Registry; Mississippi Cancer Registry; South Carolina Central Cancer Registry; Virginia Department of Health, Virginia Cancer Registry; Arkansas Department of Health, Cancer Registry, 4815 W. Markham, Little Rock, AR 72205. The Arkansas Central Cancer Registry is fully funded by a grant from National Program of Cancer Registries, Centers for Disease Control and Prevention (CDC). Data on SCCS cancer cases from Mississippi were collected by the Mississippi Cancer Registry which participates in the National Program of Cancer Registries (NPCR) of the Centers for Disease Control and Prevention (CDC). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the CDC or the Mississippi Cancer Registry. SEARCH is funded by Cancer Research UK [C490/A10124, C490/A16561] and supported by the UK National Institute for Health Research Biomedical Research Centre at the University of Cambridge. The University of Cambridge has received salary support for PDPP from the NHS in the East of England through the Clinical Academic Reserve. SEBCS was supported by the BRL (Basic Research Laboratory) program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (2012-0000347). SGBCC is funded by the NUS start-up Grant, National University Cancer Institute Singapore (NCIS) Centre Grant and the NMRC Clinician Scientist Award. Additional controls were recruited by the Singapore Consortium of Cohort Studies-Multi-ethnic cohort (SCCS-MEC), which was funded by the Biomedical Research Council, grant number: 05/1/21/19/425. The Sister Study (SISTER) is supported by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences (Z01-ES044005 and Z01-ES049033). The Two Sister Study (2SISTER) was supported by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences (Z01-ES044005 and Z01-ES102245), and, also by a grant from Susan G. Komen for the Cure, grant FAS0703856. SKKDKFZS is supported by the DKFZ. The SMC is funded by the Swedish Cancer Foundation. The SZBCS was supported by Grant PBZ_KBN_122/P05/2004. The TBCS was funded by The National Cancer Institute, Thailand. The TNBCC was supported by a Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), a grant from the Breast Cancer Research Foundation, a generous gift from the David F. and Margaret T. Grohne Family Foundation. The TWBCS is supported by the Taiwan Biobank project of the Institute of Biomedical Sciences, Academia Sinica, Taiwan. The UCIBCS component of this research was supported by the NIH [CA58860, CA92044] and the Lon V Smith Foundation [LVS39420]. The UKBGS is funded by Breast Cancer Now and the Institute of Cancer Research (ICR), London. ICR acknowledges NHS funding to the NIHR Biomedical Research Centre. The UKOPS study was funded by The Eve Appeal (The Oak Foundation) and supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. The US3SS study was supported by Massachusetts (K.M.E., R01CA47305), Wisconsin (P.A.N., R01 CA47147) and New Hampshire (L.T.-E., R01CA69664) centers, and Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. The USRT Study was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. The WAABCS study was supported by grants from the National Cancer Institute of the National Institutes of Health (R01 CA89085 and P50 CA125183 and the D43 TW009112 grant), Susan G. Komen (SAC110026), the Dr. Ralph and Marian Falk Medical Research Trust, and the Avon Foundation for Women. The WHI program is funded by the National Heart, Lung, and Blood Institute, the US National Institutes of Health and the US Department of Health and Human Services (HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C). This work was also funded by NCI U19 CA148065-01. D.G.E. is supported by the all Manchester NIHR Biomedical research center Manchester (IS-BRC-1215-20007). HUNBOCS, Hungarian Breast and Ovarian Cancer Study was supported by Hungarian Research Grant KTIA-OTKA CK-80745, NKFI_OTKA K-112228. C.I. received support from the Nontherapeutic Subject Registry Shared Resource at Georgetown University (NIH/NCI P30-CA-51008) and the Jess and Mildred Fisher Center for Hereditary Cancer and Clinical Genomics Research. K.M. is supported by CRUK C18281/A19169. City of Hope Clinical Cancer Community Research Network and the Hereditary Cancer Research Registry, supported in part by Award Number RC4CA153828 (PI: J Weitzel) from the National Cancer Institute and the office of the Directory, National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The colorectal cancer genome-wide association analyses: Colorectal Transdisciplinary Study (CORECT): The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the CORECT Consortium, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government or the CORECT Consortium. We are incredibly grateful for the contributions of Dr. Brian Henderson and Dr. Roger Green over the course of this study and acknowledge them in memoriam. We are also grateful for support from Daniel and Maryann Fong. ColoCare: we thank the many investigators and staff who made this research possible in ColoCare Seattle and ColoCare Heidelberg. ColoCare was initiated and developed at the Fred Hutchinson Cancer Research Center by Drs. Ulrich and Grady. CCFR: the Colon CFR graciously thanks the generous contributions of their study participants, dedication of study staff, and financial support from the U.S. National Cancer Institute, without which this important registry would not exist. Galeon: GALEON wishes to thank the Department of Surgery of University Hospital of Santiago (CHUS), Sara Miranda Ponte, Carmen M Redondo, and the staff of the Department of Pathology and Biobank of CHUS, Instituto de Investigación Sanitaria de Santiago (IDIS), Instituto de Investigación Sanitaria Galicia Sur (IISGS), SERGAS, Vigo, Spain, and Programa Grupos Emergentes, Cancer Genetics Unit, CHUVI Vigo Hospital, Instituto de Salud Carlos III, Spain. MCCS: this study was made possible by the contribution of many people, including the original investigators and the diligent team who recruited participants and continue to work on follow-up. We would also like to express our gratitude to the many thousands of Melbourne residents who took part in the study and provided blood samples. SEARCH: We acknowledge the contributions of Mitul Shah, Val Rhenius, Sue Irvine, Craig Luccarini, Patricia Harrington, Don Conroy, Rebecca Mayes, and Caroline Baynes. The Swedish low-risk colorectal cancer study: we thank Berith Wejderot and the Swedish low-risk colorectal cancer study group. Genetics & Epidemiology of Colorectal Cancer Consortium (GECCO): we thank all those at the GECCO Coordinating Center for helping bring together the data and people that made this project possible. ASTERISK: we are very grateful to Dr. Bruno Buecher without whom this project would not have existed. We also thank all those who agreed to participate in this study, including the patients and the healthy control persons, as well as all the physicians, technicians and students. DACHS: we thank all participants and cooperating clinicians, and Ute Handte-Daub, Renate Hettler-Jensen, Utz Benscheid, Muhabbet Celik, and Ursula Eilber for excellent technical assistance. HPFS, NHS and PHS: we acknowledge Patrice Soule and Hardeep Ranu of the Dana-Farber Harvard Cancer Center High-Throughput Polymorphism Core who assisted in the genotyping for NHS, HPFS, and PHS under the supervision of Dr. Immaculata Devivo and Dr. David Hunter, Qin (Carolyn) Guo, and Lixue Zhu who assisted in programming for NHS and HPFS and Haiyan Zhang who assisted in programming for the PHS. We thank the participants and staff of the Nurses' Health Study and the Health Professionals Follow-Up Study, for their valuable contributions as well as the following state cancer registries for their help: A.L., A.Z., A.R., C.A., C.O., C.T., D.E., F.L., G.A., I.D., I.L., I.N., I.A., K.Y., L.A., M.E., M.D., M.A., M.I., N.E., N.H., N.J., N.Y., N.C., N.D., O.H., O.K., O.R., P.A., R.I., S.C., T.N., T.X., V.A., W.A., W.Y. In addition, this study was approved by the Connecticut Department of Public Health (DPH) Human Investigations Committee. Certain data used in this publication were obtained from the DPH. We assume full responsibility for analyses and interpretation of these data. PLCO: we thank Drs. Christine Berg and Philip Prorok, Division of Cancer Prevention, National Cancer Institute, the Screening Center investigators and staff or the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, Mr. Tom Riley and staff, Information Management Services Inc., Ms. Barbara O'Brien and staff, Westat Inc. and Drs. Bill Kopp, Wen Shao and staff, SAIC-Frederick. Most importantly, we acknowledge the study participants for their contributions for making this study possible. The statements contained herein are solely those of the authors and do not represent or imply concurrence or endorsement by NCI. PMH: we thank the study participants and staff of the Hormones and Colon Cancer study. WHI: we thank the WHI investigators and staff for their dedication, and the study participants for making the program possible. A full listing of WHI investigators can be found at https://cleo.whi.org/researchers/Documents%20%20Write%20a%20Paper/WHI%20Investigator%20Short20List.pdf. CORECT: The CORECT Study was supported by the National Cancer Institute, National Institutes of Health (NCI/NIH), U.S. Department of Health and Human Services (grant numbers U19 CA148107, R01 CA81488, P30 CA014089, R01 CA197350; P01 CA196569; and R01 CA201407) and National Institutes of Environmental Health Sciences, National Institutes of Health (grant number T32 ES013678). The ATBC Study was supported by the US Public Health Service contracts (N01-CN-45165, N01-RC-45035, N01-RC-37004, and HHSN261201000006C) from the National Cancer Institute. The Cancer Prevention Study-II Nutrition Cohort is funded by the American Cancer Society. ColoCare: This work was supported by the National Institutes of Health (grant numbers R01 CA189184, U01 CA206110, 2P30CA015704-40 (Gilliland)), the Matthias Lackas-Foundation, the German Consortium for Translational Cancer Research, and the EU TRANSCAN initiative. Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO): funding for GECCO was provided by the National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services (grant numbers U01 CA137088, R01 CA059045, and U01 CA164930). This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA015704. The Colon Cancer Family Registry (CFR) Illumina GWAS was supported by funding from the National Cancer Institute, National Institutes of Health (grant numbers U01 CA122839, R01 CA143247). The Colon CFR/CORECT Affymetrix Axiom GWAS and OncoArray GWAS were supported by funding from National Cancer Institute, National Institutes of Health (grant number U19 CA148107 to S.G.). The Colon CFR participant recruitment and collection of data and biospecimens used in this study were supported by the National Cancer Institute, National Institutes of Health (grant number UM1 CA167551) and through cooperative agreements with the following Colon CFR centers: Australasian Colorectal Cancer Family Registry (NCI/NIH grant numbers U01 CA074778 and U01/U24 CA097735), USC Consortium Colorectal Cancer Family Registry (NCI/NIH grant numbers U01/U24 CA074799), Mayo Clinic Cooperative Family Registry for Colon Cancer Studies (NCI/NIH grant number U01/U24 CA074800), Ontario Familial Colorectal Cancer Registry (NCI/NIH grant number U01/U24 CA074783), Seattle Colorectal Cancer Family Registry (NCI/NIH grant number U01/U24 CA074794), and University of Hawaii Colorectal Cancer Family Registry (NCI/NIH grant number U01/U24 CA074806), Additional support for case ascertainment was provided from the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute to Fred Hutchinson Cancer Research Center (Control Nos. N01-CN-67009 and N01-PC-35142, and Contract No. HHSN2612013000121), the Hawai'i Department of Health (Control Nos. N01-PC-67001 and N01-PC-35137, and Contract No. HHSN26120100037C, and the California Department of Public Health (contracts HHSN261201000035C awarded to the University of Southern California, and the following state cancer registries: A.Z., C.O., M.N., N.C., N.H., and by the Victoria Cancer Registry and Ontario Cancer Registry. ESTHER/VERDI was supported by grants from the Baden–Württemberg Ministry of Science, Research and Arts and the German Cancer Aid. MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. GALEON: FIS Intrasalud (PI13/01136). The MCCS was further supported by Australian NHMRC grants 509348, 209057, 251553, and 504711 and by infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry (VCR) and the Australian Institute of Health and Welfare (AIHW), including the National Death Index and the Australian Cancer Database. MSKCC: the work at Sloan Kettering in New York was supported by the Robert and Kate Niehaus Center for Inherited Cancer Genomics and the Romeo Milio Foundation. Moffitt: This work was supported by funding from the National Institutes of Health (grant numbers R01 CA189184, P30 CA076292), Florida Department of Health Bankhead-Coley Grant 09BN-13, and the University of South Florida Oehler Foundation. Moffitt contributions were supported in part by the Total Cancer Care Initiative, Collaborative Data Services Core, and Tissue Core at the H. Lee Moffitt Cancer Center & Research Institute, a National Cancer Institute-designated Comprehensive Cancer Center (grant number P30 CA076292). SEARCH: Cancer Research UK (C490/A16561). The Spanish study was supported by Instituto de Salud Carlos III, co-funded by FEDER funds –a way to build Europe– (grants PI14-613 and PI09-1286), Catalan Government DURSI (grant 2014SGR647), and Junta de Castilla y León (grant LE22A10-2). The Swedish Low-risk Colorectal Cancer Study: the study was supported by grants from the Swedish research council; K2015-55 × -22674-01-4, K2008-55 × -20157-03-3, K2006-72 × -20157-01-2 and the Stockholm County Council (ALF project). CIDR genotyping for the Oncoarray was conducted under contract 268201200008I (to K.D.), through grant 101HG007491-01 (to C.I.A.). The Norris Cotton Cancer Center - P30CA023108, The Quantitative Biology Research Institute - P20GM103534, and the Coordinating Center for Screen Detected Lesions - U01CA196386 also supported efforts of C.I.A. This work was also supported by the National Cancer Institute (grant numbers U01 CA1817700, R01 CA144040). ASTERISK: a Hospital Clinical Research Program (PHRC) and supported by the Regional Council of Pays de la Loire, the Groupement des Entreprises Françaises dans la Lutte contre le Cancer (GEFLUC), the Association Anne de Bretagne Génétique and the Ligue Régionale Contre le Cancer (LRCC). COLO2&3: National Institutes of Health (grant number R01 CA060987). DACHS: This work was supported by the German Research Council (BR 1704/6-1, BR 1704/6-3, BR 1704/6-4, CH 117/1-1, HO 5117/2-1, HE 5998/2-1, KL 2354/3-1, RO 2270/8-1, and BR 1704/17-1), the Interdisciplinary Research Program of the National Center for Tumor Diseases (NCT), Germany, and the German Federal Ministry of Education and Research (01KH0404, 01ER0814, 01ER0815, 01ER1505A, and 01ER1505B). DALS: National Institutes of Health (grant number R01 CA048998 to M.L.S). HPFS is supported by National Institutes of Health (grant numbers P01 CA055075, UM1 CA167552, R01 137178, and P50 CA127003), NHS by the National Institutes of Health (grant numbers UM1 CA186107, R01 CA137178, P01 CA087969, and P50 CA127003), NHSII by the National Institutes of Health (grant numbers R01 050385CA and UM1 CA176726), and PHS by the National Institutes of Health (grant number R01 CA042182). MEC: National Institutes of Health (grant numbers R37 CA054281, P01 CA033619, and R01 CA063464). OFCCR: National Institutes of Health, through funding allocated to the Ontario Registry for Studies of Familial Colorectal Cancer (grant number U01 CA074783); see Colon CFR section above. As subset of ARCTIC, OFCCR is supported by a GL2 grant from the Ontario Research Fund, the Canadian Institutes of Health Research, and the Cancer Risk Evaluation (CaRE) Program grant from the Canadian Cancer Society Research Institute. T.J.H. and B.W.Z. are recipients of Senior Investigator Awards from the Ontario Institute for Cancer Research, through generous support from the Ontario Ministry of Research and Innovation. PLCO: Intramural Research Program of the Division of Cancer Epidemiology and Genetics and supported by contracts from the Division of Cancer Prevention, National Cancer Institute, NIH, DHHS. Additionally, a subset of control samples was genotyped as part of the Cancer Genetic Markers of Susceptibility (CGEMS) Prostate Cancer GWAS, Colon CGEMS pancreatic cancer scan (PanScan), and the Lung Cancer and Smoking study. The prostate and PanScan study datasets were accessed with appropriate approval through the dbGaP online resource (http://cgems.cancer.gov/data/) accession numbers phs000207.v1.p1 and phs000206.v3.p2, respectively, and the lung datasets were accessed from the dbGaP website (http://www.ncbi.nlm.nih.gov/gap) through accession number phs000093.v2.p2. Funding for the Lung Cancer and Smoking study was provided by National Institutes of Health (NIH), Genes, Environment and Health Initiative (GEI) Z01 CP 010200, NIH U01 HG004446, and NIH GEI U01 HG 004438. For the lung study, the GENEVA Coordinating Center provided assistance with genotype cleaning and general study coordination, 23 and the Johns Hopkins University Center for Inherited Disease Research conducted genotyping. PMH: National Institutes of Health (grant number R01 CA076366). VITAL: National Institutes of Health (grant number K05-CA154337). WHI: The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C. The head and neck cancer genome-wide association analyses: The study was supported by NIH/NCI: P50 CA097190, and P30 CA047904, Canadian Cancer Society Research Institute (no. 020214) and Cancer Care Ontario Research Chair to R.H. The Princess Margaret Hospital Head and Neck Cancer Translational Research Program is funded by the Wharton family, Joe's Team, Gordon Tozer, Bruce Galloway and the Elia family. Geoffrey Liu was supported by the Posluns Family Fund and the Lusi Wong Family Fund at the Princess Margaret Foundation, and the Alan B. Brown Chair in Molecular Genomics. This publication presents data from Head and Neck 5000 (H&N5000). H&N5000 was a component of independent research funded by the UK National Institute for Health Research (NIHR) under its Programme Grants for Applied Research scheme (RP-PG-0707-10034). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Human papillomavirus (HPV) in H&N5000 serology was supported by a Cancer Research UK Programme Grant, the Integrative Cancer Epidemiology Programme (grant number: C18281/A19169). National Cancer Institute (R01-CA90731); National Institute of Environmental Health Sciences (P30ES10126). The authors thank all the members of the GENCAPO team/The Head and Neck Genome Project (GENCAPO) was supported by the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) (Grant numbers 04/12054-9 and 10/51168-0). CPS-II recruitment and maintenance is supported with intramural research funding from the American Cancer Society. Genotyping performed at the Center for Inherited Disease Research (CIDR) was funded through the U.S. National Institute of Dental and Craniofacial Research (NIDCR) grant 1 × 01HG007780-0. The University of Pittsburgh head and neck cancer case-control study is supported by National Institutes of Health grants P50 CA097190 and P30 CA047904. The Carolina Head and Neck Cancer Study (CHANCE) was supported by the National Cancer Institute (R01-CA90731). The Head and Neck Genome Project (GENCAPO) was supported by the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) (Grant numbers 04/12054-9 and 10/51168-0). The authors thank all the members of the GENCAPO team. The HN5000 study was funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research scheme (RP-PG-0707-10034), the views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The Toronto study was funded by the Canadian Cancer Society Research Institute (020214) and the National Cancer Institute (U19-CA148127) and the Cancer Care Ontario Research Chair. The alcohol-related cancers and genetic susceptibility study in Europe (ARCAGE) was funded by the European Commission's 5th Framework Program (QLK1-2001-00182), the Italian Association for Cancer Research, Compagnia di San Paolo/FIRMS, Region Piemonte, and Padova University (CPDA057222). The Rome Study was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC) IG 2011 10491 and IG2013 14220 to S.B., and Fondazione Veronesi to S.B. The IARC Latin American study was funded by the European Commission INCO-DC programme (IC18-CT97-0222), with additional funding from Fondo para la Investigacion Cientifica y Tecnologica (Argentina) and the Fundação de Amparo à Pesquisa do Estado de São Paulo (01/01768-2). We thank Leticia Fernandez, Instituto Nacional de Oncologia y Radiobiologia, La Habana, Cuba and Sergio and Rosalina Koifman, for their efforts with the IARC Latin America study São Paulo center. The IARC Central Europe study was supported by European Commission's INCO-COPERNICUS Program (IC15- CT98-0332), NIH/National Cancer Institute grant CA92039, and the World Cancer Research Foundation grant WCRF 99A28. The IARC Oral Cancer Multicenter study was funded by grant S06 96 202489 05F02 from Europe against Cancer; grants FIS 97/0024, FIS 97/0662, and BAE 01/5013 from Fondo de Investigaciones Sanitarias, Spain; the UICC Yamagiwa-Yoshida Memorial International Cancer Study; the National Cancer Institute of Canada; Associazione Italiana per la Ricerca sul Cancro; and the Pan-American Health Organization. Coordination of the EPIC study is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The lung cancer genome-wide association analyses: Transdisciplinary Research for Cancer in Lung (TRICL) of the International Lung Cancer Consortium (ILCCO) was supported by (U19-CA148127, CA148127S1, U19CA203654, and Cancer Prevention Research Institute of Texas RR170048). The ILCCO data harmonization is supported by Cancer Care Ontario Research Chair of Population Studies to R. H. and Lunenfeld-Tanenbaum Research Institute, Sinai Health System. The TRICL-ILCCO OncoArray was supported by in-kind genotyping by the Centre for Inherited Disease Research (26820120008i-0-26800068-1). The CAPUA study was supported by FIS-FEDER/Spain grant numbers FIS-01/310, FIS-PI03-0365, and FIS-07-BI060604, FICYT/Asturias grant numbers FICYT PB02-67 and FICYT IB09-133, and the University Institute of Oncology (IUOPA), of the University of Oviedo and the Ciber de Epidemiologia y Salud Pública. CIBERESP, SPAIN. The work performed in the CARET study was supported by the National Institute of Health/National Cancer Institute: UM1 CA167462 (PI: Goodman), National Institute of Health UO1-CA6367307 (PIs Omen, Goodman); National Institute of Health R01 CA111703 (PI Chen), National Institute of Health 5R01 CA151989-01A1(PI Doherty). The Liverpool Lung project is supported by the Roy Castle Lung Cancer Foundation. The Harvard Lung Cancer Study was supported by the NIH (National Cancer Institute) grants CA092824, CA090578, CA074386. The Multi-ethnic Cohort Study was partially supported by NIH Grants CA164973, CA033619, CA63464, and CA148127. The work performed in MSH-PMH study was supported by The Canadian Cancer Society Research Institute (020214), Ontario Institute of Cancer and Cancer Care Ontario Chair Award to R.J.H. and G.L. and the Alan Brown Chair and Lusi Wong Programs at the Princess Margaret Hospital Foundation. NJLCS was funded by the State Key Program of National Natural Science of China (81230067), the National Key Basic Research Program Grant (2011CB503805), the Major Program of the National Natural Science Foundation of China (81390543). The Norway study was supported by Norwegian Cancer Society, Norwegian Research Council. The Shanghai Cohort Study (SCS) was supported by National Institutes of Health R01 CA144034 (PI: Yuan) and UM1 CA182876 (PI: Yuan). The Singapore Chinese Health Study (SCHS) was supported by National Institutes of Health R01 CA144034 (PI: Yuan) and UM1 CA182876 (PI: Yuan). The work in TLC study has been supported in part the James & Esther King Biomedical Research Program (09KN-15), National Institutes of Health Specialized Programs of Research Excellence (SPORE) Grant (P50 CA119997), and by a Cancer Center Support Grant (CCSG) at the H. Lee Moffitt Cancer Center and Research Institute, an NCI designated Comprehensive Cancer Center (grant number P30-CA76292). The Vanderbilt Lung Cancer Study—BioVU dataset used for the analyses described was obtained from Vanderbilt University Medical Center's BioVU, which is supported by institutional funding, the 1S10RR025141-01 instrumentation award, and by the Vanderbilt CTSA grant UL1TR000445 from NCATS/NIH. Dr. Aldrich was supported by NIH/National Cancer Institute K07CA172294 (PI: Aldrich) and Dr. Bush was supported by NHGRI/NIH U01HG004798 (PI: Crawford). The Copenhagen General Population Study (CGPS) was supported by the Chief Physician Johan Boserup and Lise Boserup Fund, the Danish Medical Research Council and Herlev Hospital. The NELCS study: Grant Number P20RR018787 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH). The Kentucky Lung Cancer Research Initiative was supported by the Department of Defense [Congressionally Directed Medical Research Program, U.S. Army Medical Research and Materiel Command Program] under award number: 10153006 (W81XWH-11-1-0781). Views and opinions of, and endorsements by the author(s) do not reflect those of the US Army or the Department of Defense. This research was also supported by unrestricted infrastructure funds from the UK Center for Clinical and Translational Science, NIH grant UL1TR000117 and Markey Cancer Center NCI Cancer Center Support Grant (P30 CA177558) Shared Resource Facilities: Cancer Research Informatics, Biospecimen and Tissue Procurement, and Biostatistics and Bioinformatics. The M.D. Anderson Cancer Center study was supported in part by grants from the NIH (P50 CA070907, R01 CA176568) (to X.W.), Cancer Prevention & Research Institute of Texas (RP130502) (to X.W.), and The University of Texas MD Anderson Cancer Center institutional support for the Center for Translational and Public Health Genomics. The deCODE study of smoking and nicotine dependence was funded in part by a grant from NIDA (R01- DA017932). The study in Lodz center was partially funded by Nofer Institute of Occupational Medicine, under task NIOM 10.13: Predictors of mortality from non-small cell lung cancer—field study. Genetic sharing analysis was funded by NIH grant CA194393. The research undertaken by M.D.T., L.V.W., and M.S.A. was partly funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. M.D.T. holds a Medical Research Council Senior Clinical Fellowship (G0902313). The work to assemble the FTND GWAS meta-analysis was supported by the National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) grant number R01 DA035825 (Principal Investigator [PI]: DBH). The study populations included COGEND (dbGaP phs000092.v1.p1 and phs000404.v1.p1), COPDGene (dbGaP phs000179.v3.p2), deCODE Genetics, EAGLE (dbGaP phs000093.vs.p2), and SAGE. dbGaP phs000092.v1.p1). See Hancock et al. Transl Psychiatry 2015 (PMCID: PMC4930126) for the full listing of funding sources and other acknowledgments. The Resource for the Study of Lung Cancer Epidemiology in North Trent (ReSoLuCENT)study was funded by the Sheffield Hospitals Charity, Sheffield Experimental Cancer Medicine Centre and Weston Park Hospital Cancer Charity. The ovarian cancer genome-wide association analysis: The Ovarian Cancer Association Consortium (OCAC) is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07). The scientific development and funding for this project were in part supported by the US National Cancer Institute GAME-ON Post-GWAS Initiative (U19-CA148112). This study made use of data generated by the Wellcome Trust Case Control consortium that was funded by the Wellcome Trust under award 076113. The results published here are in part based upon data generated by The Cancer Genome Atlas Pilot Project established by the National Cancer Institute and National Human Genome Research Institute (dbGap accession number phs000178.v8.p7). The OCAC OncoArray genotyping project was funded through grants from the U.S. National Institutes of Health (CA1X01HG007491-01 (C.I.A.), U19-CA148112 (T.A.S.), R01-CA149429 (C.M.P.), and R01-CA058598 (M.T.G.); Canadian Institutes of Health Research (MOP-86727 (L.E.K.) and the Ovarian Cancer Research Fund (A.B.). The COGS project was funded through a European Commission's Seventh Framework Programme grant (agreement number 223175 - HEALTH-F2-2009-223175) and through a grant from the U.S. National Institutes of Health (R01-CA122443 (E.L.G)). Funding for individual studies: AAS: National Institutes of Health (RO1-CA142081); AOV: The Canadian Institutes for Health Research (MOP-86727); AUS: The Australian Ovarian Cancer Study Group was supported by the U.S. Army Medical Research and Materiel Command (DAMD17-01-1-0729), National Health & Medical Research Council of Australia (199600, 400413 and 400281), Cancer Councils of New South Wales, Victoria, Queensland, South Australia and Tasmania and Cancer Foundation of Western Australia (Multi-State Applications 191, 211, and 182). The Australian Ovarian Cancer Study gratefully acknowledges additional support from Ovarian Cancer Australia and the Peter MacCallum Foundation; BAV: ELAN Funds of the University of Erlangen-Nuremberg; BEL: National Kankerplan; BGS: Breast Cancer Now, Institute of Cancer Research; BVU: Vanderbilt CTSA grant from the National Institutes of Health (NIH)/National Center for Advancing Translational Sciences (NCATS) (ULTR000445); CAM: National Institutes of Health Research Cambridge Biomedical Research Centre and Cancer Research UK Cambridge Cancer Centre; CHA: Innovative Research Team in University (PCSIRT) in China (IRT1076); CNI: Instituto de Salud Carlos III (PI12/01319); Ministerio de Economía y Competitividad (SAF2012); COE: Department of Defense (W81XWH-11-2-0131); CON: National Institutes of Health (R01-CA063678, R01-CA074850; and R01-CA080742); DKE: Ovarian Cancer Research Fund; DOV: National Institutes of Health R01-CA112523 and R01-CA87538; EMC: Dutch Cancer Society (EMC 2014-6699); EPC: The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF) (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health (Norway); Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC (RD06/0020) (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom); GER: German Federal Ministry of Education and Research, Programme of Clinical Biomedical Research (01 GB 9401) and the German Cancer Research Center (DKFZ); GRC: This research has been co-financed by the European Union (European Social Fund—ESF) and Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF)—Research Funding Program of the General Secretariat for Research & Technology: SYN11_10_19 NBCA. Investing in knowledge society through the European Social Fund; GRR: Roswell Park Cancer Institute Alliance Foundation, P30 CA016056; HAW: U.S. National Institutes of Health (R01-CA58598, N01-CN-55424, and N01-PC-67001); HJO: Intramural funding; Rudolf-Bartling Foundation; HMO: Intramural funding; Rudolf-Bartling Foundation; HOC: Helsinki University Research Fund; HOP: Department of Defense (DAMD17-02-1-0669) and NCI (K07-CA080668, R01-CA95023, P50-CA159981 MO1-RR000056 R01-CA126841); HUO: Intramural funding; Rudolf-Bartling Foundation; JGO: JSPS KAKENHI grant; JPN: Grant-in-Aid for the Third Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare; KRA: This study (Ko-EVE) was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), and the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (HI16C1127; 0920010); LAX: American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN) and the National Center for Advancing Translational Sciences (NCATS), Grant UL1TR000124; LUN: ERC-2011-AdG 294576-risk factors cancer, Swedish Cancer Society, Swedish Research Council, Beta Kamprad Foundation; MAC: National Institutes of Health (R01-CA122443, P30-CA15083, P50-CA136393); Mayo Foundation; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation; Fraternal Order of Eagles; MAL: Funding for this study was provided by research grant R01- CA61107 from the National Cancer Institute, Bethesda, MD, research grant 94 222 52 from the Danish Cancer Society, Copenhagen, Denmark; and the Mermaid I project; MAS: Malaysian Ministry of Higher Education (UM.C/HlR/MOHE/06) and Cancer Research Initiatives Foundation; MAY: National Institutes of Health (R01-CA122443, P30-CA15083, and P50-CA136393); Mayo Foundation; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation; MCC: Cancer Council Victoria, National Health and Medical Research Council of Australia (NHMRC) grants number 209057, 251533, 396414, and 504715; MDA: DOD Ovarian Cancer Research Program (W81XWH-07-0449); MEC: NIH (CA54281, CA164973, CA63464); MOF: Moffitt Cancer Center, Merck Pharmaceuticals, the state of Florida, Hillsborough County, and the city of Tampa; NCO: National Institutes of Health (R01-CA76016) and the Department of Defense (DAMD17-02-1-0666); NEC: National Institutes of Health R01-CA54419 and P50-CA105009 and Department of Defense W81XWH-10-1-02802; NHS: UM1 CA186107, P01 CA87969, R01 CA49449, R01-CA67262, UM1 CA176726; NJO: National Cancer Institute (NIH-K07 CA095666, R01-CA83918, NIH-K22-CA138563, and P30-CA072720) and the Cancer Institute of New Jersey; If Sara Olson and/or Irene Orlow is a co-author, please add NCI CCSG award (P30-CA008748) to the funding sources; NOR: Helse Vest, The Norwegian Cancer Society, The Research Council of Norway; NTH: Radboud University Medical Centre; OPL: National Health and Medical Research Council (NHMRC) of Australia (APP1025142) and Brisbane Women's Club; ORE: OHSU Foundation; OVA: This work was supported by Canadian Institutes of Health Research grant (MOP-86727) and by NIH/NCI 1 R01CA160669-01A1; PLC: Intramural Research Program of the National Cancer Institute; POC: Pomeranian Medical University; POL: Intramural Research Program of the National Cancer Institute; PVD: Canadian Cancer Society and Cancer Research Society GRePEC Program; RBH: National Health and Medical Research Council of Australia; RMH: Cancer Research UK, Royal Marsden Hospital; RPC: National Institute of Health (P50-CA159981, R01-CA126841); SEA: Cancer Research UK (C490/A10119 C490/A10124); UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge; SIS: NIH, National Institute of Environmental Health Sciences, Z01-ES044005 and Z01-ES049033; SMC: The bbSwedish Research Council-SIMPLER infrastructure; the Swedish Cancer Foundation; SON: National Health Research and Development Program, Health Canada, grant 6613-1415-53; SRO: Cancer Research UK (C536/A13086, C536/A6689) and Imperial Experimental Cancer Research Centre (C1312/A15589); STA: NIH grants U01 CA71966 and U01 CA69417; SWE: Swedish Cancer foundation, WeCanCureCancer and VårKampMotCancer foundation; SWH: NIH (NCI) grant R37-CA070867; TBO: National Institutes of Health (R01-CA106414-A2), American Cancer Society (CRTG-00-196-01-CCE), Department of Defense (DAMD17-98-1-8659), Celma Mastery Ovarian Cancer Foundation; TOR: NIH grants R01-CA063678 and R01 CA063682; UCI: NIH R01-CA058860 and the Lon V Smith Foundation grant LVS39420; UHN: Princess Margaret Cancer Centre Foundation-Bridge for the Cure; UKO: The UKOPS study was funded by The Eve Appeal (The Oak Foundation) and supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre; UKR: Cancer Research UK (C490/A6187), UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge; USC: P01CA17054, P30CA14089, R01CA61132, N01PC67010, R03CA113148, R03CA115195, N01CN025403, and California Cancer Research Program (00-01389V-20170, 2II0200); VAN: BC Cancer Foundation, VGH & UBC Hospital Foundation; VTL: NIH K05-CA154337; WMH: National Health and Medical Research Council of Australia, Enabling Grants ID 310670 & ID 628903. Cancer Institute NSW Grants 12/RIG/1-17 & 15/RIG/1-16; WOC: National Science Centren (N N301 5645 40). The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland. The University of Cambridge has received salary support for PDPP from the NHS in the East of England through the Clinical Academia Reserve. The prostate cancer genome-wide association analyses: we pay tribute to Brian Henderson, who was a driving force behind the OncoArray project, for his vision and leadership, and who sadly passed away before seeing its fruition. We also thank the individuals who participated in these studies enabling this work. The ELLIPSE/PRACTICAL (http//:practical.icr.ac.uk) prostate cancer consortium and his collaborating partners were supported by multiple funding mechanisms enabling this current work. ELLIPSE/PRACTICAL Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) (U19 CA148537 for ELucidating Loci Involved in Prostate Cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I). Additional analytical support was provided by NIH NCI U01 CA188392 (F.R.S.). Funding for the iCOGS infrastructure came from the European Community's Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, and C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065, and 1U19 CA148112; the GAME-ON initiative), the Department of Defense (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund. This work was supported by the Canadian Institutes of Health Research, European Commission's Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2-2009-223175), Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, C5047/A21332 and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA148537-01 (the GAME-ON initiative). We also thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, and The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. The Prostate Cancer Program of Cancer Council Victoria also acknowledge grant support from The National Health and Medical Research Council, Australia (126402, 209057, 251533, 396414, 450104, 504700, 504702, 504715, 623204, 940394, and 614296), VicHealth, Cancer Council Victoria, The Prostate Cancer Foundation of Australia, The Whitten Foundation, PricewaterhouseCoopers, and Tattersall's. E.A.O., D.M.K., and E.M.K. acknowledge the Intramural Program of the National Human Genome Research Institute for their support. The BPC3 was supported by the U.S. National Institutes of Health, National Cancer Institute (cooperative agreements U01-CA98233 to D.J.H., U01-CA98710 to S.M.G., U01-CA98216 to E.R., and U01-CA98758 to B.E.H., and Intramural Research Program of NIH/National Cancer Institute, Division of Cancer Epidemiology and Genetics). CAPS GWAS study was supported by the Swedish Cancer Foundation (grant no 09-0677, 11-484, 12-823), the Cancer Risk Prediction Center (CRisP; www.crispcenter.org), a Linneus Centre (Contract ID 70867902) financed by the Swedish Research Council, Swedish Research Council (grant no K2010-70 × -20430-04-3, 2014-2269). The Hannover Prostate Cancer Study was supported by the Lower Saxonian Cancer Society. PEGASUS was supported by the Intramural Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health. RAPPER was supported by the NIHR Manchester Biomedical Research Center, Cancer Research UK (C147/A25254, C1094/A18504) and the EU's 7th Framework Programme Grant/Agreement no 60186. Overall: this research has been conducted using the UK Biobank Resource (application number 16549). NHS is supported by UM1 CA186107 (NHS cohort infrastructure grant), P01 CA87969, and R01 CA49449. NHSII is supported by UM1 CA176726 (NHSII cohort infrastructure grant), and R01-CA67262. A.L.K. is supported by R01 MH107649. We would like to thank the participants and staff of the NHS and NHSII for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for analyses and interpretation of these data. ; Peer Reviewed

Transcript of an oral history interview with Philip R. Marsilius, conducted by Sarah Yahm on 20 May 2015 as part of the Norwich Voices oral history project of the Sullivan Museum and History Center. Philip Marsilius was a member of the Norwich University Class of 1943. The bulk of his interview focuses on his military service in World War II as well as his continuing relationship with Norwich University as a student, alumnus, and trustee. ; Philip Marsilius, NU '43, Oral History Interview May 20, 2015 Sullivan Museum and History Center Interviewed by Sarah Yahm SY: So let's start out with, where were you born? And when you were a kid, what did you want to be when you grew up? PM: Well, I was born in Woodstock, Illinois in 1921. My father was running a company there. And my family consisted of a brother four years older, and a sister two years older. The sister and I were born in Woodstock. My father had been in World War I, and an ordinance making French 75 guns. And after that, was hired by this Woodstock typewriter company, which is older than the old typewriters, who was owned by the Sears family. And they made in addition, calculators and typewriters. And so I grew up there for two years. And then my father took an opportunity in Bridgeport to run a machine tool company, hence we moved here and lived in the north end of Bridgeport. Grew up there, went to public schools. Went to Harding High school, and from Harding, then to Norwich. SY: And did your father talk about his experiences in World War I? PM: Yes. He was a Norwegian immigrant. Came over from Southern Norway when he was 14, and learned his English in Boston at the YMCA. And then was hired by a company that made shoe machinery -- big, big company. And then they recommended he go to MIT, and he went and graduated as a mechanical engineer. And went immediately into the Army, and came out as a captain. And he was in machine tools all his life. He came here, and through the younger years -- then -- and when I was at Norwich, my folks moved to Trumbull, built a house there. And I spent a little time there, but we were accelerated in our senior year at Norwich. We went out early because they wanted us in the service. And we couldn't go to summer camp in our junior year, which was the standard routine. We were horse cavalry in those days. And we would take a trip through the back roads of Vermont up to Burlington area to the fort. And they had too many trainees at that time, so they ended up saying, we can't take you. You're gonna have to go to OCS. After four years at Norwich, we still had to go to OCS. SY: So, were you mad? PM: No, because we got out early. We got out end of February. SY: And I've heard stories of everybody on campus marching down and enlisting, was that what happened? Or? PM: Well, everybody -- a lot of them left early and joined -- volunteered for the Air Force. And some went to Canada to get in the Canadian Air Force when, like, might not be able to go in the US. And then a lot who had not finished Norwich, left and enlisted. SY: So were you eager to sort of get overseas? Were you eager to kind of get into the war? PM: Very much so. Would've left early after December 7th when Pearl Harbor hit. We went -- several of us went and volunteered. They said, you're not 21, you can't go without parental approval. And my folks said, finish your college, and then you can -- you're on your own. SY: So there was no part of you that was sort of frightened to go? PM: No. I was anxious to go. SY: And why? What was your -- why -- PM: Because I'd had good military background. The war was a devastating war. And in my mind, if we didn't stop what was going on and prevail, life would not be the same -- not be. So it just made sense to go in, and I volunteered for armored. Went to Fort Knox, and there were three others from Norwich. They had room in that class -- 110 candidates. SY: And how -- let me rewind a little bit. How did you adjust to being at Norwich? How did you adjust to being a rook? Did you take to the military lifestyle or was it difficult for you? PM: It did -- wasn't difficult. I had more -- I had more fun as a rook. And we had to come out in our pajamas. I had bought fancy pair of pajamas because I had heard about -- so I just said -- you know, they did a lot of nonsense. Bracing and all that stuff. SY: But it didn't faze you? PM: Didn't faze me. And second year, I was president of the class, and I stayed president of the class for all three years. SY: So, you did well there? PM: And I was valedictorian in addition. SY: In addition. OK, so how was the decision made that in February -- oh, tell me what you remember about Pearl Harbor. How did you hear about Pearl Harbor? PM: Oh, it was basically on the radio, and I just finished a book -- and it's in my car right now -- returning it. A Day of Deceit. FDR, and not letting Hawaii know he knew it was -- he wanted the Japanese to attack so he could declare war. And I've been through that whole book. But we knew it right away, obviously, from the radio news. Everybody knew it pretty fast. SY: Did you have radios in your room in Norwich? PM: Not in our room, no -- not. I can't -- I don't think we had radios. Today, they have everything. SY: Today, they everything. Exactly. OK, so then February, were you all called together into the Amory and told that you were gonna go to war? How as the decision made? PM: Oh, we were -- what we were told to do was, we had -- we actually had a graduation, and then we had a week off. And then we were told to return to Rutland for induction. And they made us corporals, of all good things, when we were supposed to be second lieutenants. And then we departed by train to Massachusetts, and then they went through the induction shots and all that -- get you prepared. And then they scheduled wherever you were gonna go. Some went to Riley in Kansas. Some went to chemical warfare, some went to electrical. So it was -- but four of us, I was able to get a car, and so I had a car. And the four of us drove from Florida, Massachusetts -- I can't think of the name. But that's where we were told to meet, and went through five days of basic nonsense. KP duty and all that kind of stuff. And then we drove from there, I picked up the other officers. They weren't officers then, they were corporals. And we drove all the way to Camp Polk, Louisiana, where we were entered into -- well, back up. We were at Fort Knox for three months, and then battle training for a month in Elizabethtown, Kentucky. And then we were assigned -- the four of us from Norwich were assigned to the 11th Armored Division. That's when I got my car, and we drove from there down through Alabama over to Louisiana, and we arrived. And the next day, we were ordered to come to the commanding general's office. And low and behold, he was a Norwich grad, General Brooks, and a very decent individual. He came out as lieutenant general. And we went from -- they were ready to move the whole 11th Armored to the desert training in California. But we had to go to an interim location, temporary post in Texas -- Abilene, Texas. And at that point, we had six weeks wait until the other armored division that was in training had completed. And then we moved out there. What happened when we were out there, typical of -- they have -- each company has a normal staff of say, five officers. But when they're in training, they had maybe two extra lieutenants, so you all get involved. And then about every couple of months, they go by and say, boom, boom, boom, boom. You're out, you're going to overseas, or you're going someplace. SY: So did you take a ship? I'm sure you took a ship. Obviously, everybody took a ship. But do you remember the name of the ship you took overseas? PM: No, I don't really. What I did was the second the go-around in December, I went to my colonel and volunteered to go to be one of the select. I wasn't pulled out, but I volunteered, because I didn't think 11th Armory was gonna get over there for the fighting. So I volunteered, and that's a tough decision because then, you're on your own. You go -- you go back to the East, and you go to wherever they direct you. And then you get assigned to a fort, and you go as a replacement officer. And you have hundreds of enlisted men, you don't know anybody. SY: And you don't have a relationship with them. PM: You end up having to do duty on the ocean crossing. And I had about 50 men in the lowest deck, most every one of them sick all the way over. Four bunks high -- it was a mess, but you spend 8 hours on duty with them. But anyway, we got to England, and then we went from Liverpool, went on down to Frome, England, somewhat east of London. When the officers went and replaced officers, they enlisted them and went to another post. And then you waited for your assignment. And I with another officer, made a [forayed?] to the Rangers to volunteer to join our Rangers, knowing they needed officers. And both of us were accepted physically, but they made a stipulation, we can't change orders if the time you get back to your camp. If you have orders directing you to another unit, that's it, forget us. And that's what happened. I was already assigned to the 106th Cavalry Group, which was a recon outfit. And it turned out I was -- because I was Cavalry, I was in light tanks. So, I was in tanks the whole war and it was good. You know, and we got over to Normandy in late June. Not D-Day, but mostly, we joined first Army. Patton hadn't already -- his Army hadn't been formed. And we had an interesting time in Normandy. We were right on the east end, right where the water was -- and the channel. The tide would go out a mile, and we had to send a platoon of troops out every night to collect stragglers. People trying to -- were around. And right across -- SY: Who were the stragglers? PM: Well, people who wanted to get away from the Germans. French people. You didn't know whether it was spies or what they were. Could be anybody. And we had to collect them, and make sure that they were the -- had credentials and know who they were, so that they wouldn't cause trouble. If they were just going home to join friends or family, that was OK. But there were a lot of them. And the Germans were -- got quarter of a mile from where we were, and there was a river in between, flowing out. And we had to send patrols down the beach, and one other patrol across to make sure the Germans were there. And they -- we got fired on, and fortunately got back. But -- so we did all that kind of stuff while they were waiting for the breakthrough. And when we first arrived, we -- the first combat we had was with the 82nd Airborne. And they were cleaning up a couple of villages, good size villages. And that's where they -- we broke in with them, and then they left. And then we moved over to the coast. SY: So, I've interviewed a lot of Norwich grads who were in combat, and they -- a lot of them have very intense and vivid memories of their first experience with combat. Do you have intense and vivid memories of the first time you were under fire? PM: We were under fire every day. SY: Do you remember what it was like the first time? PM: Oh sure. SY: What was it like? PM: Where I mentioned about the beach area, at one point even though we were in tanks, we got out of the tanks and went down on foot with carbines and tommy guns to stop any infiltration by the Germans 50 yards in front of us. And dusk, day, and nighttime -- well, yeah, you do what you have to do. SY: Were you frightened? PM: I never was frightened. I was -- tried to be sensible, and you couldn't go into combat and be frightened all the time, because you had to lead 30 men, and I had five or six tanks. So if I was frightened, it'd be -- that wouldn't work. SY: Some people also talk about everything being very slow, and the colors being very bright, and things sounding different. Do you -- you don't remember that? PM: No. Guns sounded like guns, and they were noisy. And -- but recon, we were out in front of everything. We were the first contact, and we have to fight then until we developed how strong the enemy is. And then if we can't handle it, we move aside and bring the heavier stuff up -- infantry or armor, who are close by. So that -- that's -- and when it's under heavy fighting, often we as recon would be on the flank. We'd be making contact with the next American unit. SY: I read the sort of memoir you wrote, briefly. Your short memoir about your time at war. PM: I tried to stay away from the gruesome stuff. SY: Yeah, but I think it's important to sort of -- you know, to talk about it. Just sort of talk about what every day was like and what sticks with you. What sticks with you now? What -- do you think about your time at war now and throughout your life, did you? PM: Not really. No. Just another episode. Once in a while, you can't help but go back. But after the war, there were about eight officers in our unit, and we had a -- the original 106th was Illinois National Guard -- that's where they started. And they had a reunion every year, and we went to the reunions for about three years. And finally decided that it made more sense for us to get a group of the officers together, because half of the enlisted men we didn't even know. And they were having a good time, but we didn't want to invade their fun. So what happened was eight officers, a couple who were in our squadron and a couple that were in the other -- there were two squadrons. And we would meet in California, Texas, Kansas. I had them to my summer home in Maine twice, and usually wives were, are all part of it. So we had a nice good time. They're all dead now. SY: It sounds like in some ways, the most intense experience was in late September at the Foret de Parroy. Am I pronouncing that right? PM: Oh yeah, Foret de Parroy. That was a tough one. SY: Do you want to talk about that? PM: Well, I think I mentioned the minefields. SY: Yeah, but why don't -- I mean, I've read the description, but people who are going to be reading the oral history won't have. So what happened there? PM: Well, we as a recon unit, were asked to take the left side of the woods, and 79th Infantry had the rest of it. It was one muddy road and fortunately, the tanks could maneuver in the light wooded area. So we find our own. But it was dense wooded, rainy, mud, and the Germans were shooting into the trees. So the shrapnel was coming down on you from wherever. And the minefields were never laid in any rational form, you just didn't know. And I don't know if I mentioned, but I called one of my tank commanders and asked him to go to headquarters for the recon group. Because we were all -- five or six tanks were all here in a line. And he jumped off the tank and right on a mine, and dead just like that. And the same -- the next day, we called on the radio and said, well, it's a minefield we're in. We need the engineers to come down with the magnetic mine finders, and they came down. And had fire breaks, and they found a way to get in. But they get there and they tripped one of these what they called a Bouncing Betties, and the shrapnel goes out at three feet. I think a dozen of them were down. And I had to go with a knife blade on hands and knees to crawl in there, with a doctor behind me. And I did a lot of the shots while he was cutting off legs and obviously tourniquetting, and Novocain for pain, and then whatever else we could do. We saved them all, but it was -- it was a messy ordeal. Fortunately, we got -- we were able to get them on stretchers, and put them on the back of the tanks and get them out of there. So anyway, we were all alive, but not in good shape. SY: And it sounds like a bunch of your sergeants asked to be relieved, what was that? SY: Yeah, two of my National Guard guys. Well, this was toward the end of that month in the woods. And these were big stoic National Guard from Illinois, and I thought one was my sergeant major and the other was a sergeant. Surprisingly to me, they came one day and said, lieutenant, we've had it. We just can't handle it anymore. And I thought these guys would be sturdy and strong, and I was wrong. But I told them there's no -- if you're not up to it, you're -- got the shakes, you're not gonna do me any good. SY: Did they have the shakes? PM: Yeah, there was -- kind of think they just couldn't handle it anymore. SY: And had they been there a long time? PM: Well, they'd been with us all the way through to that point. SY: And had they -- PM: But they were in the National Guard for years before. So I thought, you know, these are guys that know it and have been promoted up the ranks. Ones I was not expecting to lose. But I replaced them with corporals and made them -- and they stayed with me the rest of the war. SY: And did the sergeants get sent home? Was it shell-shock? Was it -- PM: I never knew what they -- I wasn't gonna follow. They weren't shell-shocked, but they were just at the point of no return, I guess, best way of stating it. SY: I know, you know, it's much more common to talk about the difficulties of combat and the aftermath, but your generation doesn't talk about it that much. It wasn't something that you guys talked about with each other, and it doesn't sound like you really have lasting effects from that difficult time. PM: I don't think so. I would say that on all of the gatherings we had -- the eight officers, we never refought the war. We never get into that. We talked about things of our present day life, family, and just enjoyed each other's company socially. SY: OK. So then it sounds like you moved through, then around the Battle of the Bulge, what happened? PM: They -- by that time, we were -- then our whole corps had moved, the 7th Army. Seventh was the Army that came up from the South. And they had a couple of corps, and they split us off from Patton, and we moved. So 3rd and 7th ran parallel through France and most of Germany, but when the Bulge hit, they were the closest. So two of their armored divisions and the recon -- similar to our recon, they moved north and went, I guess, 40 or 50 miles. We had to fill that gap they left, and we had to spread our troops out, and that's what we did. And I was in touch -- one of the four officers that had gone to Fort Knox from Norwich with me, Hal [Solon?] was in that armored group -- recon group. And I sent him a note, and he was already -- he had lost a leg, and was already on his way home. So I got a note back when it caught up with him, what had happened. So he never got up to the Bulge, he had already gotten -- but I saw him afterwards. He was active with Norwich after the war. He did fine. SY: And then it sounds like, you know, by spring, the tide has turned, right? And you're having very different experiences, all of these sort of bizarre experiences that make for good stories, right? Like, rescuing the king of Belgium. PM: Well, that was the end. And that was a happenstance and -- because the town of Strobl was -- we were told to stop here in St. Gilgen, the town of Strobl was eight miles down on the lake. And this was a gorgeous lake, about 10-12 miles long. Across from where we were in St. Gilgen, was six-seven foot high mountains. Gorgeous scenery, and Wolfgangsee was where we were. And Wolfgang town was down here, and Strobl was here, and we were here. And these -- two of the prince in Teylingen, bicycled up to St. Gilgen on an afternoon. And we were staying in this hotel, which obviously, we took over. And they come up on the porch, and we offered them a scotch. And they, sure, that'd be nice. But our mission is we want you to come to Strobl and liberate us. We've got a lousy mayor who's a tough Nazi, and he's made it -- made life miserable in the community. So we said, well, we don't have any orders. But we said, well, maybe it doesn't matter. We'll just get four officers, and we'll take my tank, and we'll just go out it. At dark, got out of the motor pool. And since we're officers, we tell the guards what we're -- where we're going. So we did. Out we went about 10 o'clock, and about 11 or before that, we arrive. And they met us at the entrance of the town. It took us right to the mayor's office, where -- but it was really fun because one of the officers had been translating for the -- some part of the government. Translating German and French, censoring material. So he could speak better German. I could speak German, but not that well. And so Nat hopped out and told the mayor that he was a no-good son of a gun, and he was through. He was our prisoner, and we were liberating the town. But the whole town was out in their pajamas having a real celebration. And then they had a nice -- Teylingen had a lovely party for us. And I think we mentioned it -- SY: Because it was you or the Russians, right? In terms of getting liberated. PM: Well, the Russians would've gotten there if we hadn't gotten there. SY: And so the town was hoping it was the Americans not the Russians. SY: Oh, they certainly didn't want the Russians. And we did send a couple officers to meet the Russians. I don't know exactly where they did, but they did meet them and got drunk on vodka. But so I can't remember exactly how far they were from. But we then learned about Leopold the next day, and that's how that all -- SY: So then you already had done one thing without orders, and then you did the next thing without orders, right? PM: Well, we didn't take the tank the next day. We took that Von Ribbentrop's six-wheel Mercedes, the staff car. All full leather seats, a gun rack in the assistant driver. The driver was on the left side, same as our cars. Not like the English. And had a rifle rack right there for the assistant. And then you could have five seats in the back to (inaudible) [00:34:20], and beautiful. And we went to Prince Von Furstenberg's house. First thing he asked about 10:30, can I get you a drink? And we had Bloody Marys, and sat there and talked, and his mother came out. And [Gerhard?] was a real gentleman, and we did see him after the war. We went back again 30 years, and he as in Vienna then, and he came out to have a reunion with us. SY: This was the Prince of Belgium? PM: He was the Prince of Austria, the Von Furstenberg family, famous family. He had been fighting on the Russian front, and he'd come back -- by that time, he'd come back. SY: Fight with? PM: With German. He had a fight with a German Army against the Russians. SY: Right. So it's odd that you were -- PM: He was out of the army by then, and back in Vienna. But he had a summer home in Strobl, and that's how he -- I don't know whether he was injured or what, but he had the -- something happened, because he had been in the fight earlier. So -- SY: Was it strange to spend time with somebody who had been on the other side? PM: Oh no, he was in -- he wouldn't have been -- he wouldn't have been in the Army if he hadn't been force to be. That, he wouldn't. It's when Germany took over Austria. SY: Yeah, yeah, the Anschluss. And then there are some other things that were really interesting. First of all, you talk about hearing about Dachau. PM: We sent one our men to go to Dachau. SY: And then when he came back, did he report to you? PM: To tell us what he saw, and the horrible scenes that he saw. I have no interest in going, because I knew -- and couple of places we found -- graves with 20-30 people. They hadn't been buried, they just laid in the graves. So we saw enough of that without even -- for me, wanting to go. SY: So you weren't surprised to hear about the concentration camps? PM: No, no. We knew about that before. You know, we were well aware of the horribleness of the Holocaust. The genocide, if you will. SY: Because people back in the US didn't really know yet about the Holocaust. PM: No, they didn't. I guess they didn't realize it. I -- maybe they didn't publicize it, but of course, I was here and knew about it. And there were more than a few, because they were in Poland and Germany. What was it, six million Jews that they killed? SY: At least six million. And then there were -- and then, you know, there were other groups that they killed as well. So we don't know the total new number. So I'm wondering if there were any other distinctive memories of your time in Europe that you sort of want to get in the record. Have we talked about the highlights? Are there any other sort of, you know, critically important moments? PM: Well, there were a lot of them important moments when I got hit -- when my tank got hit with a 75 shell, bounced off, didn't hurt us. But if I'd stayed there any longer, the second shell would've gotten me. You know, we had close calls like that. And mines were really the worst, because we could find the fighting units, the guns, and avoid them if we could. But the mines, you just had to be on the alert, and suspect that this might be a place that -- fortunately, my recon guys were pretty sharp. And we noticed areas and checked them before we just ran over them. And so -- but I lost two tanks to mines, teller mines. And both cases, my guys lost their legs, because the whole plate of armor came -- folded right up, and just cut them off here. But we, again, saved them and -- with plasma and tourniquets. And I went to visit one of them after the war, and he was already outfitted with a brand-new Oldsmobile. You didn't need any feet, you could do everything from the hydra-matic drive. And so he was -- he had been a truck driver, and he was -- but my -- I had one episode when -- I don't know if I mentioned in there, when we were attacking the town, and one trooper cavalry was on the hardpan road. And we had gone up the back woods overlooking the town from another direction. We thought we'd coordinate two troops with -- and they got stopped by a road block that they couldn't penetrate. And they were fighting, and we jumped off from the woods. Turned out, the field was mud, and two of the tanks just went right in the mud. Couldn't go, they got stuck. My tank, I just told my driver, I said, George, take your hands off the laterals. Don't try to control it. Just keep the full speed. And it kept moving, and we did get to the one single road across. Fortunately, I did, because I had a platoon of the recon troops who had taken over some trenches close to the town. But they had kicked the Germans out of it and taken over, but they needed someone there to support them. So I had to stay there for about five hours, and the Germans were shooting at me. And I bet at least I had 200 rounds shot at me, but we kept moving the tank. Didn't keep it in one place. And I was firing up where I knew they were shooting. So they claim I might have gotten one of the guns. I don't know, never would worry about that. But I stayed with them until dark. When they withdrew, I withdrew. So we saved them. They -- SY: What happened to the two tanks that got stuck in the mud? PM: When I -- I called them on the radio and told them to abandon, but put grenades in the gun and blow the guns. So they were disabled. After the war, they were still there. Still there for -- I don't know where they are now. SY: Did you go -- did you see them? Did you go back to Europe and see them? PM: I didn't go back. We went back 30 years later, but someone who had been there said the tanks were there. But they were no -- well, they were no good, because the guns were ruined. SY: Right, you disabled them. I wonder how they got rid of those tanks. I wonder how they moved them eventually. PM: Well, they had to wait until there was solid ground, and they'd have to go in with a crane and pull them out. But -- so they might be in a museum somewhere around. SY: They might. Who knows? Do you think you were a good leader, and do you think Norwich prepared you well for war? PM: Oh, I think Norwich -- everything regarding the military and Norwich was fine and appropriate for what we needed as officers going into combat. We had --- even though we were on horseback, we still had a lot of background and realized what was involved in fighting. And so I have no bad feelings at all about anything that I learned at Norwich. I think I could put it to use and -- SY: And do you think you were a good leader and a good officer? PM: Well, I ended up as a captain, so I didn't -- and I couldn't get promoted. Because at the time when I was a platoon leader -- because we had three platoons, 17 tanks, and each platoon was assigned to one recon troop. So when they were out -- I usually was B Troop because I was 2nd Platoon. But the company commander and the exec officer never fought. My tank company, they were at headquarters all the time. They never were fighting and -- because 1st Platoon was A Troop, 2nd Platoon -- B Troop, and C Troop, and they -- we never fought as a tank company. So they just were -- but there were no promotions either. You couldn't get to be the company commander because -- but in the econ troops, there was movement, because they can move to headquarters. And from -- and a number of them did. They could go from captain to major, and be at headquarters in another role. And then -- and that's what happened in B Troop. Lieutenant Bennett, who was with me -- who I fought with, he got promoted to captain when his company commander moved to headquarters. But there was no movement in the tank. SY: No, that makes sense. So let's talk about -- because I know, you know, we don't have endless time. So let's talk about you getting home and what it was like. First of all, did you -- what made you decide to leave the Army? PM: I didn't. SY: You didn't? PM: I didn't. I stayed in the Reserve. SY: Oh, you did. OK. But you didn't want to be career Army? PM: Oh no. I had no idea of career Army. SY: What was you thinking about that? PM: Well, I had no intent, but since I was in the Reserve, I was part of a tank battalion that met in Stanford, Connecticut every two weeks. And I was serving -- well, I was a captain, but I was serving in a major's role. And we did training, and we did -- and I was in until '51, I guess it was. So I was still active. But right in the middle of that the Korean War was just getting going. Two business came to me and asked me to go to Washington on a dollar a year assignment to handle the tool and die industry. They hadn't had a director of the tooling industry in World War II. They'd had machine tools and related, but they never had tool and die. And then they realized that they needed that because there were about 3,000 tool and die shops, and those tools were put on machine tools. So you can't have a machine tool, you got to put the molds and dies in the fixtures. So because I would -- I had finished -- I had gone back to MIT after the war. Because I had advanced degrees -- these businessmen who ran beautiful businesses, you know, had come through apprentice route, didn't have college background. They felt they wanted a -- should have a college person down there. So I ended up doing it for a year, and it that was what I called a graduate degree in government. You learned about Washington. I was there five days a week. Came home Friday night, flew back, and then went to my office all day Saturday and Sunday morning. Got on the Sunday night train out of Bridgeport, got into Washington Monday morning at 7:00, and went right to the office. SY: That sounds exhausting. PM: Well, it was so -- it was a busy year. SY: Did you have a family at that point? PM: I had one son, and a wife, and a little house here in Fairfield close to water -- and very pleasant. And she had her own car, and we had two cars. And -- but most the time, she drove me to the station, and then she'd pick me up in Newark when I flew back. So bring the youngster down with us. But -- SY: Oh, sorry. PM: Go ahead. SY: When you first came back, what was it like to adjust to civilian life again? PM: Well, it was -- I had 90 days of leave. I got out of -- I had to go back to Massachusetts at the camp -- oh, I forget. And we had to go back there to bust her out. But -- and my sister drove up and picked me up. And I was engaged at the time, and by February, I got married. And we took a week's long honeymoon down south and visited some of the World War II officers I had served with. And then a week later, I was at MIT, and grad work for two years. And my wife and I lived in Boston in Needham, and she went to Boston University and took courses. So -- and then we had our -- we had our first son in the last semester of the second year. And -- but I had the company business where I had agreed to join the business when I was in the war. My brother -- four years older, had come back. He was in ordinance in India, and he was a major, and they sent him back to command school in Leavenworth to become a lieutenant colonel. But while he was back, he took time and took a look at our factory and what was going on. And he wrote me a -- about a 10 page letter describing what's happening, and inviting me to consider joining him as a partner if I was interested. SY: And was it -- had it been your father's business? PM: My father was the president of the business, and -- not the major owner, but he had three other owners. And what happened was I got the letter when I was in heavy combat, and I couldn't even read it for a couple of days. But then eventually I got around to answering it, and then right after, I got another letter. And I said, you know, I think two things. I've got to go back and go to MIT, and get up to date on business management and engineering. And then if I do that, I'm willing to join you, but I want equal ownership and I want equal salary, but I don't care about titles. But he was senior, and it worked for 45 years. SY: And over the course of your career, you witnessed, you know, the decline of American manufacturing. How did that affect your business and -- PM: Well, our business was -- well, I'd been out 25 years now. But the second generation -- my son who died, and my nephew who still runs the business, we didn't just -- we bought another business in Bridgeport and merged the two. And then started a whole new technology business in New Hampshire, which is doing fine. And the -- what's left here in Bridgeport is 20 percent of what it was, but the New Hampshire business has been booming. Mostly Asia and Europe, 25 percent here in America, but 50 percent at least, Asia and 25 here. And we have another third business out in New York State, and that's in small tools, and that's doing fine. And I had a business in Mexico for a while, and I started one in Canada for a while. They both -- I gave one away, and the other one just finishing up after 65 years. Winding it down, so that's gone. But the businesses are fine, and fourth generation is in it. My grand-nephews are now in their late 30s, early 40s, and they're digging in. So things have done very well. I'm out of it completely other than just life insurance -- should be. SY: So let's talk about Norwich. So when did you start getting -- when did you get on the board of trustees, and why did you want to back in -- you know, involved with Norwich again? PM: Well, when I was at Norwich, in addition to being president of the class and valedictorian -- as I told you, I was one of the trouble makers. With the fraternities, the old rules were that the freshmen would pay for the orchestra for carnival week, but not be allowed to attend. And I, for one, said that's nonsense. Either you let us in the fraternities before carnival week, or we're not about to pay a couple thousand dollars for a New York orchestra coming up for you guys to have a good time. Well, they didn't think that was -- the class ahead, who became juniors, they -- us -- they agreed to change the fraternity rushing to November. In fact, around Thanksgiving or after Thanksgiving. But they wouldn't rush the class after us, because we screwed it up. So they didn't want us. But -- and one of my father's business partners was SigEp, and he wanted me to go to SigEp. And -- but these guys were, we don't want you guys. Eventually, they invited me to Theta Chi, and I was happy. Then I became president of Theta Chi. And then later, I was president of the inter-fraternity counsel, which was quite a turnaround from screwing them up three years before. Anyway, I enjoyed it, but I -- we had bought land with Theta Chi across from where SigEp -- is where the president lives now. We had -- and Theta Chi is over there -- a new house. We were in an old three story big house on Central Avenue. We had the money and bought the land. And when I came back from the war, I wanted to find out what happened to the funds we had. Well, they had screwed around with it, and we raised hell. And finally they got back on track, and began to put some money aside and build a house. So I stayed with it. And for some reason or another, I stayed in the alumni association, but I was not president of it. I was vice president at the time. When typically, the president was invited to the board as one of the alumni, and Harmon asked me to do it rather than the president. Which was a little embarrassing. So I can came on for a five year stint. And then -- I don't know exactly what day it was, but 1970 was when I took over as chairman. And -- SY: And what was going on at Norwich in 1970? PM: Well, Harmon was the president. And at that time, we didn't have ladies in the corps, and Vermont College was independent. So a lot of things were -- I think we were 600 or so cadets, and now horses -- tanks were replacing the horses. And Norwich had built several new buildings, it was making good progress. The upper campus was -- I don't -- SY: And then Hart became president. PM: Well, Harmon -- this was let's see, 70 -- SY: Was is Hamlett after Harmon? PM: Hamlett came first. Harmon stayed until '65, and then the Vietnam War was a big factor. SY: And how did that change the climate of campus? PM: Well, I wouldn't say it -- we had to elect -- Harmon had -- I think had 15 years or whatever, and he wanted out. And we were able to get a four-star general, Hamlett, who was vice chief of staff of the Army, and a wonderful man. And -- but it was Harmon -- oh, and Bill Adams, who was chairman of the board, and Louie Cavat of the Cavat family. They left the board meeting when Bill Adams said, it's my turn to step down. So the three of them became a nominating committee of whatever we had -- 25 member board. They came back and selected me. I don't know why, because there were military officers there. There were others -- guys that -- SY: So what role -- so the Todds say you played a really critical role in kind of keeping Norwich together in hard times. So can you talk about those hard times and -- PM: Well, that was the Vietnam War, for one. And when Barksdale Hamlett had cancer in the back, and he had to leave for health reasons. It was a hell of job finding a replacement. Who in the Vietnam era at '72, wanted to be president of a military college. And we had search committee, a good search committee, and one was lieutenant general. We -- but he wasn't -- he said he's not up to doing that job. He was a good, wonderful person. And we interviewed a number of people, but military people weren't interested. So we came back to Loring Hart, who was head of the English department. And I had a difficult time -- one thing, the chairman and the president have got to have a good rapport. You got to work together, and got to understand each other. And Hamlett and I had had excellent communication, and there was never any problems. And he knew that I wouldn't interfere with his role, and I knew where the limits were. And faculty often would come to me and ask -- I'm not gonna bypass the president. You go there, not to me. And I told him explicitly and a matter of fact, I met the whole -- the staff faculty senate and told them. I'm not interfering with pay scales or tenure or anything, that's not my role. So we made that clear and -- but finding a new president, Loring was the best we could do. Well, you're on your way. SY: Nice meeting you. PM: OK. She's out to dinner. So that was an awkward period, and Loring was -- he wasn't good at selecting -- F1: Your car is blocking me. SY: Oh no. No problem, let me move it. F1: I should have thought of that sooner. PM: Anyway -- SY: So yeah, so what happened under Loring Hart? PM: Loring was a wonderful person, but difficult in selecting subordinance, putting them in the role. And that was true all the way through. And I just don't think he was a good enough administrator. At one point, I told him he had to go to -- back to -- I'm trying to think, the American -- anyway, they have courses for corporate executives. I said, you got to go to one of these for at least a week, and get some background in executive authority. And he did, because I lectured him time and again. You've got to get the right people in the right positions who are qualified to do what needs to be done. And you can't just select people because you like them. You got to know what they're capable of. So he got the message, and he did it, he went to San Francisco to let's see, American Association of whatever. I had been to courses up in New York State for corporate executives, and they were wonderful. They really helped you. And I met some Fortune 500 companies heads there. Made longtime friends with them. Anyway, we got that done, but at the end of eight years, we -- by then we had brought women into the corps. And that meant, you know, we had to clean out our barracks and allow that strictly for women, and we had to integrate them. And then Vermont College got in trouble, they didn't have sufficient endowment. And the president decided he was ready to leave, so there wasn't any conflict. And it made sense to us to merge with them, so we went through that merger during Loring's administration. And again, that was difficult because we had to change key people over there. And two or three times, he made the wrong choices. But finally at the end of eight years, I talked to the executive committee and said I think it's time we begin looking for a new president. Obviously, he and his wife resisted very much. SY: And were probably hurt. PM: Oh yeah, yeah. And -- but I said for the good of the university, we got to do -- got to do something. And it took two years to flush it out. And we were in the executive committee meeting in Boston, at the Ritz, and we had a vote. And the vote was that -- I don't know but the executive committee was probably 11 people then, and only one voted for him. And then we decided we needed to get a new president, and we had already had a search committee. And we had identified Russ Todd as the potential. And I can remember at that -- after we had made the decision on Loring, and we already had looked at and settled on five candidates, that Russ Todd was the best. And we went through a very rigorous procedure of criteria -- and of his background. And then also laid out an eight-point plan that he had to agree to as far as running Norwich, and what had to be done. SY: It seems like you two worked very well together. PM: We did. Yeah. The same with Barksdale Hamlett. SY: So what enabled you and Russ Todd to work so well together? PM: Well, because he knew right from the start that we had laid out what he had had to agree to to become president. And he didn't mince any words, he was very forthright about everything he did. Russ, you could depend on, no BS, he told you right straightforward how he felt and what he would like. And -- but as I said at the outset, you got to have a relationship -- SY: And he said, you know, that he'd call you and you'd talk for an hour -- for hours, and you'd give him advice. So what advice were you giving him? How did you sort of -- PM: Well, I can't tell you that, could I? SY: You can't tell me that. PM: Well, I don't know because whatever the issue was -- SY: And then how did -- it seems like Norwich got back on its feet, so what happened? How did it get back on its feet? PM: Well, one thing we -- when I finished as chairman, we really went after campaign fundraising. We had very little endowment back in the early days. The first job I took as I stepped down as chairman was a 16 million dollar fundraising drive to get us launched, and we did. We raised that 16. And then we had a very strong investment committee with Fred Weintz because of his Goldman Sachs background. He had connections and contacts, and so we were doing a thorough job of investment management. You know, using the right resources, and then continuing. And now -- of course, back then -- it was 40 years ago, we started doing that. A dollar is a little different today. And the new generation of business leaders and Norwich grads are much better off. And -- SY: So, I'm just wondering -- you know, I didn't ask you at the beginning of the interview why you decided to go to Norwich, but that question connects to sort of why does Norwich mean so much to you? You've dedicated a lot of your life and time to the institution. So why? What's special about it? PM: What's -- two things that started me, my family and my high school principal, Dr. -- Mr. Hedges. His sister was the registrar at Norwich. And I had grown up with horses. Two things. They felt I needed discipline, and I enjoyed the horse life. And I played polo with Norwich and things. So I -- and they had a good chemical program. And one of my dad's partners had suggested that maybe chemistry was a good start, because he had done a lot of work for DuPont. Knew about them, and said, maybe. So I said, well, why don't I take a chemistry course, and Norwich has a good one. And so the combination of all three. SY: Yeah, sure. But then why did Norwich continue to be meaningful in your life? A lot of people are like, yeah, I went to school there, who cares. But you really dedicated a lot time to it, so what is special about the institution? PM: Well, I think everything is special. Particularly, to see it prosper and grow, and begin to really have a place in the academic world -- strong place, and one you can be proud of. And comparing to Citadel and VMI and Texas A&M, and not -- nobody -- the officers that I was with in the service were Texas A&M. So they all were cavalry background too. So we had a lot of commonality. But just to -- well, the fraternity was one thing, and when we got rid of the fraternities, Harmon was still there. He called me on the phone and asked me to -- his -- my advice about the fraternities. And since I'd been head of the counsel and head of the Theta Chi, I said, well, sympathize what you're saying -- because they were disregarding the discipline. So I went up to Norwich and went to Theta Chi unannounced, and just observed and talked to few of the cadets. I called Harmon and said, I'm with you, let them go. They're a distraction for the university. And they did, and I'm still on Theta Chi's list because it's the Alpha Chapter. And I had given them some money, but I don't now. SY: How do you feel about Norwich as it is today? It's very different than it was then. I know some alumni aren't thrilled about there being civilians on campus and things like that. How do you feel about all that? PM: Well, I helped the merger, so I was there as part of -- and a lot of -- well, first, VC was in trouble. When we merged it, we were not planning to bring it over to the campus. But it became obvious after a few years that us commuting back and forth from classes and all of that, just you better have one campus, because you're not that huge a school. And I was happy at the second civilian dorm was finished -- 285 people, so that's pretty good size. And I also -- you know, this -- our society is not just the military. And I'm happy that we have civilians, but I think because of our military program and honor code and discipline, it rubs off on the rest of them. I think it makes them better than -- better students and better people, and their -- the value system. SY: Interesting. I don't know if I have any other questions for you. Anything you want to add? PM: Oh, I had not planned -- when I took the job, I -- usually, it's a five year term. And I had another board member whose father had been to Norwich, and White Chapel was -- that's the father that -- a name for him. And Bill White was a year behind me, and he was on the board then -- replaced his father. And I think we all agreed that Bill would be the next one to follow me. And I -- because I think because of his father's background and all of that, he thought maybe he would be the selected one, and he wasn't when Harmon and the others asked me to do it. But I said to him, five years is fine. He came down with cancer with four years later, and was out of it within a couple years -- he died. So then I was in deep trouble with Loring and getting into that part. Then we were into the school mergers and the women combat. Things were just ramping up, but we managed. But again, I say it's a relationship, and we had some wonderful people on the board that -- Walter Juckett who was vice chair with me. And I was a member of his foundation, and we ended with -- he had some stock in foreign companies that he'd gotten almost gratis -- Finland, Sweden, Norway, Canada, in the wood industry. And when either Goldman Sachs or someone went over and evaluated the value of all of what they all had, they came up to many millions. And when they were bought out, that went into the foundation. And when I was having lunch with Walter in Boston one day, I said, what do you think the foundation -- a portion was coming to Norwich. Oh, he said, probably a million. It ended up to be four or five million, because he had no idea what they were gonna pay. What they'd appraised it for and what it was sold for. So I stayed on his board, and he was in foundry and machine building for the paper industry. And I had a commonality of interest, and -- but Walter and I were just very good, good friends. And he was just a wonderful person, and I could go on with anecdotes about Walter. But we did a lot of things together, including lunch at the Waldorf. And when he went to Waldorf, the waiter came in, said, oh, Mr. Juckett, you want this kind of bread? And he didn't come there every day, he -- but he was very specific about what he wanted to eat. I can remember that. But anyway, those were little anecdotes of life with -- and John Charles Daly, who was on the board -- he was "What's My Line?" He was on TV. You remember that name? Goes back, you know -- SY: I think it's before my time. PM: -- 35 years. How old are you now? SY: Thirty-six. PM: Yeah, see that goes back. He was television "What's My Line?", and he was on the board of Norwich by virtue of one of the trustees. He was chairman of the -- of a boys' school in New Hampshire, and that person recommended him to come on the board, and we became close friends. And I played golf with him down in Washington where he lived. And his wife was the daughter of the former chief of Supreme Court justice, but that was his daughter. But he was -- you know, his English language was perfect for (inaudible) [01:23:19]. And he just -- he was very serious about important things, but he was just full of fun when you got through all the heavy business. He just had a good time. So -- SY: So you had a good time on the board? PM: Yeah. Those were the kind of -- but we had a 30 member board. We brought six from VC onto the board, and they were good people. Then we had -- well, we had a lovely group of women on the board, who -- one was a lawyer in Washington, who -- topnotch person. We had -- SY: Were you involved in the decision to sell VC eventually? PM: Oh, that was over -- past my time. With -- once we moved over here, there was no reason not to sell it, and it was sold to good people. So there was no question about -- it was great property. And if someone who -- from Cincinnati -- SY: Well, they actually sold it just, you know, 10 years later -- less than 10 years later. But it's doing fine now, because it's now independent, Vermont College of Fine Arts. PM: Yeah, I don't know what it is now. SY: Yes, Vermont College of Fine Arts, it's actually doing very well. But Union Institute, that was short lived and not actually great, but -- PM: We also took part of the Marshfield College -- SY: Goddard. PM: Goddard. We took the graduate program from Goddard, and they were unionized. And we got rid of the union, brought those professors over, and they were excellent professors. They were topnotch people. SY: And they were at VC. PM: At VC? SY: Yeah. PM: Yeah, but they wanted out of Goddard too. SY: They did, because it was so unstable. PM: Well, it was a commune. SY: Well, actually, because I've interviewed a bunch of them, they didn't -- they -- a lot of them believed in Goddard's educational vision, but it wasn't economically sustainable for them and their families. PM: But they lived out in the woods with a -- I went to the campus, and I agreed that they wanted to keep their undergrad program. Yeah, that's fine. And it fitted for a certain type of people, so I was happy with that. SY: Sounds like a lot of really important decisions were made during your tenure on the board. PM: Well, I think it eventually stabilized. And in perspective looking back at it, it's hard to know how we would have done it differently in light of the circumstances. Vermont's a little different state than some others, you know? Not an easy state to do things in. So you have to put that in reasonable relationship to everything else that happened. But it -- you know, it's a changing society. It's a changing technology, which I used to be involved with. When I think back when I finished work, and where the technology is today, and then when you think of the social media that all you guys fool around with -- iPhones and oh, whatcha -- Twitter and Facebook and -- you know, I say fine, that's -- social media's great. It's done a lot of business and advertising and all that. I personally prefer person-to-person discussion, either a small group or big group. I don't want to be texting -- driving along, texting. That's not -- you know, I'm not gonna do that. Period. I have a cellphone, and I don't use it much, but I have it for safety if I need it. But when you're 93, you don't -- SY: You're certainly not gonna text and drive when you're 93. PM: I still drive, but I wonder whether I should sometimes when you get on the road. The way people cut you off and zoom, zoom. SY: Yeah, it's a fast part of world too. All right, well speaking of person-to-person contact, let's let you get to your dinner with your neighbor. PM: Well, yeah. END OF AUDIO FILE

Only Vanderbilt University affiliated authors are listed on VUIR. For a full list of authors, access the version of record at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965101/ ; Identifying the underlying genetic drivers of the heritability of breast cancer prognosis remains elusive. We adapt a network-based approach to handle underpowered complex datasets to provide new insights into the potential function of germline variants in breast cancer prognosis. This network-based analysis studies similar to 7.3 million variants in 84,457 breast cancer patients in relation to breast cancer survival and confirms the results on 12,381 independent patients. Aggregating the prognostic effects of genetic variants across multiple genes, we identify four gene modules associated with survival in estrogen receptor (ER)-negative and one in ER-positive disease. The modules show biological enrichment for cancer-related processes such as G-alpha signaling, circadian clock, angiogenesis, and Rho-GTPases in apoptosis. ; CAC: We thank all the individuals who took part in these studies and all the researchers, clinicians, technicians, and administrative staff who have enabled this work to be carried out. We acknowledge all contributors to the COGS and OncoArray study design, chip design, genotyping, and genotype analyses. ABCFS: Maggie Angelakos, Judi Maskiell, Gillian Dite. ABCS: Frans Hogervorst, Sten Cornelissen and Annegien Broeks. ABCTB Investigators: Rosemary Balleine, Robert Baxter, Stephen Braye, Jane Carpenter, Jane Dahlstrom, John Forbes, Soon Lee, Debbie Marsh, Adrienne Morey, Nirmala Pathmanathan, Rodney Scott, Allan Spigelman, Nicholas Wilcken, Desmond Yip. BBCS: Eileen Williams, Elaine Ryder-Mills, Kara Sargus. BCINIS: Dr. K. Landsman, Dr. N. Gronich, Dr. A. Flugelman, Dr. W. Saliba, Dr. E. Liani, Dr. I. Cohen, Dr. S. Kalet, Dr. V. Friedman, Dr. O. Barnet. BIGGS: Niall McInerney, Gabrielle Colleran, Andrew Rowan, Angela Jones. BREOGAN: Manuela Gago-Dominguez, Jose Esteban Castelao, Angel Carracedo, Victor Munoz Garzon, Alejandro Novo Dominguez, Maria Elena Martinez, Sara Miranda Ponte, Carmen Redondo Marey, Maite Pena Fernandez, Manuel Enguix Castelo, Maria Torres, Manuel Calaza, Jose Antunez, Maximo Fraga; Joaquin Gonzalez-Carrero and the Department of Pathology and Biobank of University Hospital Complex of Vigo, Instituto de Investigacion Biomedica Galicia Sur, SERGAS. BSUCH: Peter Bugert, Medical Faculty Mannheim. CCGP: Styliani Apostolaki, Anna Margiolaki, Georgios Nintos, Maria Perraki, Georgia Saloustrou, Georgia Sevastaki, Konstantinos Pompodakis. CGPS: Dorthe Uldall Andersen, Maria Birna Arnadottir, Anne Bank, Dorthe Kjeldgard Hansen, and the Danish Cancer Biobank. CNIO-BCS: Guillermo Pita, Charo Alonso, Nuria Alvarez, Pilar Zamora, and Primitiva Menendez. CPS-II: Centers for Disease Control and Prevention National Program of Cancer Registries. The National Cancer Institute Surveillance Epidemiology, and End Results program. CTS: Leslie Bernstein, Susan Neuhausen, James Lacey, Sophia Wang, Huiyan Ma, and Jessica Clague DeHart. Dennis Deapen, Rich Pinder, and Eunjung Lee, Pam Horn-Ross, Peggy Reynolds, Christina Clarke Dur and David Nelson, Hoda Anton-Culver, Argyrios Ziogas, and Hannah Park and Fred Schumacher. DIETCOMPLYF: charity Against Breast Cancer (Registered Charity Number 1121258) and the NCRN. Participants and the investigators of EPIC (European Prospective Investigation into Cancer and Nutrition). ESTHER: Hartwig Ziegler, Sonja Wolf, Volker Hermann, Christa Stegmaier, Katja Butterbach. FHRISK: NIHR for funding. GC-HBOC: Stefanie Engert, Heide Hellebrand, Sandra Krober and LIFE. Markus Loeffler, Joachim Thiery, Matthias Nuchter, Ronny Baber. GENICA: Dr. Margarete Fischer-Bosch [HB, Wing-Yee Lo], German Cancer Consortium (DKTK), and German Cancer Research Center (DKFZ) [HB], gefordert durch die Deutsche Forschungsgemeinschaft (DFG) im Rahmen der Exzellenzstrategie des Bundes und der Lander -EXC 2180 -390900677 [HB], Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, [Yon-Dschun Ko, Christian Baisch], University of Bonn, Germany [Hans-Peter Fischer], Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany [UH], Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, Germany [Thomas Bruning, Beate Pesch, Sylvia Rabstein, Anne Lotz]; University Medical Center Hamburg-Eppendorf, Germany [Volker Harth]. HABCS: Michael Bremer. HEBCS: Rainer Fagerholm, Kirsimari Aaltonen, Karl von Smitten, Irja Erkkila. HUBCS: Shamil Gantsev. KARMA and SASBAC: Swedish Medical Research Counsel. KBCP: Eija Myohanen, Helena Kemilainen. kConFab/AOCS: Eveline Niedermayr, Family Cancer Clinics and the Clinical Follow Up Study (received funding from the NHMRC, the National Breast Cancer Foundation, Cancer Australia, and the National Institute of Health (USA)). LMBC: Gilian Peuteman, Thomas Van Brussel, EvyVanderheyden and Kathleen Corthouts. MARIE: Petra Seibold, Judith Heinz, Nadia Obi, Sabine Behrens, Ursula Eilber, Muhabbet Celik and Til Olchers. MBCSG: Paolo Radice, Jacopo Azzollini, Bernardo Bonanni, Bernard Peissel, Roberto Villa, Giulia Cagnoli, Irene Feroce, and Cogentech Cancer Genetic Test Laboratory. NBCS: Kristine K. Sahlberg (PhD), Lars Ottestad (MD), Rolf Karesen (Prof. Em.) Dr. Ellen Schlichting (MD), Marit Muri Holmen (MD), Toril Sauer (MD), Vilde Haakensen (MD), Olav Engebraten (MD), Bjorn Naume (MD), Alexander Fossa (MD), Cecile E. Kiserud (MD), Kristin V. Reinertsen (MD), Aslaug Helland (MD), Margit Riis (MD), Jurgen Geisler (MD) and OSBREAC. NHS/NHS2: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. OBCS: Arja Jukkola-Vuorinen, Mervi Grip, Saila Kauppila, Meeri Otsukka, Leena Keskitalo and Kari Mononen. OFBCR: Teresa Selander, Nayana Weerasooriya. ORIGO: E. Krol-Warmerdam, and J. Blom. PBCS: Louise Brinton, Mark Sherman, Neonila Szeszenia-Dabrowska, Beata Peplonska, Witold Zatonski, Pei Chao, Michael Stagner. The ethical approval for the POSH study is MREC/00/6/69, UKCRN ID: 1137. Experimental Cancer Medicine Centre (ECMC) supported Faculty of Medicine Tissue Bank and the Faculty of Medicine DNA Banking resource. PREFACE: Sonja Oeser and Silke Landrith. PROCAS: NIHR for funding. RBCS: Petra Bos, Jannet Blom, Ellen Crepin, Elisabeth Huijskens, Anja Kromwijk-Nieuwlaat, Annette Heemskerk, the Erasmus MC Family Cancer Clinic. SBCS: Sue Higham, Helen Cramp, Dan Connley, Ian Brock, Sabapathy Balasubramanian and Malcolm W.R. Reed. We thank the SEARCH and EPIC teams. SKKDKFZS: SUCCESS Study teams in Munich, Duessldorf, Erlangen and Ulm. SZBCS: Ewa Putresza. UCIBCS: Irene Masunaka. UKBGS: Breast Cancer Now and the Institute of Cancer Research and NHS funding to the Royal Marsden/ICR NIHR Biomedical Research Centre. WHI: investigators and staff for their dedication. BCAC is funded by Cancer Research UK [C1287/A16563, C1287/A10118], the European Union's Horizon 2020 Research and Innovation Programme (grant numbers 634935 and 633784 for BRIDGES and B-CAST respectively), and by the European Community ' s Seventh Framework Programme under grant agreement number 223175 (grant number HEALTH-F2-2009-223175) (COGS). The EU Horizon 2020 Research and Innovation Programme funding source had no role in study design, data collection, data analysis, data interpretation or writing of the report. Genotyping of the OncoArray was funded by the NIH Grant U19 CA148065, and Cancer UK Grant C1287/A16563 and the PERSPECTIVE project supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research (grant GPH-129344) and, the Ministere de l'Economie, Science et Innovation du Quebec through Genome Quebec and the PSRSIIRI-701 grant, and the Quebec Breast Cancer Foundation. Funding for the iCOGS infrastructure came from: the European Community's Seventh Framework Programme under grant agreement no 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 -the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, and Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund. The DRIVE Consortium was funded by U19 CA148065. ABCFS was supported by grant UM1 CA164920 from the National Cancer Institute (USA). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the USA Government or the BCFR. The ABCFS was also supported by the National Health and Medical Research Council of Australia, the New South Wales Cancer Council, the Victorian Health Promotion Foundation (Australia) and the Victorian Breast Cancer Research Consortium. J.L.H. is a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellow. M.C.S. is a NHMRC Senior Research Fellow. The ABCS study was supported by the Dutch Cancer Society [grants NKI 2007-3839; 2009-4363; 2015-7632]. The ABCTB was supported by the National Health and Medical Research Council of Australia, The Cancer Institute NSW and the National Breast Cancer Foundation. The work of the BBCC was partly funded by ELANFond of the University Hospital of Erlangen. The BBCS is funded by Cancer Research UK and Breast Cancer Now and acknowledges NHS funding to the NIHR Biomedical Research Centre, and the National Cancer Research Network (NCRN). For the BCFRNY, BCFR-PA, BCFR-UT this work was supported by grant UM1 CA164920 from the National Cancer Institute. For BIGGS, ES is supported by NIHR Comprehensive Biomedical Research Centre, Guy's & St. Thomas' NHS Foundation Trust in partnership with King's College London, United Kingdom. IT is supported by the Oxford Biomedical Research Centre. The BREOGAN is funded by Accion Estrategica de Salud del Instituto de Salud Carlos III FIS PI12/02125/Cofinanciado FEDER; Accion Estrategica de Salud del Instituto de Salud Carlos III FIS PI17/00918/Cofinanciado FEDER; Accion Estrategica de Salud del Instituto de Salud Carlos III FIS Intrasalud (PI13/01136); Programa Grupos Emergentes, Cancer Genetics Unit, Instituto de Investigacion Biomedica Galicia Sur. Xerencia de Xestion Integrada de Vigo-SERGAS, Instituto de Salud Carlos III, Spain; Grant 10CSA012E, Conselleria de Industria Programa Sectorial de Investigacion Aplicada, PEME I + D e I + D Suma del Plan Gallego de Investigacion, Desarrollo e Innovacion Tecnologica de la Conselleria de Industria de la Xunta de Galicia, Spain; Grant EC11-192. Fomento de la Investigacion Clinica Independiente, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain; and Grant FEDER-Innterconecta. Ministerio de Economia y Competitividad, Xunta de Galicia, Spain. The BSUCH study was supported by the Dietmar-Hopp Foundation, the Helmholtz Society and the German Cancer Research Center (DKFZ). CCGP is supported by funding from the University of Crete. The CECILE study was supported by Fondation de France, Institut National du Cancer (INCa), Ligue Nationale contre le Cancer, Agence Nationale de Securite Sanitaire, de l'Alimentation, de l'Environnement et du Travail (ANSES), Agence Nationale de la Recherche (ANR). The CGPS was supported by the Chief Physician Johan Boserup and Lise Boserup Fund, the Danish Medical Research Council, and Herlev and Gentofte Hospital. The CNIO-BCS was supported by the Instituto de Salud Carlos III, the Red Tematica de Investigacion Cooperativa en Cancer and grants from the Asociacion Espanola Contra el Cancer and the Fondo de Investigacion Sanitario (PI11/00923 and PI12/00070). The American Cancer Society funds the creation, maintenance, and updating of the CPS-II cohort. The CTS was initially supported by the California Breast Cancer Act of 1993 and the California Breast Cancer Research Fund (contract 97-10500) and is currently funded through the National Institutes of Health (R01 CA77398, UM1 CA164917, and U01 CA199277). Collection of cancer incidence data was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885. The University of Westminster curates the DietCompLyf database funded by Against Breast Cancer Registered Charity No. 1121258 and the NCRN. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by: Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Generale de l'Education Nationale, Institut National de la Sante et de la Recherche Medicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF) (Germany); the Hellenic Health Foundation, the Stavros Niarchos Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucia, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC (RD06/0020) (Spain); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPICOxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPICOxford) (United Kingdom). The ESTHER study was supported by a grant from the Baden Wurttemberg Ministry of Science, Research and Arts. Additional cases were recruited in the context of the VERDI study, which was supported by a grant from the German Cancer Aid (Deutsche Krebshilfe). FHRISK is funded from NIHR grant PGfAR 0707-10031. Prof D Gareth Evans is supported by the NIHR Manchester Biomedical Research Centre (IS-BRC-1215-20007). The GC-HBOC is supported by the German Cancer Aid (grant no 110837, coordinator: Rita K. Schmutzler, Cologne). This work was also funded by the European Regional Development Fund and Free State of Saxony, Germany (LIFE -Leipzig Research Centre for Civilization Diseases, project numbers 713241202, 713-241202, 14505/2470, 14575/2470). The GENICA was funded by the Federal Ministry of Education and Research (BMBF) Germany grants 01KW9975/5, 01KW9976/8, 01KW9977/0, and 01KW0114, the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, the Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, as well as the Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany. The GESBC was supported by the Deutsche Krebshilfe e. V. [70492] and the German Cancer Research Center (DKFZ). The HABCS study was supported by the Claudia von Schilling Foundation for Breast Cancer Research, by the Lower Saxonian Cancer Society, and by the Rudolf Bartling Foundation. The HEBCS was financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (266528), the Finnish Cancer Society, and the Sigrid Juselius Foundation. The HUBCS was supported by a grant from the German Federal Ministry of Research and Education (RUS08/017), and by the Russian Foundation for Basic Research and the Federal Agency for Scientific Organizations for support the Bioresource collections and RFBR grants 14-04-97088, 1729-06014 and 17-44-020498. Financial support for KARBAC was provided through the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet, the Swedish Cancer Society, The Gustav V Jubilee foundation and Bert von Kantzows foundation. The KARMA study was supported by Marit and Hans Rausings Initiative Against Breast Cancer. The KBCP was financially supported by the special Government Funding (EVO) of Kuopio University Hospital grants, Cancer Fund of North Savo, the Finnish Cancer Organizations, and by the strategic funding of the University of Eastern Finland. kConFab is supported by a grant from the National Breast Cancer Foundation, and previously by the National Health and Medical Research Council (NHMRC), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. LMBC is supported by the "Stichting tegen Kanker." The MARIE study was supported by the Deutsche Krebshilfe e.V. [70-2892-BR I, 106332, 108253, 108419, 110826, 110828], the Hamburg Cancer Society, the German Cancer Research Center (DKFZ) and the Federal Ministry of Education and Research (BMBF) Germany [01KH0402]. MBCSG is supported by grants from the Italian Association for Cancer Research (AIRC) and by funds from the Italian citizens who allocated the 5/1000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects "5x1000"). The MCBCS was supported by the NIH grants CA192393, CA116167, CA176785 an NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer [CA116201], and the Breast Cancer Research Foundation and a generous.pngt from the David F. and Margaret T. Grohne Family Foundation. MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants 209057 and 396414, and by infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry (VCR) and the Australian Institute of Health and Welfare (AIHW), including the National Death Index and the Australian Cancer Database. The MEC was supported by NIH grants CA63464, CA54281, CA098758, CA132839 and CA164973. The MISS study is supported by funding from ERC-2011294576 Advanced grant, Swedish Cancer Society, Swedish Research Council, Local hospital funds, Berta Kamprad Foundation, Gunnar Nilsson. The MMHS study was supported by NIH grants CA97396, CA128931, CA116201, CA140286 and CA177150. The NBCS has received funding from the K.G. Jebsen Centre for Breast Cancer Research; the Research Council of Norway grant 193387/V50 (to A-L Borresen-Dale and V.N. Kristensen) and grant 193387/H10 (to A-L Borresen-Dale and V.N. Kristensen), South Eastern Norway Health Authority (grant 39346 to A-L Borresen-Dale) and the Norwegian Cancer Society (to A-L Borresen-Dale and V.N. Kristensen). The NC-BCFR and OFBCR were supported by grant UM1 CA164920 from the National Cancer Institute (USA). The NCBCS was funded by Komen Foundation, the National Cancer Institute (P50 CA058223, U54 CA156733, U01 CA179715), and the North Carolina University Cancer Research Fund. The NHS was supported by NIH grants P01 CA87969, UM1 CA186107, and U19 CA148065. The NHS2 was supported by NIH grants UM1 CA176726 and U19 CA148065. The OBCS was supported by research grants from the Finnish Cancer Foundation, the Academy of Finland (grant number 250083, 122715 and Center of Excellence grant number 251314), the Finnish Cancer Foundation, the Sigrid Juselius Foundation, the University of Oulu, the University of Oulu Support Foundation and the special Governmental EVO funds for Oulu University Hospital-based research activities. The ORIGO study was supported by the Dutch Cancer Society (RUL 19971505) and the Biobanking and Biomolecular Resources Research Infrastructure (BBMRINL CP16). The PBCS was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. Genotyping for PLCO was supported by the Intramural Research Program of the National Institutes of Health, NCI, Division of Cancer Epidemiology and Genetics. The PLCO is supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics and supported by contracts from the Division of Cancer Prevention, National Cancer Institute, National Institutes of Health. The POSH study is funded by Cancer Research UK (grants C1275/A11699, C1275/C22524, C1275/A19187, C1275/A15956 and Breast Cancer Campaign 2010PR62, 2013PR044. PROCAS is funded from NIHR grant PGfAR 0707-10031. PROCAS is funded from NIHR grant PGfAR 0707-10031. The RBCS was funded by the Dutch Cancer Society (DDHK 2004-3124, DDHK 2009-4318). The SASBAC study was supported by funding from the Agency for Science, Technology and Research of Singapore (A*STAR), the US National Institute of Health (NIH) and the Susan G. Komen Breast Cancer Foundation. The SBCS was supported by Sheffield Experimental Cancer Medicine Centre and Breast Cancer Now Tissue Bank. SEARCH is funded by Cancer Research UK [C490/A10124, C490/A16561] and supported by the UK National Institute for Health Research Biomedical Research Centre at the University of Cambridge. The University of Cambridge has received salary support for PDPP from the NHS in the East of England through the Clinical Academic Reserve. SKKDKFZS is supported by the DKFZ. The SMC is funded by the Swedish Cancer Foundation and the Swedish Research Council (SIMPLER, VR 2017-00644). The SZBCS was supported by Grant PBZ_KBN_122/P05/2004. The UCIBCS component of this research was supported by the NIH [CA58860, CA92044] and the Lon V Smith Foundation [LVS39420]. The UKBGS is funded by Breast Cancer Now and the Institute of Cancer Research (ICR), London. ICR acknowledges NHS funding to the NIHR Biomedical Research Centre. The USRT Study was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. The WHI program is funded by the National Heart, Lung, and Blood Institute, the US National Institutes of Health and the US Department of Health and Human Services (HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C). This work was also funded by NCI U19 CA148065-01.

Barack Hussein Obama aparece cada vez con más claridad –aunque aún la última palabra no está dicha- como el próximo presidente de los Estados Unidos. Simultáneamente, la aún indefinida situación económica global –no hay ninguna duda de la magnitud histórica de la crisis del sector financiero, pero hay opiniones diversas respecto del nivel y carácter de su impacto futuro en el resto de la economía - ha inaugurado una serie de declaraciones fuertemente críticas acerca de la situación y el rol pasado, presente y futuro de los Estados Unidos en el mundo. Leyendo las informaciones y noticias que llegan desde Uruguay y desde otras zonas de América Latina –por ejemplo, algunas declaraciones particularmente fuertes de los presidentes de Brasil y Argentina en las últimas semanas- da la impresión que la crisis financiera ha servido de catalizador del fuerte antinorteamericanismo que ha caracterizado especialmente los últimos cinco años, a partir de la invasión a Irak en 2003. ¿Cuál sería el impacto de una eventual elección de Obama en ese discurso anti-norteamericano? Este impacto está ligado a dos grandes factores: la política exterior que el nuevo presidente siga, y el grado de predisposición de los críticos de Estados Unidos en el mundo a considerar los posibles cambios y sucesos internos en ese país como relevantes o no para formar su opinión sobre los Estados Unidos. En efecto, para nuestro razonamiento, se podría dividir, grosso modo, la actitud anti-norteamericana, en dos grandes posturas. Una es una postura que podemos llamar filosóficamente anti-norteamericana, y que, debido a que tiene tales diferencias de fondo con el capitalismo, la democracia liberal, y la política exterior de Estados Unidos, que califica en todos los casos de imperialista, resulta –en lo que toca a Estados Unidos- inmune a cualquier cambio interno del sistema, pues es el sistema mismo lo que se rechaza. Para esa forma de mirar, probablemente sería más cómodo que ganase McCain, pues un triunfo de McCain desestabilizaría menos el presente rechazo a Estados Unidos en el mundo, rechazo que incluye, entre otras, la noción de que se trata de una sociedad racista que, por definición, jamás podría elegir a un afroamericano como presidente (tal convicción, y la perplejidad ante los hechos presentes, la ha manifestado Fidel Castro en una declaración muy reciente). La otra gran zona de la actitud anti-norteamericana incluye la posibilidad de debatir rasgos y acentos internos de liberalismo y capitalismo, e incluso considerar diferentes formas y valores de la presencia norteamericana fuera de fronteras. Esta es una zona de la opinión que se ha visto fuertemente impactada, negativamente, por las acciones de la administración Bush, especialmente su intervención en Irak. La administración Bush y la política llevada adelante por el sector que ha controlado el partido Republicano en la última década ha funcionado como confirmación de que los Estados Unidos dieron la espalda a ciertos intereses ampliamente compartidos en el resto del mundo (globalización con respeto a la diversidad, no violencia, lucha por el mejoramiento del medio ambiente). El consiguiente rechazo a la presencia y rol norteamericanos –que ha crecido de modo exponencial en el último lustro-, puede experimentar cambios que lo maticen y lo disminuyan si, como cree la mayoría de los observadores políticos, Obama gana la elección el 4 de noviembre. Un factor decisivo en la formación de opinión de este segundo grupo será la política exterior de la nueva administración. ¿Cuál es, entonces, el posicionamiento de Obama respecto de la tradición de la política exterior americana? Pese a lo que la campaña republicana ha dicho, Obama no es un radical de izquierda, ni siquiera dentro del espectro del partido Demócrata. Se puede definir como un demócrata de centro, con una tendencia aproximadamente equilibrada respecto de las dos tradiciones principales de política exterior en su partido, en especial respecto de la guerra. Para explicar esto, hay que descartar primero toda idea de que el partido Demócrata sea una fuerza fundamentalmente contraria a las guerras. Para mostrarlo, basta recordar que el partido Demócrata estuvo en el poder en el inicio de todas las guerras importantes que los Estados Unidos pelearon durante el siglo XX: Woodrow Wilson tuvo que tomar la decisión de intervenir en la Primera Guerra mundial, Franklin Delano Roosevelt luego de Pearl Harbor en la Segunda, y Harry Truman inició la Guerra Fría con su decisión de arrojar las dos bombas atómicas en Hiroshima y Nagasaki en agosto de 1945, y estuvo involucrado en el lanzamiento de la guerra de Corea. También fue durante la administración de otro demócrata, John F. Kennedy, que se inició la guerra de Vietnam. De modo que no hay nada particularmente anti-belicista en la historia del partido Demócrata. Sí es cierto que se formó, frente al desarrollo de la guerra de Vietnam, una facción fuertemente anti-guerra dentro de ese partido, que elaboró en la década de los '60 su propia teoría doméstica del carácter imperialista de los Estados Unidos. Esa es la facción que alimentó el fuerte pacifismo de los años 60 que terminó con el retiro en derrota de los Estados Unidos de Vietnam. Esta facción radical del partido Demócrata (representada sobre todo por McGovern en los tempranos años '70) es la que debe contarse como representante de una postura no intervencionista, y como fuente de una crítica a muchas de las políticas contemporáneas del país, especialmente en lo que tiene relación con las dictaduras latinoamericanas de los años 70 –Jimmy Carter accedió al poder en parte apoyándose en el discurso creado por esta facción, y tuvo en su agenda el desmantelamiento de la CIA que había operado en los sesentas y primeros setentas, y lideró el cambio de rumbo de los Estados Unidos respecto a este tema en la última parte de aquella década. Pero Obama no representa simplemente a ese sector, aunque tenga algunos lazos con él. En la presente campaña se ha pronunciado muy claramente por una continuación de la intervención militar norteamericana en Medio Oriente. Por cierto, Obama se ha opuesto a la intervención en Irak, y fue uno de los parlamentarios que no apoyó con su voto la intervención desde el primer momento –a diferencia de su candidato a la vicepresidencia Joe Biden, quien sí lo hizo. Obama no apoya Irak, no porque considere que toda guerra es un crimen, sino porque considera que la guerra de Irak es la guerra equivocada. Pero, en cambio, ha repetido que debe incrementarse la presencia y la fuerza militar en Afganistán –en donde las cosas no están marchando bien para los relativamente escasos contingentes que permanecen en el territorio—, y también ha marcado la necesidad de "alinear" a Pakistán para que colabore más con los Estados Unidos en la guerra contra Al-Qaeda en las montañas del noroeste del país. Un segundo factor –descontado un anti-militarismo y anti-intervencionismo simple y llano de Obama, que no corresponde a la realidad— será la relación de Estados Unidos con sus aliados, especialmente europeos –priorizar las relaciones con Europa ha sido tradición del Partido Demócrata. Es aquí en donde más se ha marcado la potencialidad de Obama de devolver a Estados Unidos al diálogo internacional que virtualmente abandonó bajo el gobierno de Bush. Obama tiene uno de sus costados más interesantes en la lucidez con la que ha encarado la urgente necesidad de hacer reencontrar a los Estados Unidos con diversos actores mundiales que no tendrían razones filosóficas de fondo para estar tan distantes de ese país como están hoy –típicamente Francia y Alemania. Pero cuando Obama intente recuperar fuertes alianzas con las democracias europeas, se topará seguramente con tres factores: a) los problemas de presupuesto que esos países afrontan en medio de una crisis globalizada, que les limitan en su capacidad de acción militar; b) con los diversos compromisos de esas naciones –especialmente importantes los alemanes, que dependen de energía que viene de oriente- con Rusia; y c) con el fuerte anti-norteamericanismo que ha crecido entre la población europea en los últimos cinco años. Rusia, nuevamente, aparece como un actor decisivo, que parece dispuesto a empujar el tablero internacional hacia un formato de segunda guerra fría que, en muchos sentidos, sería un paso atrás respecto de los esfuerzos de desarme de los años 90. En este punto, no hay que descartar que Rusia (que ha dejado un pie en Georgia) haga alguna movida fuerte en estas próximas semanas, aprovechando la debilidad y el relativo caos interno por el que están pasando los Estados Unidos en este contexto de cambio de gobierno y complicaciones financieras y militares. Finalmente, la cuestión de la amenaza explícita de Irán sobre Israel y la consiguiente tensión en sentido contrario por parte de los israelitas, puede volverse más seria a medida que pase el tiempo. Y especialmente Irán y Rusia saben, como lo sabe Obama (quien lo repitió en los tres debates con McCain) que ninguna potencia puede mantener su supremacía militar si pierde su supremacía económica. El mensaje es claro: Estados Unidos tiene que solucionar sí o sí su situación económica si pretende aplicar cualquier política exitosa a nivel exterior. El panorama hoy, en ese aspecto, es sombrío para Estados Unidos; pero también es cierto que los recursos de renovación y recuperación de los Estados Unidos se han demostrado muy fuertes a lo largo de su historia, y no hay ninguna razón clara que haga pensar que no lo harán de nuevo en esta coyuntura. Esta cuestión de la necesaria independencia financiera que los estadounidenses contemplan con preocupación tiene un capítulo totalmente central en la necesidad de conquistar independencia energética. Este tema ha sido central a la campaña de ambos candidatos, y curiosamente no aparece destacado en las noticias sobre la misma que se publican fuera de Estados Unidos. Sin embargo, la centralidad de la cuestión energética está ligada directamente a un tema que interesa a todo el planeta, que es la cuestión del calentamiento global. Es sorprendente que los críticos de los Estados Unidos por su indiferencia –tenaz bajo la administración Bush- respecto de los problemas del cambio climático global, no hayan notado que van a ser probablemente los Estados Unidos, y muy probablemente en un plazo históricamente insignificante (Obama y McCain hablan de entre 5 y 10 años) los que ofrecerán al mundo las primeras soluciones tecnológicas viables en términos de energías alternativas. Para poner solo un ejemplo, relativo al transporte, digamos que el creador de eBay, Elon Musk ha fundado una nueva empresa, Tesla, y con ella ha producido, en pleno Silicon Valley, una zona carente de tradición en la industria automotriz, ya el prototipo de un coche eléctrico, el Roadster , que funciona con 6,000 baterías de iones de litio (las mismas que lleva un laptop) del tamaño de un dedo, y que es ya aproximadamente el doble más eficiente en términos de consumo de combustible que los actuales híbridos –sobre todo japoneses— a disposición en el mercado. El Roadster, recién en fase experimental, cuesta por ahora 109,000 dólares la unidad, pero Musk ya ha recibido unos 1,000 pedidos de gente que puede pagarlo, como Arnold Schwarzenegger y George Clooney. En cualquier caso, ya el combustible necesario para producir la energía eléctrica para recargar las baterías de estos coches es muy inferior al que sería consumido si anduvieran con nafta, de modo que su generalización sería un golpe gigantesco a la dependencia del petróleo que debilita a Estados Unidos (el transporte se lleva un escalofriante 30% de todo el consumo de petróleo del país), y la generalización en el mundo de soluciones de este tipo, y no solo en el transporte, significaría un cambio global de proporciones históricas. El Roadster, en su imperfecto estado inicial, puede ya recorrer 200 millas sin ver un enchufe, y para recargarlo sólo hace falta conectarlo a una toma común de corriente doméstica, que se puede instalar en cualquier garage. La General Motors, uno de los gigantes de la industria automovilística de Detroit (industria contemplada en los últimos tiempos por el país como un espacio torpe e incapaz de innovaciones) ha comprometido sin embargo su palabra y prestigio al decir que su primer coche eléctrico, el Chevy Volt, estará en venta al público en general en 2010. El Volt se basa en una filosofía algo más conservadora, pero ha optado por una perspectiva híbrida también mucho más eficiente que los modelos existentes ya hoy. Los estudios de la GM han indicado que el norteamericano medio recorre unas 40 millas (unos 60 km) por día en su coche. De modo que el Volt tendrá esa autonomía, y luego encenderá un pequeño motor de nafta para recargar las baterías, sin necesidad de enchufar o detener el coche. El sistema va unido a un GPS que viene de fábrica con el vehículo, en el que el conductor puede ingresar el destino de su viaje. Con esa información, el Volt encenderá su motor sólo el tiempo necesario para que la carga dada a las baterías permita llegar a ese destino, en donde el coche se podría enchufar, ahorrando así combustible fósil. Estos y otros programas actualmente en curso –y otros que un gobierno de Obama, especialmente, ha prometido aplicar o apoyar como prioridad nacional número uno- apuntan al gran objetivo de alcanzar independencia energética de las naciones petroleras, algunas de las cuales como Irán, Rusia o Venezuela están en las antípodas ideológicas y filosóficas de los Estados Unidos. De lograrlo, la consiguiente disminución de la importancia global de los países petroleros, y el mejoramiento del medio ambiente, contribuirían a hacer del mundo un lugar más limpio y, al menos potencialmente, más pacífico. Finalmente, América Latina no parece ocupar ningún lugar prominente en este mapa futuro de prioridades de política exterior para Obama. En su última polémica con McCain, oponiéndose a un reproche que el republicano le hizo porque los demócratas, que controlan el Congreso, no votaron el TLC con Colombia y lo hicieron fracasar, Obama respondió atacando al actual gobierno de Colombia por "violar los derechos humanos", una línea probablemente informada a Obama por sus asesores sobre América Latina, que parecen, por ahora, más partidarios de un apoyo a las izquierdas latinoamericanas representadas por Chávez, Evo Morales y Correa, en detrimento de los regímenes democrático liberales como los de Colombia, Perú o Chile. Si ese es realmente el rumbo que Obama va a tomar respecto de América Latina –cosa que aún no está clara, en la medida en que las señales de Obama sobre América Latina han sido tenues—, los próximos años verán un interesante intercambio de posiciones (lo que generaría una suerte de perplejidad ideológica continental) entre los 'antiimperialistas' por un lado, y los 'liberales de izquierda' (no se conoce casi ningún gobierno que no se considere "de izquierda" en América Latina, sea cual sea el contenido de su política social o económica) por otro. La perplejidad a que me refiero viene de la evidente contradicción existente entre futuros aliados ideológicos que sostienen, sin embargo, posiciones discursivas incompatibles respecto del capitalismo y el liberalismo. En el discurso de Evo Morales, Chávez o Correa –y aún hasta cierto punto en el de Cristina Kirchner— el capitalismo y el liberalismo son repetidamente atacados como formas malignas de organización económica y política. Si Obama se inclina a apoyar a esos regímenes y discursos en América Latina, veremos en los Estados Unidos a un aliado discursivo de los antiliberales y anticapitalistas latinoamericanos, pero que seguirá siendo totalmente liberal y capitalista –eso está, desde luego, completamente fuera de toda discusión-, y que además no tendrá sumas de dinero especialmente relevantes para enviar a Latinoamérica. Además, la nueva política energética norteamericana, como hemos visto, va en el sentido de cortar del todo su relativa dependencia de Venezuela, principal motor del nuevo antiimperialismo sureño. Si esto es así, los antiimperialistas de antaño tendrán a un extraño "aliado" ideológico en la Casa Blanca que, sin embargo, les dará muy poco en términos prácticos, aunque quizá al mismo tiempo les envíe nueva legitimidad discursiva desde el centro del mundo desarrollado. Al mismo tiempo, una administración de Obama puede contribuir a debilitar los principales dogmas que los antiimperialistas (especialmente los de línea dura como Chávez, Evo Morales o Kirchner) siempre han mantenido respecto a la política exterior yanqui, si ese país se retira de Irak, limita su intervención a una defensa legítima respecto de los atentados del 11 de setiembre, mejora sus alianzas globales, elige a un negro desvirtuando el racismo, aumenta su supremacía económica y militar (si el plan energético y de renovación tecnológica de Obama funciona, eso es probablemente lo que va a pasar), y elimina los aspectos irritantes de la política abiertamente intervencionista que bajo la administración Bush permitió, con toda razón, a los imperialistas de ambas clases ilustrar su postura con numerosos ejemplos cercanos en el tiempo. Como culminación de todo esto, semejantes cambios demostrarían que la democracia liberal goza de buena salud, en la medida en que sigue siendo capaz de criticarse a sí misma y cambiar de modo tan sustancial el rumbo de un país, en medio de tan grandes dificultades. En cambio, los liberales latinoamericanos, cuyo discurso aparece en derrota y marginado por todas partes en el continente en los últimos años, verán una continuación del triunfo de la economía de mercado y la globalización, al tiempo que no podrán ser ya acusados de ser apañados por los yanquis, quienes estarán quizá enviando ejércitos de jóvenes universitarios a colaborar en las campañas de alfabetización venezolanas. Un panorama interesantísimo, que al colapsar las trincheras ideológicas históricas, podría abrir un contacto y diálogo diferente entre las dos Américas, históricamente empantanado por la rigidez de esos esquemas ideológicos, característicos del siglo XX, y que aún orientan la discusión en tantos casos. Los asesores de Obama pueden estar equivocados en algunos puntos de su visión sobre América Latina (de hecho, creo que no reconocer la legitimidad de un gobierno con el apoyo popular del de Uribe en Colombia es un error), pero al menos cometen errores diferentes de los de sus predecesores, los que pueden llevar a una movida general de las fichas y a un nuevo diseño de la comprensión mutua entre dos continentes que, de momento, siguen entendiéndose muy poco. .- Para una visión persuasiva que mantiene que la crisis financiera no significa fatalmente crisis económica global, véase por ejemplo la columna de Casey B. Mulligan, profesor de Economía de la Universidad de Chicago, en el New York Times del 10 de octubre pasado: http://www.nytimes.com/2008/10/10/opinion/10mulligan.html?_r=1&scp=1&sq=Casey%20B.%20Mulligan&st=cse&oref=slogin * Assistant Professor en el Departamento de Estudios Hispánicos de la Universidad de Brown. Obtuvo su Doctorado en letras en la Universidad de Stanford. Se especializa en historia cultural de América Latina durante la modernización y en teoría de la literatura.

DER HERBST-FELDZUG 1914 ; 2. DER ABSCHLUSS DER OPERATIONEN IM WESTEN UND OSTEN Der Weltkrieg 1914 bis 1918 (-) Der Herbst-Feldzug 1914 ; 2. Der Abschluß der Operationen im Westen und Osten (6. 1929) ( - ) Einband ( - ) Titelseite ([IV]) Einführung zum fünften und sechsten Band. ([VII]) Inhaltsverzeichnis. ([IX]) Karten und Skizzen. (XII) Anmerkungen zu den Karten und Skizzen. (XIII) I. Neue Pläne für die Führung des Zweifrontenkrieges. ([1]) II. Der Krieg im Westen vom 4. bis zum 18. November bis zum Abschluß der Ypern-Kämpfe. ([10]) A. Die Kämpfe um Ypern. ([10]) 4. Armee 4. bis 9. November [38. Landwehr-brigade, 4. Ersatz-Division, 43. Reserve-Division, XXII. Reservekorps, XXIII. Reservekorps, III. Reservekorps, XXVI. und XXVII. Reservekorps]. (11) 6. Armee 3. bis 9. November [Menin, Ypern, Comines, XV. Armeekorps, II. bayerisches Armeekorps, Eikhof, St. Eloi, Wytschaete, Generalleutnant Wilhelm Herzog von Urach]. (12) 10. November [4. Armee, Dixmude, 4. Ersatz-Division, 43. Reserve-Division, XXIII. Reservekorps, 45. Reserve-Division]. (16) 11. November [4. Armee, XXII. und XIII. Reservekorps, III. Reservekorps, 9. Reserve-Division, 38. Landwehr-Brigade]. (17) 12. November [4. Armee, Marine-Division, Nieuport, 9. und 44. Reserve-Division, XXIII. Reservekorps, XXVI. und XXVII. Reservekorps, Brodfeinde, Comines]. (18) 13. bis 18. November [4. und 6. Armee, 9. und 44. Reserve-Division]. (21) B. Die Ereignisse an der übrigen Heeresfront. (25) C. Die Vorgänge beim Gegner. (29) III. Der Krieg im Osten bis zum Siege von Kutno. ([34]) A. Der "Oberbefehlshaber Ost" und seine ersten Entschlüsse. ([34]) 1. Die Gesamtlage an der Ostfront Ende Oktober. ([34]) Ende Oktober [Polen, Serbien, Feldzeugmeister Potiorek, Rumänien, Italien]. ([34]) 28. Oktober [Petrikau, General v. Mackensen, Gnesen, Thorn]. (36) 30. Oktober [General v. Falkenhayn, General v. Conrad, General v. Ludendorff]. (36) 1. November [General v. Mackensen]. (37) Anfang November [Generaloberst v. Hindenburg]. (38) 2. Die Ereignisse bis zum 3. November. (39) 27. Oktober [Österreichisch-ungarische 1. Armee, deutsche 9. Armee, San, Kjelzy, Freiherr v. Hauer, Gruppe Mackensen, XVII. Armeekorps, Korps Frommel, XI. Armeekorps, Noworadomsk, Wjelun, Kavalleriekorps Korda, Kalisch]. (39) 28. Oktober [9. Armee, Neu-Sandez, San, Kjelzy]. 30. Oktober [General v. Conrad, Garde-Reservekorps, XX. Armeekorps, Kjelzy, Noworadomsk, Generaloberst v. Hindenburg, Oberstleutnant Hoffmann]. (40) 31. Oktober [General v. Conrad, Oberst v. Sauberzweig, deutsche 9. Armee, 1. Armee, Kjelzy]. (40) 2. November [Generaloberst v. Hindenburg, General v. Mackensen, 9. Armee, Noworadomsk, Wjelun, Piliza]. (42) 3. Die ersten Maßnahmen für den Angriff auf den russischen Nordflügel. Meinungsverschiedenheiten mit General v. Conrad. (45) 3. November [Pschedborsh, russische 2. Armee, General Rennenkampf, Weichsel, Plozk, Gosthynin, 5. Armee, Msurki, Rospschy, Pschedborsy, 2. Armee]. (45) 4. November [Posen, Thorn, 9. Armee, XX. und XVII. Armeekorps, XXV. Reservekorps, 36. Reserve-Division, Thorn]. (48) Ende Oktober und Anfang November [Neu-Sandez, General v. Conrad, Berlin, Generalleutnant Freiherr v. Freytag-Loringhoven, Posen]. (49) 3. November [General v. Conrad]. (50) 5. November [Neu-Sandez, 1. Armee]. (51) 6. November [Generaloberst v. Hindenburg, General v. Conrad, Hauptmann v. Fleischmann, 1. Armee, Skala, Kromolow]. (51) 7. November [9. Armee, österreichische 1. Armee]. (52) 8. November [Oberberg, Ratibor, Oppeln, österreichisch-ungarische 2. Armee]. (53) 9. November [Krakau, österreichische 1. Armee]. (54) 11. November [Oberstleutnant Hentsch, Posen, General v. Falkenhayn, Schlesien]. (55) 12. November [Mézières, General Ludendorff, Galizien, General v. Conrad]. (55) B. Die Kämpfe bei Wlozlawek und Kutno. ([58]) 1. Die Bereitstellung der deutschen 9. Armee. ([58]) 4. November [Warthe, Weichsel, General v. Mackensen]. ([58]) 5. November [General v. Frommel, Kavalleriekorps Nowikow, General Nowikow, Krotoschin, Wreschen]. 7. November [Kosaken-Abteilung]. 9. November [General v. Frommel, Konin, General Nowikow]. (59) 10. November [General Nowikow, Kalisch, Warta, XI. Armeekorps]. (59) 2. Die Schlacht bei Wlozlawek. (65) 10. November [Wlozlawek, V. sibirische Korps, General v. Mackensen, , russische 2. und 1. Armee]. (65) 11. November [V. sibirische Korps, Bshechtj, Lubranjez, 6. Kavallerie-Division, 41. Infanterie-Diivision, Kavalleriekorps Schmettow, Isbiza, Lubranjec, General v. Scholtz, Generalleutnant v. Morgen, General Freiherr v. Scheffer-Boyadel]. (67) 12. November [V. sibirische Korps, 9. Armee, Lubjen, 9. Kavallerie-Division, Generalmajor Graf v. Schmettow (Eberhard), Chodetsch, Chozen]. (67) 13. November [XI. und XVII. Armeekorps, Kowal, Kavalleriekorps Schmettow, Gosthynin, Lubjen, XX. Armeekorps]. (69) 12. bis 13. November [Wlozlawek, Weichsel, V. sibirische Korps, Thorn, Lipno, Rypin, russisches VI. Korps, Generalleutnant v. Wrochen]. (71) 3. Die Schlacht bei Kutno. (71) 13. November [General Tschagin, 2. Armee, Wjelun, Kalisch, Thorn, Domb, Wjelki, Dsiankow, Lanjenta, Pjerowawola, Bsowki, Kosserz, Plozk]. (71) Die Kämpfe am 14. November. (73) Die Kämpfe am 15. November. (79) Die Kämpfe am 16. November. (85) Bewegungen der Russen - Würdigung der Schlacht von Kutno. (88) IV. Die Wandlung in den Entschlüssen des Generals v. Falkenhayn. ([92]) V. Der Krieg im Osten bis zum Jahresschluß. ([98]) A. Die Schlacht bei Lods. ([98]) 1. Die Maßnahmen des Oberbefehlshabers Ost. ([98]) 11. November [9. Armee]. ([98]) 12. November [Generaloberst v. Hindenburg, Thorn, General v. Conrad, Krakau]. ([98]) 13. November [Generaloberst v. Hindenburg, Warthe, Jarotschin, Kattowitz, Schlesien, Posen]. (99) 13. und 14. November [Generaloberst v. Hindenburg, Armee Woyrsch]. (100) 15. November [General v. Conrad, 4. Armee, Krakau]. (101) 16. November [Kutno]. (102) 17. November [9. Armee, Lods, Kalisch, Korps Posen, Korps Breslau]. (103) 2. Der Angriff der 9. Armee vom 17. bis 22. November. (104) a) Der Versuch zur überholenden Verfolgung am 17. und 18. November. (104) 16. November [9. Armee, Kavalleriekorps Nowikow, russische XXIII. Korps, Dombje, Piontek, russische IV. Korps, Warta, Aleksandrow, Sgjersh, Lods, Sdunska-Wola, Schadek]. (104) 17. November [Korps Posen, Schadek, Korps Plüskow, Poddembize, Aleksandrow, Korps Pannewitz]. (105) 18. November [XXV. Reservekorps, General v. Scheffer, Bshesiny, Strykow, Glowno, Wola-Zyrusowa, Njesulkow, Generalleutnant v. Thiesenhausen]. (108) 17 und 18. November [Lods, 9. Armee, I. Reservekorps, Lowitsch]. (112) b) Der umfassende Angriff gegen die Russen bei Lods vom 19. bis 22. November. (114) Die Auffassung des Oberkommandos. (114) Die Kämpfe am 19. November. (117) Das Armee-Oberkommando am 19. November. (122) Die Kämpfe am 20. November. (129) Das Armee-Oberkommando am 20. November. (138) Die Kämpfe am 21. November. (141) Das Armee-Oberkommando am 21. November. (149) Der 22. November. Das Ende der Umfassungsoperation. (152) 3. Die Wiederherstellung der Front vom 22. bis 25. November. (158) a) Die Gefahr im Rücken des XX. Armeekorps bis zum 24. November mittags. (158) 22. November [General v. Mackensen, Lods, Gruppe Scheffer, Kavalleriekorps Nowikow, XXV. Reservekorps]. (158) 23. November [Korps Breslau, Schtscherzow, Widawa, Warthe, Sdunska-Wola, Landwehr-brigade Schmiedecke, Kavalleriekorps Frommel, Korps Posen]. (161) 24. November [Warschau, Skjernewize, General v. Scheffer]. (166) b) Die Ereignisse bei der Gruppe Scheffer. (169) Der 22. November. (169) Der 23. November. (176) Der 24. November. (182) c) Das Ende der Krise. (185) 24. November [Bshesiny, XVII. Armeekorps, Biala, Strykow, Lods]. (186) 25. November [General v. Mackensen, russische 1. Armee, Lods, Lowitsch, XX. Armeekorps, 3. Garde-Division, Njesulkow, XXV. Reservekorps, Glowno]. (187) 4. Der Oberbefehlshaber Ost und die Schlacht von Lods. (188) 17. November [Kutno, Armee Woyrsch, Lods, 9. Armee, Hauptmann v. Fleischmann]. (188) 18. November [General Ludendorff]. (189) 19. November [Ostpreußen, Lötzen, Tschenstochau, Lods, 8. Armee]. (189) 20. November [Lods, 38. Infanterie-Division, Lowitsch, Gruppe Plozk, 9. Armee]. (190) 21. November [Generaloberst v. Hindennburg, , Lods, Woyrsch]. (191) 22. November [Mézières, Korps Breslau]. (192) 23. November [XXV. Reservekorps, Miasga, XX. Armeekorps, Krakua, Korps Thorn]. (192) 24. November [General v. Scheffer, 9. Armee, XX. Armeekorps, Lowitsch, I. Reservekorps, Posen, XXV. Reservekorps]. (193) 25. November [Generaloberst v. Hindenburg]. (193) 5. Die Operationen der Russen. (194) a) Die russischen Operationen von Anfang bis Mitte November. (194) Anfang November [General Rußki, 10. Armee, Lods, General Iwanow]. (194) 2. November [Großfürst Nikolaus, Thorn, Kalisch, Kjelzy, Weichsel, Kolo, Tschenstochau, Aufschwitz]. (196) 3. November. [San, General Joffre, Galizien]. (196) 10. November [Weichsel, Kalisch, Wjelun, Jarotschin, Kattowitz, Aufschwitz]. (197) 11. November [Thorn, Ostpreußen, Tschenstochau]. (198) 12. November [Großfürst Nikolaus]. (198) 13. November [Wlozlawek, Weichsel, V. sibirisches Korps, Gostynin, VI. sibirisches Korps, General Rußki]. (200) 14. November [Kutno, Weichsel, Warthe, Dombje, General Rennenkampf]. (201) 15. November [General Rußki, Warschau, Weichsel, Warthe, Klodawa, Kalisch]. (202) 16. November [Bsura-Ner-Abschnitt, Kavalleriekorps Nowikow, Sgiersy, General Rußki]. (203) 17. November [V. und VI. sibirisches Korps, Plozk, Weichsel, Sychlin, Pschysowa]. (204) 18. November [General Rußki, IV. Korps, Lowitsch, Wyschogrod, General Scheidemann]. (206) b) Die Abwehr der deutschen Umfassung bei Lods. (207) 18. November. (208) 19. November [6. Kavallerie-Division, General Rußki, General Plehwe, General Rennenkampf, 1. Armee, Bsura, Lods, Sanniki, Abteilung Schmid]. (208) 20. November [Korps Breslau, Sjerads, Gruppe Scheffer, Pabianize, General Rußki, Lods] (209) 21. November [1. Armee, Bsura, sibirische Korps, Lowitsch, General Plehwe]. (211) 22. November [Kavalleriekorps Nowikow, 10. Infanterie-Division, 1. sibirische Division, 6. Kavallerie-Division, XXV. Reservekorps, XX. Armeekorps]. (212) 23. November [1. Armee, Bsura, General von Rennenkampf, Wola-Rakowa]. (214) 24. November [XXV. Reservekorps, Bshesiny, russisches I. Korps, Galkowek, General Plehwe, General Scheidemann, 1. sibirische und 10. Division]. (216) 6. Betrachtungen. (218) B. Die österreichisch-ungarische Front bis zum 22. November. - Der Anteil der unterstellten deutschen Verbände. ([227]) 1. Der Rückzug vom San. ([227]) Anfang November [Weichsel]. ([227]) 2. November [1. Armee, Opatow, General v. Conrad, San, Generaloberst v. Hindenburg, Pschemysl]. 5. und 6. November [General Böhm-Ermolli, Pschemysl]. (231) 7. und 8. November [General v. Conrad, Karpaten, General Dankl, Neu-Sandez, Krakau]. (231) 9. November [Teschen, Oberstleutnant Hentsch, General v. Falkenhayn, Thorn, Schlesien, General v. Conrad]. (232) 13. November [Wlozlawek, Thorn, Generaloberst v. Hindenburg, General v. Conrad, General v. Woyrsch]. (233) 2. Die Schlacht nördlich Krakau. (233) 13. November [Karpaten, Generaloberst v. Hindenburg, 9. Armee]. (234) 15. November [General Freiherr v. Pflanzer-Baltin, Lysa-Paß, General Boroevic, Ushoker-Paß, Neu-Sandez, Pschemysl, Erzherzog Josef Ferdinand, Krakau]. (235) 16. November [4. Armee, Armee Woyrsch] (239) 17. bis 19. November [General v. Conrad, Armee Woyrsch]. (239) 20. bis 22. November [General v. Conrad, Krakau, Armee Woyrsch, 9. Armee, Slomniki, Proschowize]. (240) 3. Die Kämpfe der Armee Woyrsch. (241) 6. bis 13. November [Armee-Abteilung Woyrsch, 9. Armee, Oberleutnant Heye, Thorn, Sarki, Wjelun]. (241) 14. November [General v. Woyrsch, Lublinitz, Erzherzog Friedrich]. (241) 15. November [Österreichisch-ungarische 4. und 1. Armee, Krakau, Armee Woyrsch, General v. Gallwitz, Garde-Reservekorps Bredow, Tschenstochau]. (242) 16. November [Tschenstochau, Armee Woyrsch]. 17. November [General v. Woyrsch, 35. Reserve-Division, Warthe, Dsjaloschyn]. 18. November [35. Reserve-Division, österreichisch-ungarische 16. Infanterie-Division, Noworadomsk] (243) 19. und 20. November [General v. Conrad, österreichisch-ungarische 2. Armee, Noworadomsk, Korps Breslau, Schtscherzow, Widawa]. (244) 21. November [Österreichisch-ungarische 35. Infanterie-Division]. (245) 22. November [Warthe, österreichisch-ungarische 32. und 35. Infanterie-Division, Armee Woyrsch, General v. Conrad, Tschenstochau]. (245) 4. Hoffnungen und Entäuschungen bei der österreichisch-ungarischen Heeresleitung. (246) 16. und 17. November [4. Armee, General v. Conrad, General v. Falkenhayn]. (246) 19. November [General v. Falkenhayn, General v. Conrad, Galzien, Lods, Feldzeugmeister Potiorek, General v. Bolfras]. (247) 21. bis 23. November [Lods, Krakau, Weichsel, Dunajez]. (248) C. Der Einsazu der Verstärkungen aus dem Westen und der Fortgang der Kämpfe in Polen und Galizien. ([249]) 1. Wie sollten die Operationen weitergeführt werden? ([249]) 15. November [Generaloberst v. Hndenburg]. ([249]) 20. November [General v. Falkenhayn]. ([249]) 22. November [9. Armee, Lods, Thorn, Kutno, Lowitsch, Strykow, Kreuzburg, Ostrowo, Njeschawa]. (250) 23. November [Hauptmann v. Fleischmann, Krakau, General Ludendorff, Oberst Tappen, Lods]. (251) 24. November [9. Armee, XXIV. Reservekorps, XIII. Armeekorps]. (252) 25. November [Hauptmann v. Fleischmann, Teschen, General v. Falkenhayn]. (252) 26. November [General v. Falkenhayn, Spirding-See]. (254) 27. November [Generaloberst v. Hindenburg]. (256) 2. Die Einnahme von Lods. (257) a) Die Abwehr der 9. Armee bis zum 29. November. (257) 23. November [General v. Mackensen, II. Armeekorps]. (257) 25. November [General v. Scheffer, Sdunka-Wola]. (257) 26. November [Lentschyza, XXV. Reservekorps, Bshesiny, General v. Scheffer, Mroga, Glowno, Bsura]. (258) 27. November [Bjelawy, russisches VI. Korps, General v. Nowikow, Piontek, XX. Armeekorps]. (259) 28. November [Nowikow, Piontek, Strykow, XX. Armeekorps, XXV. Reservekorps, Bjelawy, Sobota, Mroga, Bsura]. (260) 29. November [Bsura, General Nowikow, Lentschyza, russisches II. Korps, Bjelawy, Glowno]. (261) 30. November [General v. Morgen, Sobota, Bsura, Mroga]. (262) b) Der Angriff der 9. Armee und die Kämpfe auf dem Nordflügel der Armee Woyrsch vom 30. November bis zum 6. Dezember. (263) Bis zum 29. November [9. Armee, II. Armeekorps, Kalisch, Schildberg, XXIV. Reservekorps, Kreuzberg, Armee Woyrsch, Noworadomsk, Warthe, Schtscherzow, Kavalleriekorps Hauer, General Terszthanszky]. (263) 29. November [XXIV. Reservekorps, Warthe, Widawa, General v. Gerok, Korps Breslau, Kavalleriekorps Frommel, Landwehr-Brigade Schmiedecke, Korps Breslau]. (264) 30. November [II. Armeekorps, General v. Linsingen, Landwehr-Brigade Schmiedecke, Sdunska-Wola, Korps Plüskow]. (269) 1. Dezember [General v. Woyrsch, General v. Böhm, Gruppe Linsingen, Kavalleriekorps Frommel, Korps Plüskow]. (271) 2. Dezember [Armee Woyrsch, Gruppe Linsingen, Schtscherzow, Belchatow, 48. Reserve-Division, Korps Gerok, Kavalleriekorps Frommel]. (273) 3. Dezember [Pabianize, Bjelawy, General v. Terszthanszky, 32. Infanterie-Division, Belchatow, Oberst v. Nostitz, Msurky, Kavalleriekorps Hauer]. (274) 4. Dezember [Korps Terszthyanszky, Borowa-Berg, Msurki]. (276) 5. Dezember [Korps Terszthyanszky, Feldmarschalleutnant, General v. Linsingen, Tuschyn, Jutroschew, Pabianize, Armee Woyrsch]. (278) 6. Dezember [9. Armee, Lentschyza, General Nowikow, XIX. Korps]. (279) c) Die Operationen der Russen und Betrachtungen. (280) 3. Der Angriff der 9. Armee gegen die untere Bsura. (285) 2. Dezember [Generalfeldmarschall v. Hindenburg, General Ludendorff, Breslau, General v. Falkenhayn, General v. Conrad, Deutscher Kaiser, Erzherzog Friedrich]. (285) 4. Dezember [9. Armee, Pabianize, Armee Woyrsch, III. kaukasisches Korps, Petrikau, Sjerads]. (286) 5. Dezember [General v. Fabeck] (287) 6. Dezember [General v. Conrad, Krakau, Armee Woyrsch, Sjerads, Weichsel, Polen, Lowitsch]. (287) 7. Dezember [Korps Fabeck, , II. Armeekorps, Weichsel, 21. Landwehr-Brigade, Plozk, Wolborsh, Wolborka, Miasga, Nowosolna, Rawka, Skjernewize, Sochatschew, Shirardow, Blonje, Grodsisk]. (288) 8. Dezember [Ilow, II. kaukasisches Korps, 7. und 8. sibirische Division, Gombin, Bjelawy, Lowitsch, Korps Fabeck]. (290) 9. Dezember [Korps Gerok, II. und XI. Armeekorps, Miasga, Korps Fabeck, Wsheliwy, III. Reservekorps, General Beseler, Slubize, 6. Reserve-Division]. (292) 10. Dezember [II. und XI. Armeekorps, General v. Linsingen, Miasga, XXV. Reservekorps, XVII. Armeekorps, Korps Fabeck, General v. Beseler]. (294) 11. Dezember [Miasga, General v. Linsingen, Wsheliwy, XVII. Armeekorps, 1. Infanterie-Division, 25. Reserve-Divsion, III. Reservekorps, Weichsel, General v. Beseler]. (295) 12. Dezember [XVII. Armeekorps, Korps Fabeck, 36. Infanterie-Division, Generalleutnant v. Heineccius, 5. Reserve-Division, General v. Beseler]. (295) 13. Dezember [XVII. Armeekorps, Korps Fabeck, III. und I. Reservekorps, Wyschogrod, Generalmajor Grünert, Bsura]. (297) 14. Dezember [General v. Mackensen]. (297) 4. Die Schlacht südlich Krakau. (299) Ende November [Österreichisch-ungarische 4. Armee, General v. Conrad, Krakau, 47. Reserve-Division]. (299) 2. Dezember [Breslau, Neu-Sandez, Teschen, Krakau, Dunajez, West-Beskiden, Weichsel]. (299) 3. bis 6. Dezember [XIV. Korps, Tymbark, 47. Reserve-Division, Korps Ljubicic, Bochnia]. (301) 7. bis 11. Dezember [Limanova, Raba-Knie, Bochnia, 47. Reserve-Division, Rschegozina, Rajbrot, VI. und XIV. Korps, Limanowa, Lapanow, Bochnia]. (302) Bis zum 14. Dezember [Weichsel, Gruppe Roth, General v. Conrad, 3. und 4. Armee]. (303) 5. Der Rückzug der Russen und die Verfolgung. (305) 15. Dezember [russische XIV. Korps, Petrikau, Wolborsh, Krakau, österreichisch-ungarische 4. und 1. Armee, Bsura] (305) 16. Dezember [4. und 1. Armee, XVII. Armeekorps, Korps Fabeck, Sochatschew, Bsura, Korps Gallwitz, Armee Woyrsch, Krakau, Tarnow, Rscheschow]. (307) 17. Dezember [9. Armee, Piliza, Utrata, Nowogeorgiewsk, Warschau, Generaloberst v. Mackensen, Bolimow, Grodsisk, III. Reservekorps]. (309) 18. Dezember [General v. Frommel, Wolborsh, Miasga, Piliza, Nowo-mjasto, Grojez, Tartschyn, Mschtschonow]. (311) 19. Dezember [Bsura, Korps Fabeck, Rawka, Weichsel]. (313) 19 und 20. Dezember [Rawka, Bsura, III. Reservekorps, Piliza]. (314) 21. Dezember [General v. Conrad, San, Weichsel]. (315) 6. Die Operationen der Russen und Betrachtungen. (317) Ende November [Galizien, Mlawa]. (317) 30. November [General Iwanow, Krakau, Petrikau]. (318) 4. Dezember [Lods, General Joffre]. (318) Nordwestfront unter General Rußki. (319) Südwestfront unter General Iwanow. (319) Nach dem 6. Dezember [11. Armee, Pschemysl]. (320) 13. und 14. Dezember [Bsura, Krakau, Brest-Litowsk, Piliza]. (320) 15. Dezember [1. Armee, V. und VI. sibirische und II. kaukasische Korps]. (321) 17. Dezember [General Rußki, Bsura, Rawka, Iwangorod, Galizien]. (321) 18. Dezember [IV. sibirische Korps, General Rußki, Bsura, Rawka]. (322) D. Die ostpreußische Front im November und Dezember. ([324]) 1. Die Kämpfe der 8. Armee. ([324]) a) Die Einleitung des Rückzuges in die Lötzen-Angerapp-Stellung unter General v. Francois. ([324]) 2. Dezember [XVII. Armeekorps, Thorn, Danzig, Neidenburg, Graudenz, Generalmajor Grünert, Freiherr Schmidt v. Schmidtseck, General v. Francois]. ([324]) 2. bis 4. Dezember [36. Reserve-Division, Lötzen, Gumbinnen, Insterburg, General v. Francois, XXV. Reservekorps, Bialla, Lyck, Marggrabowa, Pscherosl, Gruppe Jacobi]. (326) 5. November [27. Infanterie-Division, Pillupönen, 1. Reserve-Division, Generalleutnant v. Förster]. (326) 5. und 6. November [Marggrabowa, russisches III. Korps, General v. Below]. (328) 7. November [I. Armeekorps, Generalleutnant Brecht, Korps Below, Mehlkehmen, Stallupönen, General v. Francois, Tollmingkehmen, Soginten]. (328) 8. November [I. Armeekorps, Pillupönen]. (329) b) Die Durchführung des Rückzuges unter General Otto v. Below und die Abwehr bis zum Jahresschluß. (331) 9. bis 12. November [Tollmingkehmen, Stallupönen, Lötzen, Angerapp, 3. Reserve-Division, Darkehmen, Trakehnen]. (332) 13. November [I. Armeekorps, 9. und 70. Landwehr-Brigade, Generalmajor v. Böckmann, Generalleutnant Kosch, Gawaiten, Kleszowen]. (332) 14. November [3. Reserve-Division]. (333) 14. bis 16. November [Gawaiten, 1. Kavallerie-Division, General v. Below, Gumbinnen]. (334) 15. bis 17. November [XXV. Reservekorps, Generalleutnant v. Einem, Löwentin-See, III. sibirisches Korps, Kruglinner-See, russisches XXVI. Korps, Landwehr-Division Jacobi]. (336) 18. bis 20. November [III. sibirisches Korps, General v. Below, Lötzen, General v. Below]. (337) 20. bis 30. November [Generalleutnant Kosch, I. Armeekorps, Neidenburg, Ortelsburg, Nikolaiken, Lötzen, Darkehmen, Gumbinnen]. (338) Dezember [II. kaukasisches Korps, Lötzen, Paprodtker]. (338) 2. Die Kämpfe an der ostpreußischen Südfront. (340) Anfang November [Ostpreußen, Generaloberst v. Hindenburg, Tannenberg, Soldau, Thorn, Neidenburg, Jedwabno, Graudenz]. (340) 7. bis 16. November [I. turkestanische Korps, Division Breugel, Soldau, Neidenburg, Thorn]. (341) 16. und 17. November [Soldau, Generalleutnant v. Zastrow, Neidenburg]. (342) 19. bis 22. November [Korps Graudenz, Mlawa, Zjechanow, Generalleutnant v. Garnier, 4. Kavallerie-Division]. (342) 23. bis 25. November [Generalleutnant v. Hollen, Generalleutnant v. Zastrow, Korps Graudenz, Zjechanow, Division Wernitz, Prasnysch, Opinogora]. (343) 25. und 26. November [Sjerpez, 2. Kavallerie-Division]. (344) 29. November [Mlawa, I. turkestanisches Korps, General v. Zastrow, Prasnysch]. 3. bis 7. Dezember [2. Kavallerie-Division, 8. Kavallerie-Brigade, Prasnysch, Generalmajor Freiherr v. Thumb, Generalleutnant v. Zastrow, Zjechanow]. (345) 9. bis 18. dezember [Generalleutnant v. Zastrow, Mlawa, Soldau, Neidenburg]. (346) 19. bis 31. Dezember [Generalleutnant v. Zastrow, Generalmajor Surén, Grandenz, 2. Kavallerie.Division]. (346) 3. Die Operationen der Russen. (347) Bis 2. November [Ostpreußen, VI. und I. turkestanisches Korps, Grajewo, Lyck, Narew, 1. und 10. Armee, General Siewers]. (347) Bis 15. November [General Rußki, Kowno, Olita, 6. sibirische Division, General Siewers, Lyck, XX., II. kaukasisches, XXII., XXVI. Reservekorps, Kavalleriekorps Gurko, Marggrabowa, Angerapp]. (348) Bis Ende November [10. Armee, 6. sibirische Division, II. kaukasische, 5. Schützen-Brigade, General Siewers]. (349) Dezember [10. Armee, Lods, Lötzen, General Oranowski, General Siewers]. (350) Bis 17. November [Ostpreußen, 1. russische Armee, Weichsel, General v. Rennenkampf, I. turkestanisches Korps, 4. Don-Kosaken-Division, Mlawa, Plonsk, VI sibirische Korps, Sjerpez, Soldau]. (352) Bis Ende Dezember [Mlawa, Lods, Polen, turkestanische Korps, Prasnysch, Zjechanow]. (353) E. Die Lage im Osten bei Jahresschluß und Ergebnisse des Feldzuges im Osten. ([354]) 1. Der Abschluß der Kämpfe in Polen und Galizien. - Auffassungen der Führer im Osten. ([354]) 16. bis 21. Dezember [General v. Conrad, Karpathen, General v. Falkenhayn, General Ludendorff, Oppeln]. ([354]) Bis Ende Dezember [Weichsel, Rida]. (355) Ende Dezember [Generalfeldmarschall v. Hindenburg, Piliza, Rawka, Bsura]. (358) 2. Betrachtungen. (364) VI. Der Krieg im Westen bis zum Jahresschluß. ([371]) A. Stellungskämpfe bis zum 31. Dezember. ([371]) 1. Die Neuordnung des Westheeres bis zum 10. Dezember. ([371]) 2. Die Entlastungsoffensive der Alliierten. (380) 3. Betrachtungen. (385) B. Die Entwicklung des Stellungskrieges. ([394]) Das Werden des Stellungskrieges auf der Westfront. ([394]) Die Anerkennung des Stellungskrieges als Kampfform des Westheeres. (398) Der Stand der Taktik und Technik des Stellungskrieges gegen Ende 1914. (401) VII. Entscheidungslose Kriegführung. ([405]) Rückblick. ([433]) [Anhang] ([449]) Anlage 1. Kriegsgliederung. ([449]) Das deutsche Westheer. ([449]) Das französische Heer. (456) Das britische Heer. Das belgische Heer. (458) Das deutsche Ostheer. (459) Das österreichisch-ungarische Heer. (461) Das russische Heer. (463) Anlage 2. Truppenverschiebungen (468) [Tabelle]: Truppenverschiebungen an der deutschen Westfront und von dort nach dem Osten vom 3. November bis 31. Dezember 1914. (468) [Tabelle]: Truppenverschiebungen an der deutschen Ostfront vom 3. November bis 31. Dezember 1914. (477) Anlage 3. Allgemeine Bemerkungen. (480) Quellennachweis. (483) 1. Deutsche Quellen. 2. Österreichisch-ungarische Quellen. (483) 3. Französische Quellen. (483) 4. Englische Quellen. (484) 5. Belgische Quelle. (485) 6. Russische Quellen. (485) Personenverzeichnis. ([487]) Truppenverzeichnis. ([493]) Deutschland. ([493]) Österreich-Ungarn. (497) Türkei. Belgien. England. (498) Frankreich. (498) Rußland. (499) [Karten] ( - ) [Karte]: Nr. 1. Die Kriegsschauplätze der Mittelmächte im Dezember 1914. ( - ) [Karte]: Nr. 2. Das deutsche Westheer am 18. November 1914. ( - ) [Karte]: Nr. 3. Der Kampf an der Yser und im Ypernbogen vom 10. bis 12. November 1914. ( - ) [2 Karten]: Nr. 4. u. Nr. 5. Der Kampf um den Ypernbogen vom 4. bis 11. November 1914. (1)Nr. 4. Nach deutschen Quellen. (2)Nr. 5. Nach französisch-englischen Quellen. ( - ) [Karte]: Nr. 6. Die Gesamtfront gegen Rußland am 3. November 1914. ( - ) [2 Karten]: Nr. 7. u. Nr. 8. Die Schlacht bei Wlozlawek am 11. und 12. November 1914. (1)Nr. 7. (2)Nr. 8. ( - ) [Karte]: Nr. 9. Die Schlacht bei Kutno vom 14. bis 16. November 1914. ( - ) [Karte]: Nr. 10. Die Gesamtfront gegen Rußland am 16. November 1914 abends. ( - ) [2 Karten]: Nr. 11. u. Nr. 12. Die Schlacht bei Lods (1)Nr. 11. vom 17. bis 19. November 1914. (1)Nr. 12. am 20. und 21. November 1914. ( - ) [2 Karten]: Nr. 13. u. Nr. 14. Die Schlacht bei Lods am 22. und 23. November 1914. (1)Nr. 13. (2)Nr. 14. ( - ) [2 Karten]: Nr. 15. (1)Die Gesamtfront gegen Rußland am 25. November 1914. (2)Die Schlacht nördl. Krakau ( - ) [2 Karten]: Nr. 16. u. Nr. 17. (1)Nr. 16. Der Abschluß der Schlacht bei Lods am 24. und 25. November 1914. (2)Nr. 17. Die Kämpfe auf dem Nordflügel der 9. Armee vom 26. bis 30. November 1914. ( - ) [2 Karten]: Nr. 18. u. Nr. 20. (1)Nr. 18. Die Einnahme von Lods. Die Kämpfe vom 30. November bis 6. Dezember 1914. (2)Nr. 20. Der Angriff gegen Bsura und Rawka vom 6. bis 29. Dezember 1914. ( - ) [Karte]: Nr. 19. Die Gesamtfront gegen Rußland am 6. Dezember 1914 und die Verfolgung bis zum Jahresschluß. ( - ) [4 Karten]: Nr. 21. (1)Die Kämpfe in Ostpreußen im November und Dezember 1914. (2)Die Kämpfe um die Feldstellung Lötzen. (3)Die Kämpfe am 7. und 8. November (4)Die Kämpfe am 12. u. 13. November ( - ) Einband ( - ) Einband ( - )

Abstract Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move into early stage clinical trials as quickly as it is safe, and if successful, these therapies should efficiently obtain regulatory approval and widespread clinical application. In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an "Immunotherapy Summit" with representatives from immunotherapy organizations representing Europe, Japan, China and North America to discuss collaborations to improve development and delivery of cancer immunotherapy. One of the concepts raised by SITC and defined as critical by all parties was the need to identify hurdles that impede effective translation of cancer immunotherapy. With consensus on these hurdles, international working groups could be developed to make recommendations vetted by the participating organizations. These recommendations could then be considered by regulatory bodies, governmental and private funding agencies, pharmaceutical companies and academic institutions to facilitate changes necessary to accelerate clinical translation of novel immune-based cancer therapies. The critical hurdles identified by representatives of the collaborating organizations, now organized as the World Immunotherapy Council, are presented and discussed in this report. Some of the identified hurdles impede all investigators; others hinder investigators only in certain regions or institutions or are more relevant to specific types of immunotherapy or first-in-humans studies. Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer.

Acknowledgements A full list of acknowledgments appears in the Supplementary Note 4. Co-author A.J.M.d.C. recently passed away while this work was in process. This work was performed under the auspices of the Genetic Investigation of ANthropometric Traits (GIANT) consortium. We acknowledge the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium for encouraging CHARGE studies to participate in this effort and for the contributions of CHARGE members to the analyses conducted for this research. Funding for this study was provided by the Aase and Ejner Danielsens Foundation; Academy of Finland (41071, 77299, 102318, 110413, 117787, 121584, 123885, 124243, 124282, 126925, 129378, 134309, 286284); Accare Center for Child and Adolescent Psychiatry; Action on Hearing Loss (G51); Agence Nationale de la 359 Recherche; Agency for Health Care Policy Research (HS06516); ALF/LUA research grant in Gothenburg; ALFEDIAM; ALK-Abelló A/S; Althingi; American Heart Association (13POST16500011); Amgen; Andrea and Charles Bronfman Philanthropies; Ardix Medical; Arthritis Research UK; Association Diabète Risque Vasculaire; Australian National Health and Medical Research Council (241944, 339462, 389875, 389891, 389892, 389927, 389938, 442915, 442981, 496739, 552485, 552498); Avera Institute; Bayer Diagnostics; Becton Dickinson; BHF (RG/14/5/30893); Boston Obesity Nutrition Research Center (DK46200), Bristol-Myers Squibb; British Heart Foundation (RG/10/12/28456, RG2008/08, RG2008/014, SP/04/002); Medical Research Council of Canada; Canadian Institutes for Health Research (FRCN-CCT-83028); Cancer Research UK; Cardionics; Cavadis B.V., Center for Medical Systems Biology; Center of Excellence in Genomics; CFI; CIHR; City of Kuopio; CNAMTS; Cohortes Santé TGIR; Contrat de Projets État-Région; Croatian Science Foundation (8875); Danish Agency for Science, Technology and Innovation; Danish Council for Independent Research (DFF-1333-00124, DFF-1331-00730B); County Council of Dalarna; Dalarna University; Danish Council for Strategic Research; Danish Diabetes Academy; Danish Medical Research Council; Department of Health, UK; Development Fund from the University of Tartu (SP1GVARENG); Diabetes Hilfs- und Forschungsfonds Deutschland; Diabetes UK; Diabetes Research and Wellness Foundation Fellowship; Donald W. Reynolds Foundation; Dr Robert Pfleger-Stiftung; Dutch Brain Foundation; Dutch Diabetes Research Foundation; Dutch Inter University Cardiology Institute; Dutch Kidney Foundation (E033); Dutch Ministry of Justice; the DynaHEALTH action No. 633595, Economic Structure Enhancing Fund of the Dutch Government; Else Kröner-Fresenius-Stiftung (2012_A147, P48/08//A11/08); Emil Aaltonen Foundation; Erasmus University Medical Center Rotterdam; Erasmus MC and Erasmus University Rotterdam; the Municipality of Rotterdam; Estonian Government (IUT20-60, IUT24-6); Estonian Research Roadmap through the Estonian Ministry of Education and Research (3.2.0304.11-0312); European Research Council (ERC Starting Grant and 323195:SZ-245 50371-GLUCOSEGENES-FP7-IDEAS-ERC); European Regional Development Fund; European Science Foundation (EU/QLRT-2001-01254); European Commission (018947, 018996, 201668, 223004, 230374, 279143, 284167, 305739, BBMRI-LPC-313010, HEALTH-2011.2.4.2-2-EU-MASCARA, HEALTH-2011-278913, HEALTH-2011-294713-EPLORE, HEALTH-F2-2008-201865-GEFOS, HEALTH-F2-2013-601456, HEALTH-F4-2007-201413, HEALTH-F4-2007-201550-HYPERGENES, HEALTH-F7-305507 HOMAGE, IMI/115006, LSHG-CT-2006-018947, LSHG-CT-2006-01947, LSHM-CT-2004-005272, LSHM-CT-2006-037697, LSHM-CT-2007-037273, QLG1-CT-2002-00896, QLG2-CT-2002-01254); Faculty of Biology and Medicine of Lausanne; Federal Ministry of Education and Research (01ZZ0103, 01ZZ0403, 01ZZ9603, 03IS2061A, 03ZIK012); Federal State of Mecklenburg-West Pomerania; Fédération Française de Cardiologie; Finnish Cultural Foundation; Finnish Diabetes Association; Finnish Foundation of Cardiovascular Research; Finnish Heart Association; Fondation Leducq; Food Standards Agency; Foundation for Strategic Research; French Ministry of Research; FRSQ; Genetic Association Information Network (GAIN) of the Foundation for the NIH; German Federal Ministry of Education and Research (BMBF, 01ER1206, 01ER1507); GlaxoSmithKline; Greek General Secretary of Research and Technology; Göteborg Medical Society; Health and Safety Executive; Healthcare NHS Trust; Healthway; Western Australia; Heart Foundation of Northern Sweden; Helmholtz Zentrum München—German Research Center for Environmental Health; Hjartavernd; Ingrid Thurings Foundation; INSERM; InterOmics (PB05 MIUR-CNR); INTERREG IV Oberrhein Program (A28); Interuniversity Cardiology Institute of the Netherlands (ICIN, 09.001); Italian Ministry of Health (ICS110.1/RF97.71); Italian Ministry of Economy and Finance (FaReBio di Qualità); Marianne and Marcus Wallenberg Foundation; the Ministry of Health, Welfare and Sports, the Netherlands; J.D.E. and Catherine T, MacArthur Foundation Research Networks on Successful Midlife Development and Socioeconomic Status and Health; Juho Vainio Foundation; Juvenile Diabetes Research Foundation International; KfH Stiftung Präventivmedizin e.V.; King's College London; Knut and Alice Wallenberg Foundation; Kuopio University Hospital; Kuopio, Tampere and Turku University Hospital Medical Funds (X51001); La Fondation de France; Leenaards Foundation; Lilly; LMUinnovativ; Lundberg Foundation; Magnus Bergvall Foundation; MDEIE; Medical Research Council UK (G0000934, G0601966, G0700931, MC_U106179471, MC_UU_12019/1); MEKOS Laboratories; Merck Santé; Ministry for Health, Welfare and Sports, The Netherlands; Ministry of Cultural Affairs of Mecklenburg-West Pomerania; Ministry of Economic Affairs, The Netherlands; Ministry of Education and Culture of Finland (627;2004-2011); Ministry of Education, Culture and Science, The Netherlands; Ministry of Science, Education and Sport in the Republic of Croatia (108-1080315-0302); MRC centre for Causal Analyses in Translational Epidemiology; MRC Human Genetics Unit; MRC-GlaxoSmithKline pilot programme (G0701863); MSD Stipend Diabetes; National Institute for Health Research; Netherlands Brain Foundation (F2013(1)-28); Netherlands CardioVascular Research Initiative (CVON2011-19); Netherlands Genomics Initiative (050-060-810); Netherlands Heart Foundation (2001 D 032, NHS2010B280); Netherlands Organization for Scientific Research (NWO) and Netherlands Organisation for Health Research and Development (ZonMW) (56-464-14192, 60-60600-97-118, 100-001-004, 261-98-710, 400-05-717, 480-04-004, 480-05-003, 481-08-013, 904-61-090, 904-61-193, 911-11-025, 985-10-002, Addiction-31160008, BBMRI–NL 184.021.007, GB-MaGW 452-04-314, GB-MaGW 452-06-004, GB-MaGW 480-01-006, GB-MaGW 480-07-001, GB-MW 940-38-011, Middelgroot-911-09-032, NBIC/BioAssist/RK 2008.024, Spinozapremie 175.010.2003.005, 175.010.2007.006); Neuroscience Campus Amsterdam; NHS Foundation Trust; National Institutes of Health (1RC2MH089951, 1Z01HG000024, 24152, 263MD9164, 263MD821336, 2R01LM010098, 32100-2, 32122, 32108, 5K99HL130580-02, AA07535, AA10248, AA11998, AA13320, AA13321, AA13326, AA14041, AA17688, AG13196, CA047988, DA12854, DK56350, DK063491, DK078150, DK091718, DK100383, DK078616, ES10126, HG004790, HHSN268200625226C, HHSN268200800007C, HHSN268201200036C, HHSN268201500001I, HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, HHSN271201100004C, HL043851, HL45670, HL080467, HL085144, HL087660, HL054457, HL119443, HL118305, HL071981, HL034594, HL126024, HL130114, KL2TR001109, MH66206, MH081802, N01AG12100, N01HC55015, N01HC55016, N01C55018, N01HC55019, N01HC55020, N01HC55021, N01HC55022, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, N01HC95159, N01HC95160, N01HC95161, N01HC95162, N01HC95163, N01HC95164, N01HC95165, N01HC95166, N01HC95167, N01HC95168, N01HC95169, N01HG65403, N01WH22110, N02HL6‐4278, N01-HC-25195, P01CA33619, R01HD057194, R01HD057194, R01AG023629, R01CA63, R01D004215701A, R01DK075787, R01DK062370, R01DK072193, R01DK075787, R01DK089256, R01HL53353, R01HL59367, R01HL086694, R01HL087641, R01HL087652, R01HL103612, R01HL105756, R01HL117078, R01HL120393, R03 AG046389, R37CA54281, RC2AG036495, RC4AG039029, RPPG040710371, RR20649, TW008288, TW05596, U01AG009740, U01CA98758, U01CA136792, U01DK062418, U01HG004402, U01HG004802, U01HG007376, U01HL080295, UL1RR025005, UL1TR000040, UL1TR000124, UL1TR001079, 2T32HL007055-36, T32GM074905, HG002651, HL084729, N01-HC-25195, UM1CA182913); NIH, National Institute on Aging (Intramural funding, NO1-AG-1-2109); Northern Netherlands Collaboration of Provinces; Novartis Pharma; Novo Nordisk; Novo Nordisk Foundation; Nutricia Research Foundation (2016-T1); ONIVINS; Parnassia Bavo group; Pierre Fabre; Province of Groningen; Päivikki and Sakari Sohlberg Foundation; Påhlssons Foundation; Paavo Nurmi Foundation; Radboud Medical Center Nijmegen; Research Centre for Prevention and Health, the Capital Region of Denmark; the Research Institute for Diseases in the Elderly; Research into Ageing; Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center; Roche; Royal Society; Russian Foundation for Basic Research (NWO-RFBR 047.017.043); Rutgers University Cell and DNA Repository (NIMH U24 MH068457-06); Sanofi-Aventis; Scottish Government Health Directorates, Chief Scientist Office (CZD/16/6); Siemens Healthcare; Social Insurance Institution of Finland (4/26/2010); Social Ministry of the Federal State of Mecklenburg-West Pomerania; Société Francophone du 358 Diabète; State of Bavaria; Stiftelsen för Gamla Tjänarinnor; Stockholm County Council (560183, 592229); Strategic Cardiovascular and Diabetes Programmes of Karolinska Institutet and Stockholm County Council; Stroke Association; Swedish Diabetes Association; Swedish Diabetes Foundation (2013-024); Swedish Foundation for Strategic Research; Swedish Heart-Lung Foundation (20120197, 20150711); Swedish Research Council (0593, 8691, 2012-1397, 2012-1727, and 2012-2215); Swedish Society for Medical Research; Swiss Institute of Bioinformatics; Swiss National Science Foundation (3100AO-116323/1, 31003A-143914, 33CSCO-122661, 33CS30-139468, 33CS30-148401, 51RTP0_151019); Tampere Tuberculosis Foundation; Technology Foundation STW (11679); The Fonds voor Wetenschappelijk Onderzoek Vlaanderen, Ministry of the Flemish Community (G.0880.13, G.0881.13); The Great Wine Estates of the Margaret River Region of Western Australia; Timber Merchant Vilhelm Bangs Foundation; Topcon; Tore Nilsson Foundation; Torsten and Ragnar Söderberg's Foundation; United States – Israel Binational Science Foundation (Grant 2011036), Umeå University; University Hospital of Regensburg; University of Groningen; University Medical Center Groningen; University of Michigan; University of Utrecht; Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) (b2011036); Velux Foundation; VU University's Institute for Health and Care Research; Västra Götaland Foundation; Wellcome Trust (068545, 076113, 079895, 084723, 088869, WT064890, WT086596, WT098017, WT090532, WT098051, 098381); Wissenschaftsoffensive TMO; Yrjö Jahnsson Foundation; and Åke Wiberg Foundation. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute (NHLBI); the National Institutes of Health (NIH); or the U.S. Department of Health and Human Services. ; Peer reviewed ; Publisher PDF

Purpose: Enrolling traumatic brain injury (TBI) patients with an inability to provide informed consent in research is challenging. Alternatives to patient consent are not sufficiently embedded in European and national legislation, which allows procedural variation and bias. We aimed to quantify variations in informed consent policy and practice. Methods: Variation was explored in the CENTER-TBI study. Policies were reported by using a questionnaire and national legislation. Data on used informed consent procedures were available for 4498 patients from 57 centres across 17 European countries. Results: Variation in the use of informed consent procedures was found between and within EU member states. Proxy informed consent (N = 1377;64%) was the most frequently used type of consent in the ICU, followed by patient informed consent (N = 426;20%) and deferred consent (N = 334;16%). Deferred consent was only actively used in 15 centres (26%), although it was considered valid in 47 centres (82%). Conclusions: Alternatives to patient consent are essential for TBI research. While there seems to be concordance amongst national legislations, there is regional variability in institutional practices with respect to the use of different informed consent procedures. Variation could be caused by several reasons, including inconsistencies in clear legislation or knowledge of such legislation amongst researchers. ; Peer reviewed

Abstract: Background: The European Union (EU) aims to optimize patient protection and efficiency of health-care research by harmonizing procedures across Member States. Nonetheless, further improvements are required to increase multicenter research efficiency. We investigated IRB procedures in a large prospective European multicenter study on traumatic brain injury (TBI), aiming to inform and stimulate initiatives to improve efficiency. Methods: We reviewed relevant documents regarding IRB submission and IRB approval from European neurotrauma centers participating in the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI). Documents included detailed information on IRB procedures and the duration from IRB submission until approval(s). They were translated and analyzed to determine the level of harmonization of IRB procedures within Europe. Results: From 18 countries, 66 centers provided the requested documents. The primary IRB review was conducted centrally (N = 11, 61%) or locally (N = 7, 39%) and primary IRB approval was obtained after one (N = 8, 44%), two (N = 6, 33%) or three (N = 4, 23%) review rounds with a median duration of respectively 50 and 98 days until primary IRB approval. Additional IRB approval was required in 55% of countries and could increase duration to 535 days. Total duration from submission until required IRB approval was obtained was 114 days (IQR 75–224) and appeared to be shorter after submission to local IRBs compared to central IRBs (50 vs. 138 days, p = 0.0074). Conclusion: We found variation in IRB procedures between and within European countries. There were differences in submission and approval requirements, number of review rounds and total duration. Research collaborations could benefit from the implementation of more uniform legislation and regulation while acknowledging local cultural habits and moral values between countries.

The 10Kin1day workshop was generously sponsored by the Neuroscience and Cognition program Utrecht (NCU) of the Utrecht University (https://www.uu.nl/en/research/neuroscience-and-cognition-utrecht), the ENIGMA consortium (http://enigma.ini.usc.edu), and personal grants: MvdH: NWO-VIDI (452-16-015), MQ Fellowship; SB-C: the Wellcome Trust; Medical Research Council UK; NIHR CLAHRC for Cambridgeshire and Peterborough Foundation National Health Services Trust; Autism Research Trust; LB: New Investigator Award, Canadian Institutes of Health Research; Dara Cannon: Health Research Board (HRB), Ireland (grant code HRA-POR-2013-324); SC: Research Grant Council (Hong Kong)-GRF 14101714; Eveline Crone: ERC-2010-StG-263234; UD: DFG, grant FOR2107 DA1151/5-1, DA1151/5-2, SFB-TRR58, Project C09, IZKF, grant Dan3/012/17; SD: MRC-RFA-UFSP-01-2013 (Shared Roots MRC Flagship grant); TF: Marie Curie Programme, International Training Programme, r'Birth; DG: National Science Centre (UMO-2011/02/A/NZ5/00329); BG: National Science Centre (UMO-2011/02/A/NZ5/00329); JH: Western Sydney University Postgraduate Research Award; LH: Science Foundation Ireland, ERC; HH: Research Grant Council (Hong Kong)-GRF 14101714; LJ: Velux Stiftung, grant 369 & UZH University Research Priority Program Dynamics of Healthy Aging; AJ: DFG, grant FOR2107 JA 1890/7-1; KJ: National Science Centre (UMO-2013/09/N/HS6/02634); VK: The Russian Foundation for Basic Research (grant code 15-06-05758 A); TK: DFG, grant FOR2107 KI 588/14-1, DFG, grant FOR2107 KI 588/15-1; AK: DFG, grant FOR2107 KO 4291/4-1, DFG, grant FOR2107 KO 4291/3-1; IL: The Russian Foundation for Basic Research (grant code 15-06-05758 A); EL: Health and Medical Research Fund - 11121271; SiL: NHMRC-ARC Dementia Fellowship 1110414, NHMRC Dementia Research Team Grant 1095127, NHMRC Project Grant 1062319; CL-J: 537-2011, 2014-849; AM: Wellcome Trust Strategic Award (104036/Z/14/Z), MRC Grant MC_PC_17209; CM: Heisenberg-Grant, German Research Foundation, DFG MO 2363/3-2; PM: Foundation for Science and Technology, Portugal - PDE/BDE/113601/2015; KN: National Science Centre (UMO-2011/02/A/NZ5/00329); PN: National Science Centre (UMO-2013/09/N/HS6/02634); JiP: NWO-Veni 451-10-007; PaR: PER and US would like to thank the Schizophrenia Research Institute and the Chief-Investigators of the Australian Schizophrenia Research Bank V. Carr, U. Schall, R. Scott, A. Jablensky, B. Mowry, P. Michie, S. Catts, F. Henskens, and C. Pantelis; AS: National Science Centre (UMO-2011/02/A/NZ5/00329); SS: European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 707730; CS-M: Carlos III Health Institute (PI13/01958), Carlos III Health Institute (PI16/00889), Carlos III Health Institute (CPII16/00048); ES: National Science Centre (UMO-2011/02/A/NZ5/00329); AT: The Russian Foundation for Basic Research (grant code 15-06-05758 A); DT-G: PI14/00918, PI14/00639; Leonardo Tozzi: Marie Curie Programme, International Training Programme, r'Birth; SV: IMPRS Neurocom stipend; TvE: National Center for Research Resources at the National Institutes of Health (grant numbers: NIH 1 U24 RR021992 (Function Biomedical Informatics Research Network), NIH 1 U24 RR025736-01 (Biomedical Informatics Research Network Coordinating Center; http://www.birncommunity.org) and the NIH Big Data to Knowledge (BD2K) award (U54 EB020403 to Paul Thompson). NvH: NWO-VIDI (452-11-014); MW: National Science Centre (UMO-2011/02/A/NZ5/00329); Veronica O'Keane: Meath Foundation; AV and AW: CRC Obesity Mechanism (SFB 1052) Project A1 funded by DFG. The funding sources had no role in the study design, data collection, analysis, and interpretation of the data ; We organized 10Kin1day, a pop-up scientific event with the goal to bring together neuroimaging groups from around the world to jointly analyze 10,000+ existing MRI connectivity datasets during a 3-day workshop. In this report, we describe the motivation and principles of 10Kin1day, together with a public release of 8,000+ MRI connectome maps of the human brain. Ongoing grand-scale projects like the European Human Brain Project (1), the US Brain Initiative (2), the Human Connectome Project (3), the Chinese Brainnetome (4) and exciting world-wide neuroimaging collaborations such as ENIGMA (5) herald the new era of big neuroscience. In conjunction with these major undertakings, there is an emerging trend for bottom-up initiatives, starting with small-scale projects built upon existing collaborations and infrastructures. As described by Mainen et al. (6), these initiatives are centralized around self-organized groups of researchers working on the same challenges and sharing interests and specialized expertise. These projects could scale and open up to a larger audience and other disciplines over time, eventually lining up and merging their findings with other programs to make the bigger picture.

BACKGROUND: Low-risk limits recommended for alcohol consumption vary substantially across different national guidelines. To define thresholds associated with lowest risk for all-cause mortality and cardiovascular disease, we studied individual-participant data from 599 912 current drinkers without previous cardiovascular disease. METHODS: We did a combined analysis of individual-participant data from three large-scale data sources in 19 high-income countries (the Emerging Risk Factors Collaboration, EPIC-CVD, and the UK Biobank). We characterised dose-response associations and calculated hazard ratios (HRs) per 100 g per week of alcohol (12·5 units per week) across 83 prospective studies, adjusting at least for study or centre, age, sex, smoking, and diabetes. To be eligible for the analysis, participants had to have information recorded about their alcohol consumption amount and status (ie, non-drinker vs current drinker), plus age, sex, history of diabetes and smoking status, at least 1 year of follow-up after baseline, and no baseline history of cardiovascular disease. The main analyses focused on current drinkers, whose baseline alcohol consumption was categorised into eight predefined groups according to the amount in grams consumed per week. We assessed alcohol consumption in relation to all-cause mortality, total cardiovascular disease, and several cardiovascular disease subtypes. We corrected HRs for estimated long-term variability in alcohol consumption using 152 640 serial alcohol assessments obtained some years apart (median interval 5·6 years [5th-95th percentile 1·04-13·5]) from 71 011 participants from 37 studies. FINDINGS: In the 599 912 current drinkers included in the analysis, we recorded 40 310 deaths and 39 018 incident cardiovascular disease events during 5·4 million person-years of follow-up. For all-cause mortality, we recorded a positive and curvilinear association with the level of alcohol consumption, with the minimum mortality risk around or below 100 g per week. Alcohol consumption was roughly linearly associated with a higher risk of stroke (HR per 100 g per week higher consumption 1·14, 95% CI, 1·10-1·17), coronary disease excluding myocardial infarction (1·06, 1·00-1·11), heart failure (1·09, 1·03-1·15), fatal hypertensive disease (1·24, 1·15-1·33); and fatal aortic aneurysm (1·15, 1·03-1·28). By contrast, increased alcohol consumption was log-linearly associated with a lower risk of myocardial infarction (HR 0·94, 0·91-0·97). In comparison to those who reported drinking >0-≤100 g per week, those who reported drinking >100-≤200 g per week, >200-≤350 g per week, or >350 g per week had lower life expectancy at age 40 years of approximately 6 months, 1-2 years, or 4-5 years, respectively. INTERPRETATION: In current drinkers of alcohol in high-income countries, the threshold for lowest risk of all-cause mortality was about 100 g/week. For cardiovascular disease subtypes other than myocardial infarction, there were no clear risk thresholds below which lower alcohol consumption stopped being associated with lower disease risk. These data support limits for alcohol consumption that are lower than those recommended in most current guidelines. FUNDING: UK Medical Research Council, British Heart Foundation, National Institute for Health Research, European Union Framework 7, and European Research Council.

HapMap imputed genome-wide association studies (GWAS) have revealed >50 loci at which common variants with minor allele frequency >5% are associated with kidney function. GWAS using more complete reference sets for imputation, such as those from The 1000 Genomes project, promise to identify novel loci that have been missed by previous efforts. To investigate the value of such a more complete variant catalog, we conducted a GWAS meta-analysis of kidney function based on the estimated glomerular filtration rate (eGFR) in 110,517 European ancestry participants using 1000 Genomes imputed data. We identified 10 novel loci with p-value < 5 × 10−8 previously missed by HapMap-based GWAS. Six of these loci (HOXD8, ARL15, PIK3R1, EYA4, ASTN2, and EPB41L3) are tagged by common SNPs unique to the 1000 Genomes reference panel. Using pathway analysis, we identified 39 significant (FDR < 0.05) genes and 127 significantly (FDR < 0.05) enriched gene sets, which were missed by our previous analyses. Among those, the 10 identified novel genes are part of pathways of kidney development, carbohydrate metabolism, cardiac septum development and glucose metabolism. These results highlight the utility of re-imputing from denser reference panels, until whole-genome sequencing becomes feasible in large samples. ; 3C. Three-City Study. The work was made possible by the participation of the control subjects, the patients, and their families. We thank Dr. Anne Boland (CNG) for her technical help in preparing the DNA samples for analyses. This work was supported by the National Foundation for Alzheimer's disease and related disorders, the Institut Pasteur de Lille and the Centre National de Génotypage. The 3C Study was performed as part of a collaboration between the Institut National de la Santé et de la Recherche Médicale (Inserm), the Victor Segalen Bordeaux II University and Sanofi-Synthélabo. The Fondation pour la Recherche Médicale funded the preparation and initiation of the study. The 3C Study was also funded by the Caisse Nationale Maladie des Travailleurs Salariés, Direction Générale de la Santé, MGEN, Institut de la Longévité, Agence Française de Sécurité Sanitaire des Produits de Santé, the Aquitaine and Bourgogne Regional Councils, Fondation de France and the joint French Ministry of Research/INSERM "Cohortes et collections de données biologiques" programme. Lille Génopôle received an unconditional grant from Eisai. AGES. Age, Gene/Environment Susceptibility-Reykjavik Study. This study has been funded by NIH contract N01-AG-1-2100, the NIA Intramural Research Program, Hjartavernd (the Icelandic Heart Association), and the Althingi (the Icelandic Parliament). The study is approved by the Icelandic National Bioethics Committee, VSN: 00-063. The researchers are indebted to the participants for their willingness to participate in the study. ARIC. Atherosclerosis Risk in Communities study. The ARIC study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C), R01HL087641, R01HL59367 and R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. The authors thank the staff and participants of the ARIC study for their important contributions. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research. This work as well as YL and AK were supported by the German Research Foundation (KO 3598/2-1, KO 3598/3-1 and CRC1140 A05 to AK). ASPS. Austrian Stroke Prevention Study. The research reported in this article was funded by the Austrian Science Fond (FWF) grant number P20545-P05 and P13180. The Medical University of Graz supports the databank of the ASPS. The authors thank the staff and the participants of the ASPS for their valuable contributions. We thank Birgit Reinhart for her long-term administrative commitment and Ing Johann Semmler for the technical assistance at creating the DNA-bank. BMES. Blue Mountains Eye Study. The BMES has been supported by the Australian RADGAC grant (1992- 94) and Australian National Health & Medical Research Council, Canberra Australia (Grant Nos: 974159, 211069, 991407, 457349). The GWAS studies of Blue Mountains Eye Study population are supported by the Australian National Health & Medical Research Council (Grant Nos: 512423, 475604, 529912) and the Wellcome Trust, UK (2008). EGH and JJW are funded by the Australian National Health & Medical Research Council Fellowship Schemes. CILENTO. Italian Network on Genetic Isolates – Cilento. We thank the populations of Cilento for their participation in the study. The study was supported by the Italian Ministry of Universities and CNR 36 (PON03PE_00060_7, Interomics Flagship Project), the Assessorato Ricerca Regione Campania, the Fondazione con il SUD (2011-PDR-13), and the Istituto Banco di Napoli - Fondazione to MC. COLAUS. The CoLaus authors thank Yolande Barreau, Mathieu Firmann, Vladimir Mayor, Anne-Lise Bastian, Binasa Ramic, Martine Moranville, Martine Baumer, Marcy Sagette, Jeanne Ecoffey and Sylvie Mermoud for data collection. The CoLaus study received financial contributions from GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, the Swiss National Science Foundation (33CSCO- 122661, 3200BO-111361/2, 3100AO-116323/1, 310000-112552). The computations for CoLaus imputation were performed in part at the Vital-IT center for high performance computing of the Swiss Institute of Bioinformatics. We thank Vincent Mooser for his contribution to the CoLaus study. EGCUT. Estonian Genome Center University of Tartu. EGCUT received financing from FP7 grants (278913, 306031, 313010) and targeted financing from Estonian Government (SF0180142s08). EGCUT studies were covered from Infra-structure grant no. 3.2.0304.11-0312 funded mostly by the European Regional Development Fund, Center of Excellence in Genomics (EXCEGEN) and University of Tartu (SP1GVARENG). We acknowledge EGCUT technical personnel, especially Mr V. Soo and S. Smit. Data analyses were carried out in part in the High Performance Computing Center of the University of Tartu. FamHS. Family Heart Study. The FHS work was supported in part by NIH grants 5R01HL08770003, 5R01HL08821502 (Michael A. Province) from the NHLBI and 5R01DK07568102, 5R01DK06833603 from the NIDDK (I.B.B.). The authors thank the staff and participants of the FamHS for their important contributions. FHS. Framingham Heart Study. This research was conducted in part using data and resources from the Framingham Heart Study of the National Heart Lung and Blood Institute of the National Institutes of Health and Boston University School of Medicine. The analyses reflect intellectual input and resource development from the Framingham Heart Study investigators participating in the SNP Health Association Resource (SHARe) project. This work was partially supported by the National Heart, Lung and Blood Institute's Framingham Heart Study (Contract No. N01-HC-25195) and its contract with Affymetrix, Inc. for genotyping services (Contract No. N02-HL-6-4278). A portion of this research utilized the Linux Cluster for Genetic Analysis (LinGA-II) funded by the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center. GENDIAN. GENetics of DIAbetic Nephropathy study. The support of the physicians, the patients, and the staff of the Diabetes Zentrum Mergentheim (Head: Prof. Dr. Thomas Haak), the diabetes outpatient clinic Dr Nusser - Dr Kreisel, the dialysis centers KfH Amberg, KfH Bayreuth, KfH Deggendorf, KfH Donauwörth, KfH Freising, KfH Freyung, KfH Fürth, KfH Hof, KfH Ingolstadt, KfH Kelheim, KfH München Elsenheimerstraße, KfH München-Schwabing, KfH Neumarkt, KfH Neusäß, KfH Oberschleißheim, KfH Passau, KfH Plauen, KfH Regensburg Günzstraße, KfH Regensburg Caritas-Krankenhaus, KfH Straubing, KfH Sulzbach-Rosenberg, KfH Weiden, Dialysezentrum Augsburg Dr. Kirschner, Dialysezentrum Bad Alexandersbad, KfH Bamberg, Dialysezentrum Emmering, Dialysezentrum Klinikum Landshut, Dialysezentrum Landshut, Dialysezentrum Pfarrkirchen, Dialysezentrum Schwandorf, Dr. Angela Götz, the medical doctoral student Johanna Christ and the Study Nurse Ingrid Lugauer. The expert technical assistance of Claudia Strohmeier is acknowledged. Phenotyping was funded by the Dr. Robert PflegerStiftung (Dr Carsten A. Böger), the MSD Stipend Diabetes (Dr Carsten A. Böger) and the University Hospital of Regensburg (intramural grant ReForM A to Dr. A. Götz, ReForM C to Dr. Carsten Böger). Genome-wide genotyping was funded by the KfH Stiftung Präventivmedizin e.V. (Dr. Carsten A. Böger, Dr. Jens Brüning), the Else Kröner-Fresenius-Stiftung (2012_A147 to Dr Carsten A. Böger and Dr Iris M. Heid) and the University Hospital Regensburg (Dr Carsten A. Böger). Data analysis was funded by the Else 37 Kröner-Fresenius Stiftung (Dr. Iris M. Heid and Dr. Carsten A. Böger: 2012_A147; Dr. Carsten A. Böger and Dr. Bernhard K. Krämer: P48/08//A11/08). GENDIAN Study Group: Mathias Gorski, Iris M. Heid, Bernhard K. Krämer, Myriam Rheinberger, Michael Broll, Alexander Lammert, Jens Brüning, Matthias Olden, Klaus Stark, Claudia Strohmeier, Simone Neumeier, Sarah Hufnagel, Petra Jackermeier, Emilia Ruff, Johanna Christ, Peter Nürnberg, Thomas Haak, Carsten A. Böger. HABC. Health Aging and Body Composition Study. The HABC study was funded by the National Institutes of Aging. This research was supported by NIA contracts N01AG62101, N01AG62103, and N01AG62106. The genome-wide association study was funded by NIA grant 1R01AG032098-01A1 to Wake Forest University Health Sciences and genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, contract number HHSN268200782096C. This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging. HCS. Hunter Community Study. The University of Newcastle provided $300,000 from its Strategic Initiatives Fund, and $600,000 from the Gladys M Brawn Senior Research Fellowship scheme; Vincent Fairfax Family Foundation, a private philanthropic trust, provided $195,000; The Hunter Medical Research Institute provided media support during the initial recruitment of participants; and Dr Anne Crotty, Prof. Rodney Scott and Associate Prof. Levi provided financial support towards freezing costs for the long-term storage of participant blood samples. The authors would like to thank the men and women participating in the HCS as well as all the staff, investigators and collaborators who have supported or been involved in the project to date. A special thank you should go to Alison Koschel and Debbie Quain who were instrumental in setting up the pilot study and initial phase of the project. HPFS. Health Professionals Follow-Up Study. The NHS/HPFS type 2 diabetes GWAS (U01HG004399) is a component of a collaborative project that includes 13 other GWAS (U01HG004738, U01HG004422, U01HG004402, U01HG004729, U01HG004726, U01HG004735, U01HG004415, U01HG004436, U01HG004423, U01HG004728, RFAHG006033; National Institute of Dental & Craniofacial Research: U01DE018993, U01DE018903) funded as part of the Gene Environment-Association Studies (GENEVA) under the NIH Genes, Environment and Health Initiative (GEI). Assistance with phenotype harmonization and genotype cleaning, as well as with general study coordination, was provided by the GENEVA Coordinating Center (U01HG004446). Assistance with data cleaning was provided by the National Center for Biotechnology Information. Genotyping was performed at the Broad Institute of MIT and Harvard, with funding support from the NIH GEI (U01HG04424), and Johns Hopkins University Center for Inherited Disease Research, with support from the NIH GEI (U01HG004438) and the NIH contract "High throughput genotyping for studying the genetic contributions to human disease"(HHSN268200782096C). Additional funding for the current research was provided by the National Cancer Institute (P01CA087969, P01CA055075), and the National Institute of Diabetes and Digestive and Kidney Diseases (R01DK058845). We thank the staff and participants of the NHS and HPFS for their dedication and commitment. INGI-CARLANTINO. Italian Network on Genetic Isolates – Carlantino. We thank Anna Morgan and Angela D'Eustacchio for technical support. We are grateful to the municipal administrators for their collaboration on the project and for logistic support. We thank all participants to this study. INGI-FVG. Italian Network on Genetic Isolates – Friuli Venezia-Giulia. We thank Anna Morgan and Angela D'Eustacchio for technical support. We are grateful to the municipal administrators for their collaboration on the project and for logistic support. We thank all participants to this study. 38 INGI-VAL BORBERA. Italian Network on Genetic Isolates – Val Borbera. We thank the inhabitants of the Val Borbera who made this study possible, the local administrations and the ASL-Novi Ligure (Al) for support. We also thank Clara Camaschella for data collection supervision and organization of the clinical data collection, Fiammetta Vigano` for technical help and Corrado Masciullo for building the analysis platform. The research was supported by funds from Compagnia di San Paolo, Torino, Italy; Fondazione Cariplo, Italy and Ministry of Health, Ricerca Finalizzata 2008 and 2011/2012, CCM 2010, PRIN 2009 and Telethon, Italy to DT. IPM. Mount Sinai BioMe Biobank Program. The Mount Sinai BioMe Biobank Program is supported by The Andrea and Charles Bronfman Philanthropies. KORA-F3 and F4. The genetic epidemiological work was funded by the NIH subcontract from the Children's Hospital, Boston, US, (H.E.W., I.M.H, prime grant 1 R01 DK075787-01A1), the German National Genome Research Net NGFN2 and NGFNplus (H.E.W. 01GS0823; WK project A3, number 01GS0834), the Munich Center of Health Sciences (MC Health) as part of LMUinnovativ, and by the Else KrönerFresenius-Stiftung (P48/08//A11/08; C.A.B., B.K.K; 2012_A147 to CAB and IMH.). The Genetic Epidemiology at the University of Regensburg received financial contributions from the BMBF (01ER1206 and 01ER1507). The kidney parameter measurements in F3 were funded by the Else Kröner-FreseniusStiftung (C.A.B., B.K.K.) and the Regensburg University Medical Center, Germany; in F4 by the University of Ulm, Germany (W.K.). Genome wide genotyping costs in F3 and F4 were in part funded by the Else Kröner-Fresenius-Stiftung (C.A.B., B.K.K.). De novo genotyping in F3 and F4 were funded by the Else Kröner-Fresenius-Stiftung (C.A.B., B.K.K.). The KORA research platform and the MONICA Augsburg studies were initiated and financed by the Helmholtz Zentrum München, German Research Center for Environmental Health, by the German Federal Ministry of Education and Research and by the State of Bavaria. Genotyping was performed in the Genome Analysis Center (GAC) of the Helmholtz Zentrum München. The LINUX platform for computation were funded by the University of Regensburg for the Department of Epidemiology and Preventive Medicine at the Regensburg University Medical Center. LIFELINES. The authors wish to acknowledge the services of the Lifelines Cohort Study, the contributing research centers delivering data to Lifelines, and all the study participants. Lifelines group authors: Behrooz Z Alizadeh1 , H Marike Boezen1 , Lude Franke2 , Pim van der Harst3 , Gerjan Navis4 , Marianne Rots5 , Harold Snieder1 , Morris Swertz2 , Bruce HR Wolffenbuttel6 and Cisca Wijmenga2 1. Department of Epidemiology, University of Groningen, University Medical Center Groningen, The Netherlands 2. Department of Genetics, University of Groningen, University Medical Center Groningen, The Netherlands 3. Department of Cardiology, University of Groningen, University Medical Center Groningen, The Netherlands 4. Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, The Netherlands 5. Department of Medical Biology, University of Groningen, University Medical Center Groningen, The Netherlands 6. Department of Endocrinology, University of Groningen, University Medical Center Groningen, The Netherlands MESA. Multi-Ethnic Study of Atherosclerosis. University of Washington (N01-HC-95159),Regents of the University of California (N01-HC-95160), Columbia University (N01-HC-95161), Johns Hopkins University 39 (N01-HC-95162, N01-HC-95168), University of Minnesota (N01-HC-95163), Northwestern University (N01-HC-95164), Wake Forest University (N01-HC-95165), University of Vermont (N01-HC-95166), New England Medical Center (N01-HC-95167), Harbor-UCLA Research and Education Institute (N01-HC- 95169), Cedars-Sinai Medical Center (R01-HL-071205), University of Virginia (subcontract to R01-HL- 071205) MICROS. Microisolates in South Tyrol study. We owe a debt of gratitude to all participants. We thank the primary care practitioners R. Stocker, S. Waldner, T. Pizzecco, J. Plangger, U. Marcadent and the personnel of the Hospital of Silandro (Department of Laboratory Medicine) for their participation and collaboration in the research project. In South Tyrol, the study was supported by the Ministry of Health and Department of Educational Assistance, University and Research of the Autonomous Province of Bolzano, the South Tyrolean Sparkasse Foundation, and the European Union framework program 6 EUROSPAN project (contract no. LSHG-CT-2006-018947). NESDA. The Netherlands Study of Depression and Anxiety. The infrastructure for the NESDA study is funded through the Geestkracht programme of the Dutch Scientific Organization (ZON-MW, grant number 10-000-1002) and matching funds from participating universities and mental health care organizations. Genotyping in NESDA was funded by the Genetic Association Information Network (GAIN) of the Foundation for the US National Institutes of Health. NHS. Nurses' Health Study. The NHS/HPFS type 2 diabetes GWAS (U01HG004399) is a component of a collaborative project that includes 13 other GWAS (U01HG004738, U01HG004422, U01HG004402, U01HG004729, U01HG004726, U01HG004735, U01HG004415, U01HG004436, U01HG004423, U01HG004728, RFAHG006033; National Institute of Dental & Craniofacial Research: U01DE018993, U01DE018903) funded as part of the Gene Environment-Association Studies (GENEVA) under the NIH Genes, Environment and Health Initiative (GEI). Assistance with phenotype harmonization and genotype cleaning, as well as with general study coordination, was provided by the GENEVA Coordinating Center (U01HG004446). Assistance with data cleaning was provided by the National Center for Biotechnology Information. Genotyping was performed at the Broad Institute of MIT and Harvard, with funding support from the NIH GEI (U01HG04424), and Johns Hopkins University Center for Inherited Disease Research, with support from the NIH GEI (U01HG004438) and the NIH contract "High throughput genotyping for studying the genetic contributions to human disease"(HHSN268200782096C). The NHS renal function and albuminuria work was supported by DK66574. Additional funding for the current research was provided by the National Cancer Institute (P01CA087969, P01CA055075), and the National Institute of Diabetes and Digestive and Kidney Diseases (R01DK058845). We thank the staff and participants of the NHS and HPFS for their dedication and commitment. NSPHS. The Northern Swedish Population Health Study. The NSPHS was supported by grants from the Swedish Natural Sciences Research Council, the European Union through the EUROSPAN project (contract no. LSHG-CT-2006-018947), the Foundation for Strategic Research (SSF) and the Linneaus Centre for Bioinformatics (LCB). We are also grateful for the contribution of samples from the Medical Biobank in Umeå and for the contribution of the district nurse Svea Hennix in the Karesuando study. RS-I. The Rotterdam Study. The GWA study was funded by the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012), the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Consortium for Healthy Aging (NCHA) project nr. 050-060-810. We thank Pascal Arp, Mila Jhamai, Dr Michael 40 Moorhouse, Marijn Verkerk, and Sander Bervoets for their help in creating the GWAS database. The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The authors are very grateful to the participants and staff from the Rotterdam Study, the participating general practitioners and the pharmacists. We would like to thank Dr. Tobias A. Knoch, Luc V. de Zeeuw, Anis Abuseiris, and Rob de Graaf as well as their institutions the Erasmus Computing Grid, Rotterdam, The Netherlands, and especially the national German MediGRID and Services@MediGRID part of the German D-Grid, both funded by the German Bundesministerium fuer Forschung und Technology under grants #01 AK 803 A-H and # 01 IG 07015 G, for access to their grid resources. Abbas Dehghan is supported by NWO grant (vici, 918-76-619). SAPALDIA. Swiss Study on Air Pollution and Lung Diseases in Adults. The SAPALDIA Team: Study directorate: T Rochat (p), NM Probst Hensch (e/g), N Künzli (e/exp), C Schindler (s), JM Gaspoz (c) Scientific team: JC Barthélémy (c), W Berger (g), R Bettschart (p), A Bircher (a), O Brändli (p), C Brombach (n), M Brutsche (p), L Burdet (p), M Frey (p), U Frey (pd), MW Gerbase (p), D Gold (e/c/p), E de Groot (c), W Karrer (p), R Keller (p), B Martin (pa), D Miedinger (o), U Neu (exp), L Nicod (p), M Pons (p), F Roche (c), T Rothe (p), E Russi (p), P Schmid-Grendelmeyer (a), A Schmidt-Trucksäss (pa), A Turk (p), J Schwartz (e), D. Stolz (p), P Straehl (exp), JM Tschopp (p), A von Eckardstein (cc), E Zemp Stutz (e). Scientific team at coordinating centers: M Adam (e/g), C Autenrieth (pa), PO Bridevaux (p), D Carballo (c), E Corradi (exp), I Curjuric (e), J Dratva (e), A Di Pasquale (s), E Dupuis Lozeron (s), E Fischer (e), M Germond (s), L Grize (s), D Keidel (s), S Kriemler (pa), A Kumar (g), M Imboden (g), N Maire (s), A Mehta (e), H Phuleria (exp), E Schaffner (s), GA Thun (g) A Ineichen (exp), M Ragettli (e), M Ritter (exp), T Schikowski (e), M Tarantino (s), M Tsai (exp) (a) allergology, (c) cardiology, (cc) clinical chemistry, (e) epidemiology, (exp) exposure, (g) genetic and molecular biology, (m) meteorology, (n) nutrition, (o) occupational health, (p) pneumology, (pa) physical activity, (pd) pediatrics, (s) statistics. Funding: The Swiss National Science Foundation (grants no 33CSCO-134276/1, 33CSCO-108796, 3247BO-104283, 3247BO-104288, 3247BO- 104284, 3247-065896, 3100-059302, 3200-052720, 3200-042532, 4026-028099), the Federal Office for Forest, Environment and Landscape, the Federal Office of Public Health, the Federal Office of Roads and Transport, the canton's government of Aargau, Basel-Stadt, Basel-Land, Geneva, Luzern, Ticino, Valais, and Zürich, the Swiss Lung League, the canton's Lung League of Basel Stadt/ Basel Landschaft, Geneva, Ticino, Valais and Zurich, SUVA, Freiwillige Akademische Gesellschaft, UBS Wealth Foundation, Talecris Biotherapeutics GmbH, Abbott Diagnostics, European Commission 018996 (GABRIEL), Wellcome Trust WT 084703MA. The study could not have been done without the help of the study participants, technical and administrative support and the medical teams and field workers at the local study sites. Local fieldworkers : Aarau: S Brun, G Giger, M Sperisen, M Stahel, Basel: C Bürli, C Dahler, N Oertli, I Harreh, F Karrer, G Novicic, N Wyttenbacher, Davos: A Saner, P Senn, R Winzeler, Geneva: F Bonfils, B Blicharz, C Landolt, J Rochat, Lugano: S Boccia, E Gehrig, MT Mandia, G Solari, B Viscardi, Montana: AP Bieri, C Darioly, M Maire, Payerne: F Ding, P Danieli A Vonnez, Wald: D Bodmer, E Hochstrasser, R Kunz, C Meier, J Rakic, U Schafroth, A Walder. Administrative staff: C Gabriel, R Gutknecht. SHIP and SHIP-TREND. The Study of Health in Pomerania. SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania, and the network 41 'Greifswald Approach to Individualized Medicine (GANI_MED)' funded by the Federal Ministry of Education and Research (grant 03IS2061A). Genome-wide data have been supported by the Federal Ministry of Education and Research (grant no. 03ZIK012) and a joint grant from Siemens Healthcare, Erlangen, Germany and the Federal State of Mecklenburg- West Pomerania. The University of Greifswald is a member of the 'Center of Knowledge Interchange' program of the Siemens AG and the Caché Campus program of the InterSystems GmbH. The SHIP authors are grateful to Mario Stanke for the opportunity to use his Server Cluster for the SNP imputation as well as to Holger Prokisch and Thomas Meitinger (Helmholtz Zentrum München) for the genotyping of the SHIP-TREND cohort. TRAILS. TRacking Adolescents' Individual Lives. Trails is a collaborative project involving various departments of the University Medical Center and University of Groningen, the Erasmus University Medical Center Rotterdam, the University of Utrecht, the Radboud Medical Center Nijmegen, and the Parnassia Bavo group, all in the Netherlands. TRAILS has been financially supported by grants from the Netherlands Organization for Scientific Research NWO (Medical Research Council program grant GB-MW 940-38-011; ZonMW Brainpower grant 100-001-004; ZonMw Risk Behavior and Dependence grants 60- 60600-98-018 and 60-60600-97-118; ZonMw Culture and Health grant 261-98-710; Social Sciences Council medium-sized investment grants GB-MaGW 480-01-006 and GB-MaGW 480-07-001; Social Sciences Council project grants GB-MaGW 457-03-018, GB-MaGW 452-04-314, and GB-MaGW 452-06- 004; NWO large-sized investment grant 175.010.2003.005; NWO Longitudinal Survey and Panel Funding 481-08-013); the Sophia Foundation for Medical Research (projects 301 and 393), the Dutch Ministry of Justice (WODC), the European Science Foundation (EuroSTRESS project FP-006), and the participating universities. We are grateful to all adolescents, their parents and teachers who participated in this research and to everyone who worked on this project and made it possible. Statistical analyses were carried out on the Genetic Cluster Computer (http://www.geneticcluster.org), which is financially supported by the Netherlands Scientific Organization (NWO 480-05-003) along with a supplement from the Dutch Brain Foundation. WGHS. Women's Genome Health Study. The WGHS is supported by the National Heart, Lung, and Blood Institute (HL043851 and HL080467) and the National Cancer Institute (CA047988 and UM1CA182913), with collaborative scientific support and funding for genotyping provided by Amgen. YFS. Young Finns Study. The YFS has been financially supported by the Academy of Finland: grants 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi), and 41071 (Skidi), the Social Insurance Institution of Finland, Kuopio, Tampere and Turku University Hospital Medical Funds (grant 9M048 and 9N035 for TeLeht), Juho Vainio Foundation, Paavo Nurmi Foundation, Finnish Foundation of Cardiovascular Research and Finnish Cultural Foundation, Tampere Tuberculosis Foundation and Emil Aaltonen Foundation (T.L). The technical assistance in the statistical analyses by Ville Aalto and Irina Lisinen is acknowledged. ; Peer Reviewed

Transcript of an oral history interview with Richard H. Cummings, conducted by Joseph Cates at Cummings' home in Hanover, New Hampshire, on 31 May 2016 as part of the Norwich Voices oral history project of the Sullivan Museum and History Center. Richard Cummings was a member of the Norwich University Class of 1951. His interview includes discussion of his experiences as a student at Norwich University, his military service in the Korean War, and his family's business, the E. Cummings Leather Company. ; Richard H. Cummings, Class of 1951, Oral History Interview May 31, 2016 Hanover, New Hampshire Interviewed by Joseph Cates JOSEPH CATES: This is Joseph Cates. Today is May 31, 2016. I'm interviewing Richard H. Cummings. This interview is taking place at his home in Hanover, New Hampshire. This interview is sponsored by the Sullivan Museum and History Center, and is part of the Norwich Voices History Project. Mr. Cummings, can you please state your full name? RICHARD CUMMINGS: My name is Richard Haven Cummings. JC: What day were you born? RC: I was born January 19, 1929. JC: Where were you born? RC: I was born in Woburn, Massachusetts. JC: Woburn? RC: W-o-b-u-r-n. JC: What Norwich class are you? RC: Class of 1951. JC: Tell me about where you grew up and what you did as a child. RC: I spent the first ten years in my life in Woburn, Massachusetts, where [sic] we moved to Lebanon, New Hampshire, establishing E. Cummings Letter Company, which we had in Woburn. I worked at D.B. because of the second world war. Labor was very much needed and that's when women started to work in industry. And teenage boys that weren't in the war, or in the service, worked – I worked – after school, three hours from 3:00 in the afternoon to 6:00, Monday through Friday and eight hours on Saturday. All vacation days, holidays, we worked in the factory. Upon my 15th birthday or so, I was registered at Kimball Union Academy where I attended two years in preparation for Norwich. JC: What was is like working in the leather tannery? Is that the right way to say it, "leather tannery?" RC: E. Cummings was a company which was a tannery. You couldn't work overtime and you couldn't work on machinery if you were under 18. It was hard work, 2 particularly, depending on the season, the drying areas in the summer were very uncomfortable. However, the pay was very good. The people in the community benefit from the location of the tannery because of the pay scale. I was fortunate that I could save my money to go toward my education costs. JC: What made you decide to choose Norwich? RC: I think it was probably the recommendation from the faculty at Kimball Union Academy at that time. JC: What was your major when you went there? RC: Government. JC: Government? Why did you choose government? RC: I have always been interested in government. I did well in the courses, and all my adult life I've been involved in local, county and state government. Topping off as being one of the original members of the Public Employee Labor Relation Board in the State of New Hampshire. JC: Who was your roommate and Norwich, and where – what dorm – what barracks did you live in? RC: My first semester, I was in the band, so that's what we called Headquarters Company. And I lived in Hawkins Hall all the time I was at Norwich. My first semester roommate was Bud Moffett from Braintree, Mass. And my second semester roommate was Seth Wiard from Norwalk, Connecticut. My roommate my sophomore year and junior year was Bruce Kenerson from Lynfield, Mass. JC: What was it like being in the band? Describe the band for us. RC: Well, I think it brought, every member, all the band closer together in a military environment which Norwich, the entire school was, at that time. We were always together and never breaking up after freshman year or sophomore year and we practiced together, we lived together, we worked together. JC: What instrument did you play? RC: I played the E flat alto horn, which is an easy way to say French horn. JC: Was there a favorite song you liked to play? RC: "On the Steps of Jackman." JC: (Laughs) 3 RC: And, "The Thunderer." JC: Do you remember "On the Steps of Jackman?" RC: Yes. JC: Can you sing it? RC: (Singing) "On the steps of Jackman, crying like hell, eyes a new born baby…" [0:06:44], and it goes on from there. (Laughs) JC: (Laughs) And what was the other song? RC: "The Thunderer," which was a marching song which we always opened up with in pass and review. JC: Oh, ok. As a member of the band, were you part of any fraternity? RC: Yes, I joined. I was pledged to Phi Kappa Delta. I was the last class to join Phi Kappa Delta. The next year, they became affiliated with the national fraternity Sigma Nu. So, I was the first class to be initiated at Norwich in Sigma Nu. JC: And, what was the fraternity like? RC: Well, at the time, about a third of the population of the cadet corps were in fraternities. At the time, there was Phi Kappa Delta, SAE, Sigma Phi Epsilon, Theta Chi. Shortly after that, two or three other fraternities were brought on campus. But the originals were those first ones I mentioned. It was – it was the only social life we really had and it was necessary because of limited facilities to feed to corps of cadets. So, the fraternities ran dining rooms. In our fraternity, there was a man and wife, and a young daughter and they lived up on the third floor. And they provided all the meals, seven days a week. The cost to belong was $55.00 a month, $5.00 dues, $50.00 for the food. JC: Was the food good? RC: Very good. JC: Good. What company were you in? RC: Headquarters Company. JC: Headquarters Company. You said that. Did you play any sports or did you just – RC: No. 4 JC: No. What did you do to relax when you were at Norwich? RC: Well, as I said, we had the fraternity house, where we had a small library, we subscribed to magazines and living room couches and so we could – that was our [sic] really place to relax. Many times, we brought friends that were not in the fraternity would come, particularly the big weekends of the year, Homecoming, May Day – when we got the ring dance. JC: The ring ceremony? RC: Yes. What'd they call that? There were three major weekends a year. JC: Was there – RC: Homecoming, Winter Carnival, Junior Week. JC: Junior Week. RC: And, we had to sign up if we had a date. We had to find the facilities, rooms in town if the girl came from out of town. But, most of them came from Vermont Junior College. And several of my classmates married girls from Vermont Junior College. JC: Talk about what Homecoming was like back then? RC: Oh, I think it was a – for the cadets. For the alumni, it was a big affair. But for the cadets, it offered no classes on Saturday, which means they were really free Friday late afternoon until Sunday. And, believe it or not, we'd go up to Montpelier. And, there was a restaurant up in Montpelier called The Gardens. I forgot the name of the street, but I can take you to it. It was on the street where – of the state capitol, on the right before you got to the state capitol. A little street, no sidewalk and you could sit at a table and a car would come up to park right by the window because there was no sidewalk, and one spring day, this gets off Homecoming, but one spring day we cut class. Section leader was Russ Todd. He asked me one time not to repeat that. And we asked Russ to cover for us, because we were going to cut that class and go to Montpelier, which he did. While we're sitting there having a pitcher of beer for a dollar, a car pulls up, gets out, and it was Professor Willey, our class professor that we cut. Now, he knew there was no way that we could have cut there and be in that restaurant and also have attended class. JC: (Laughs) RC: But, we used to go up there – at one time, we're talking homecoming, we all sat down at the table and said, "Let's go to Montreal." "Well, first of all, how much 5 money do we got [sic]?" Well, I pulled out my $2.00. Somebody else had a dollar and a half. Somebody else had $3.00. So, we had a two-door 1936 Ford. Ooh. First thing we did was go to the gas station and gassed the car up, and went off to Montreal. Drove up to St. Catherine Street. Went in and had a bottle of beer. In those days, it was – the measurement was probably a liter. One. And passed it around. Got back in the car and drove back to Norwich. That was our outing. JC: (Laughs) Sounds like a pretty good outing. RC: Oh, it – and once again, it isn't – to have a good time and enjoy yourself doesn't necessarily mean you have to have money. You have to have just have ideas and something different. JC: What was Winter Carnival like? RC: Well, it all hinged on the dance and the parties at the fraternities. We would have – we were not supposed to have alcohol in the fraternities. But, we did. I'm sure it was known, but we kind of covered it up. We built a bar in that fraternity house downstairs on a rail. And when it was closed, it was a library (?) [0:15:33]. When we pushed it back, it was a bar. We had a buzzer upstairs, and if any of the faculty members came into the house, they pushed the buzzer. We'd get out from behind it, pull the bar forward and sit down. JC: (Chuckles) RC: And, we had – as I said, we had very good meals. Our entertainment was there. We'd go to the dance and from the dance at the fraternity house. JC: What about Junior Week? RC: Junior Week was probably the highlight of the year. Not only because a long winter season was over, and school was wrapping down, I think we got out somewhere around the 20th of June in those days. Somewhere in the third week of June. And, also it was the highlight of your Norwich career to get your ring. I got my ring when I was stationed at Fort Sill, I made the mistake of going in the latrine to wash and shave and leave my ring on the – by the sink and when I got back, it was gone. JC: Oh, no. RC: I went down, went all through the pawn shops and there are a lot in Oklahoma, trying to find it. I didn't. But, several years later, after I was home and married, my mother got me one for Christmas. But Balfour was a dealer, was in Hanover. I can always tell because my mother's handwriting and printing was terrible. So, it says, my initials are R. H. Cummings and this is R. M. Cummings. 6 JC: Oh! (Laughs) What does the ring symbolize for you? RC: You belong. It still does. It's probably (?) [0:18:11] my choicest [sic] possession, the Norwich ring. I have, I think I had it built up once. It gets a little thin there. And I wear it probably 75 percent of the time. My roommate said when he stationed at Germany, at the officer's club the trick was [taps ring on table three times] and that meant all the West Point guys. JC: (Laughs) RC: So, you went into an officer's club and did that, and all the West Point guys looked up and said, "What's that?" It's Norwich University. (Laughs) JC: (Laughs) What were the instructors that were most influential to you when you were at Norwich? RC: One of the advantages at that time at Norwich was, in your advanced classes, junior and senior year, you had, as actual instructors, the head of the department. And, at that time, we had some very good professors. I had him, but I didn't major in the subject, I think of Shorty Hamilton, professor of chemistry. Under him, was O'Neill who was a, ranked first lieutenant so he was an instructor. He was a recent graduate of Norwich and he stayed there and he went on to head the chemist [sic] department at Norwich. I had K.R.B. Flint was a government professor. Excellent professor. I had Pop Peach, English. Pop Peach was a graduate of Middlebury. K.R.B. Flint graduated Norwich. Shorty Hamilton graduated from Norwich. They all went on and got masters degrees. In my junior year, I mention now (?) (inaudible) [0:21:01] because of the professors. In my junior year, it was suggested that I probably had better take a fifth year towards my degree. I explained this to my father who said that that would be alright, however, after that I would go to Pratt Institute in Brooklyn, New York, which offered, in their engineering department, offered a special course in leather and tanning technology. And he wanted me to take that course, to which I responded, "If that's the way it's going to be, I'd rather go now." So, I went to Pop Peach, K.R.B. Flint, who was my academic advisor, and told him what I wanted to do. And if I could, my second semester of my junior year, if I could take senior courses in comparative government, constitutional law, advanced public speaking and he allowed me to. So, I took all the courses that Norwich offered for a government major. So, in my junior year, the second semester, all my classes were with seniors. I remember once again, Russ Todd was in all those classes with me. So, as the years went by, they always thought I was in their class. But I learned a great deal from – that I carried out all through my life, in my work with the Public Employees Labor Relations Board in the State of New Hampshire. Chairman of the Republican town committee in Hanover, co-chairman of Grafton County Republican Committee, delegate to the state republican conventions three times. I learned a great deal from those men in how to present myself and understand the field that I was endeavored in. 7 JC: What was your favorite class at Norwich? RC: Comparative government. JC: What was your least favorite? RC: Spanish. JC: (Laughs) I was told you had some stories about General Harmon. RC: Well, my stories about General Harmon, are not to criticize the man because he was a fine soldier. And he was a combat commander, as against political generals, Bradley, Eisenhower, Marshall, they were political generals out of the pentagon. Patton and Harmon, they were combat commanders. Harmon took over the university at a time that it was probably, nearly going out of business. For lack of money, lack of endowment, lack of students, the faculty needed to be built up, the student body needed to be built up, the physical plant needed improvement and Harmon accomplished those things in his time and put the school on the road to recovery. Very successfully. He brought in speakers. He got Eisenhower to the university. He brought in a great deal of capital. He built up the endowment. He improved the faculty as I said. Built one new dormitory plus of course he built Harmon Hall. The mess hall was in the White Chapel and that's why, when he moved the mess hall into Harmon Hall, he needed all the student body in that mess hall to make it pay. So, he closed down the fraternities. And the way he closed down the fraternities is a lesson in parliamentary procedure. If you want to get something across, you wait until the chairman closes the meeting, to which he closes the meeting and says, "Is there anything else to brought before this meeting?" That's when you introduce your bombshell, and which Harmon did. He said, "Yes." He said, "I'd like permission to close down the fraternities and sell the property or buy the property to enlarge the facilities of the university. If I do not get a favorable vote, you have my resignation." And whereupon, he got up and left the room. He got what he wanted. As you know, they took Sigma Phi Epsilon as the president's house. And Theta Chi they made into a club or – it was Flint Hall or Flint – it's right there next to the armory. Not SAE, the big one. The little one, across the street from the president's house, I think it's a club. I don't know what it is. JC: Do you think he did the right thing, closing the fraternities? RC: He had to. Yes, yes, he had to. And, he also improved the discipline of the cadet corps. There was (sic) a lot of things he did, he had to do because the school was really sliding. And, I have – my father-in-law, Nancy's (?) [0:28:35] father, was Class of '28. Civil Engineer. And, as he was telling the president at one time, that Norwich engineers built these interstates. Because, when those interstates were being built, what, in the 1960's were they? 8 JC: Yes. RC: The civil engineers were from Norwich. They were in the intra-highway department, and they were in Vermont highway department. He was – in my – I had two nephews who went to Norwich. One, last I knew, was with the FBI in Hartford, Connecticut and the other one owned a dental school and he had a practice in the western part of Connecticut. And they both dropped their affiliation with Norwich because they didn't agree with letting in girls and they didn't agree with letting in civilians, so they dropped their affiliation. I don't say I agree, but I realize that they really had to in order to keep the student body up and fill the classrooms and bring in tuition money. JC: So, is there anything else about General Harmon that you'd like to say? RC: I think I generally said he put the school on its feet. And, he did. But, I think the catalog (?) [0:30:32] put it, he really saved the university. JC: Now, it was after your junior year that you left? RC: Yes. JC: And went to Pratt Institute? RC: Yes. And then of course, I'm out from cover. Up comes the draft board. I got drafted. Well, if you can imagine, I spent three years in military discipline at Norwich University, showing up at Camp Chaffie is a buck private. Teach you how to make a bed. And they didn't like the fact that they could bounce a dime off my bed. JC: (Laughs) RC: So, they tore it apart and made me do it again. To which you're supposed to get mad. Your Norwich training. Yes, sir. Don't do that again. And then, that's where you get your respect. And then I belonged to the Vermont National Guard for five months. I wrote home to my mother, send me my discharge. Which I took to the CP and they went to E1 to E2 immediately, which meant $5.00 or $6.00 a month. And they made me squad leader. And, sometimes the sergeants didn't like that because I could drill better than they could. And then, instead of going overseas to Korea, or far east or Europe, and there was three in Alaska. A few went to Alaska. A lot went to Europe and a lot went to far east. I went to far east. But before that, after I got through basic training they sent me to code school. I took code. And then after code school, at Chaffie, they sent me down to Ft. Soda, radio repair. So, I went into radio repair. Then they shipped me out. So, I had a year here. And, then they shipped me out and assigned me to the 38th Infantry Regiment, the second division. And, I went by ship to Tokyo. And then, 9 down at – then they flew us to Inchon. No, the ship took us there because I remember going over the side of the ship with the bag. And, they put me in as radio operator. Hey, I've been away from radio operator for six months. Code. I'd lost it. So, they were thinking what they were going to do with me. Well, I finally said, "Look, I'm rotating home. Give him my job (which was signal supply)." All signal supply came from division, but division was too far away to make it manageable, so we just took it up by the regiment. It was closer by. So, I set that up. I requisitioned. It was a great job and in other words, another thing is don't ever have a driver's license in the military. Because you might get picked to drive ammo up. And, so I could requisition a vehicle to go to Seoul to get supplies. But, what did that mean? Go to Seoul, have dinner, a few drinks. Trip around for an hour or two and go back up again with the supplies. And, anything you wanted, what you need, I bought a nice bamboo pole, a fishing pole over there in the PX. A big, huge PX in Seoul. I shipped home. Then, I had all those supplies and everything, I was in contact with all of our regiment, including the Dutch, which were assigned to us. And the Dutch had a good deal. They had a – there was a Dutch colonel that was their commander and he was a real nice guy. He always came to shows with his troops and sat with his troops at the shows and things. He was (inaudible) [0:36:39] over the guy. And, in later years, my daughter and her husband lived in Holland and I was over there Memorial Day at the America Cemetery and there were the Dutch that I served with in Korea. And so, we got together much later in life. That's about it. JC: When you landed at Inchon, where did you go from there? RC: (?) [0:37:23] Up to Seoul. JC: Up to Seoul? RC: Yes. JC: I've got us a map. RC: Oh, yes. Went up to here. And this is where I was. JC: And where's that? RC: Pork Chop, Old Baldy. We went up Old Baldy twice. And it literally, we bombed the hell out of them. We'd go up there and they bombed for over an hour. And we pull off and blow it. And then, this was always kept quiet. The ROKs, Republic of Korea soldiers, they were an army of their own. We'd go up Baldy and they'd go with us. On our right flank or our left flank. And we get up there to do our work, and we'd look over and our left flank is not covered. Word came from here. They bugged out. And that's when we very quietly broke up the ROK division and infiltrated them with us. And, it didn't do any more bugging out. If it did, we shot them. That stopped it. And the good side of it is I had a 10 poor boy with me, (?) [0:38:56] in the radio repair tent, he lived with us. We taught him English. We taught him radio repair. We gave him clothes to wear. His mother did all our laundry for us. Ironed our clothes on hot rocks. He was really a great kid. I'm sure when we left, he had a head's up in society because of his training with us. JC: And that was in July '52? RC: Yes. JC: Where did you go after that? RC: Oh, we stayed right here. All the time. JC: Oh, okay. RC: And we'd pull off hill about – I think it was three months. And they'd pull us off. And it was New Year's Eve 1952, New Year's Eve. And we pulled off, off, off and went down. All that means is that you've got to move your communications, you've got to move your mess hall, you've got to move your water, your latrine. Everything you had to do and we moved that day. And a telephone rings from the company that replaced us up there. And there's noise, and I got the phone. "Who's this?" "This is Lt. Swift." I said, "Rollie?" He says, "Yes.' I said, "Dick Cummings." "Oh, for God's sakes! How are you?" I said, "I'm fine. What's your problem?" He says, "We don't have anywhere near enough equipment up here." I said, "Really? I'll tell you what I'll do. It's snowing to beat hell. The roads are slippery. I'll load up a deuce and a half." I go down to the motor pool and find the soberest driver. And in those days, blacks were in either the motor pool or the mess hall. "Go down to the motor pool and find the soberest driver and I'll come up there and you give me a jeep, because I don't want to stay. I'll swap you a truck with equipment and you give me a jeep." "Fine." Now how are you going to take care of this equipment? Battle fatigue. (inaudible) [0:41:51] Boom! Truck gone. (Laughs) JC: (Laughs) RC: That was Rollie. I never saw him. I just talked to him. JC: What did you do after Korea? RC: I came home. And I went to work in the factory. Tanning. My – our company corporate lawyer was an uncle of mine. Ray, his last name, my mother's brother. And he suggested that I, I got discharged the 3rd of July. They got us out for the 4th of July. Really rushed us down (?) [0:42:52] to get us out. Instead of having a hold-over for the 4th of July weekend and wait until like the 6th of July. So, that got us off the 3rd. Discharged. And, my uncle said, "Don't be in a hurry to go to 11 work. Because this is the last time in your life you can do what you want to do. Once you start to go to work, you're plugged in for the rest of your life." (Laughs) So, my roommate and I, he got home from Germany and we got together and went to work August 16, 1953, 2, 3. Yes, '53. That's when I went to work, 1953. And Bruce and I traveled New England. He got new a Chevrolet, I had a new Chevrolet, all paid for. Paid $2,000 for it. Brand new. And, -- with money that I sent home. I made money selling whiskey over in Korea. We had a liquor allocation, particularly if you were in combat. A private got a fifth a week, a month. A corporal got two fifths a month. A lieutenant got three fifths a month. So, and for $2.00 a bottle. And even the liquor was Cadillac, Cadillac Club or something like that. So, you got three fifths a month but you only wanted one. So, I'd give you $4.00 for your two fifths. And, I'd build up, oh, about a dozen bottles of whiskey, and I'd keep it under my bunk. And I had a little dog. And word "little" in Korean is "scosh (?) [0:45:13], so I used to call him Scoshie. He stayed right under my bunk and got into (?) my whiskey. JC: (Laughs) RC: And, so on the 10th of the month I had three bucks and the 15th of the month I'd get maybe 5, 6. 28th of the month or so, 10 bucks, whatever traffic will bear. Ship the money home. $2,000. And so, when I got out, we had the money and Bruce and I went to Montreal together. We went to Eastern State Exposition together. We just played for about six weeks. And he went to work in the family shoe lasts business. I went to work in a tannery. Got up in the morning to go to work. We got to work at 7:00 so we were up and having breakfast at about 6:15. Got up. Put a suit and tie on, jacket. Head down to the office (inaudible) [0:46:35]. Went in a little locker room. Opened the door and says, "There's your clothes." Old wool pants and old wool shirt. "You're not going to wear any suit. You're out there." JC: (Laughs) RC: (Laughs) And that's where I started out, working every department. Doing every job in every department from bundling a green saw hides from cutting the rope off and shaking the sod out and preparing them to get washed and that whole process all the way through to rolling them up, finished leather to go to the shoe factory. All the way through. Then, I became kind of like a shop foreman. And around Christmas time, we had hired a finishing foreman. He's in charge of the black finish, the brown finish and the colors in other words. And we were closing shop up for Christmas weekend and he was drunk. So, I fired him. So, Christmas at my father's house, we were outside, said, "Yes, we've got a problem, we've got to find somebody to replace him." My father says, "I already have." I said, "Yes, who?" "You." Oh, I had to study damn fast! JC: (Chuckles) 12 RC: Like a day! (Chuckles) And I ran that finish room – I think I was running it when we got married. Yes. At least a year. And then my father's health was going. In 1960, I took over as, in those days we called it superintendent, and then I started organizing the staff, and organizing the foremen. I got a letter here somewhere, my nephew found here, a few months ago when my father was in Florida, came home from – (?) [0:49:13] in very poor health. He had colitis all of his adult life. Never weighed over 140 pounds. Never. And he wrote my brother, my older brother that came back and never found the shop in better shape in the 20 years he'd been in Lebanon. And I had taken it, and I really worked hard. And when he died, I really went to town and I borrowed money, which is a no-no. And I got modern equipment in. Like I got one piece of equipment, run by one man, one shift. It would replace four machines that were run two shifts. That's eight men. Pretty soon, paid that thing off in two months. I did start doing that. And we belonged to the Tanners Council, which was housed in, headquarters in New York City. And they called me up one time, he said, "We usually don't do this, because everybody is under a code name." So when they send out asking for information, and your code – your name's not on it. There's a code name only they know who it is. He said, "We usually don't do this, but we thought under the circumstances, we'd call you up and tell you that you have the lowest labor costs per foot in the country." JC: Wow. RC: Well, anyhow, that was – and then of course, Uncle Sam put us out of business, all of us. There's not a tannery in – I believe there's one tannery, and it's Prime Tanning in Berwick, Maine. And I heard a few years ago that a shoe company out in St. Louis bought them. So they could be sure of having a source of leather. JC: So how did the government put them all out of business? RC: Environmental. See, we're on the river and we need – and I used to have those figures, and I really have forgotten what they are – it was thousands of gallons of water a day. And there was no way any municipal water system could supply us. No way. That's why they're on the river. To pump the water out of the river. And, they got a problem there. In the wintertime the water is 30 degrees. You got that 30 degree water you got to raise it to 70 degrees, that's a hell of a lot of steam. And in summertime, the water can get up to 75 degrees. And you got to lower it to 70 degrees. So that's a hell of a problem. How are you going to – this is only a short time, a matter of a few weeks, you know. So, we'd buy ice and dump it in. It took a hell of a lot of ice to do it. That's what we did. That's why – and then you surge. A hell of a surge. Everything, you wash and rinse, wash and rinse. Into the river. Out into the Connecticut, down to Long Island Sound. All the town (?) [0:53:29] sewer system, dumped right into the (inaudible) [0:53:32] lake, up until a few years ago. The woolen mills in Enfield (?) dumped into the lake. The lake went down the river, the woolen mills, and leather and the tanning, dumped into the river. And half the woolen mill, all the way down. 13 What could we do? I mean, that's how the government, you say, put us out of business. JC: Oh, okay. RC: I think the largest producing leather today is Argentina. Because that's where the (inaudible) [0:54:13] cow hides were. Used to ship them by boat. To New York, Boston. JC: So, when did you meet, how did you meet Nancy? When did you meet? RC: I got out of the army. I came home. And, went to church. And coming out of church, Brownie was there. And I spoke to him, I said, "Who's that good-looking daughter of yours, Nancy?" He says, "She's over at Colby Junior College." And I said, "I think I'll go see her." So he gets home and calls her up. (Chuckles) And I went over to see her. That was in the fall. We were married the next September. (Chuckles) JC: And how long have y'all been married now? RC: 62 years in September. JC: Wow. Congratulations. What did you do after the tannery closed? RC: Find a job. Sitting down reading the paper, not knowing what the hell I'm going to do. Big tanneries out in the Midwest. That was a consideration, in some capacity. Night foreman or night shift superintendent, anything. And, reading this paper, department of resources and economic development, officer industrial development needed. Industrial agent for the northern three counties in New Hampshire. Paul Gilderson (?) [0:56:25], telephone number. I knew Paul. He says, "I was hoping you'd call." JC: (Chuckles) RC: Had 60 people call him. He interviewed me about 10:00 in the morning, over in Plymouth, a bank in Plymouth. And, the next day Paul called me up, says, "You got it." So that's – I spent 16 years doing that. And I loved it and I was good at it. I – even today, I see television ads that I'm responsible for. When I ride up country, I see factories that were built by companies that I moved in, from Canada, Sherbrooke, outside out Montreal. Massachusetts. My objective always was not to hit them hard but suggest a branch, suggest a satellite, suggest the reason why. Taxes, labor costs, transportation costs is less expensive and it's offset by your savings on labor. No union. One of my – I picked this up from my father, when he was asked a question about the labor, in New Hampshire against Massachusetts, he says, "All the labor are capitalists. They own a piece of land. They own an animal. They cultivate vegetables. They buy grain. They buy 14 fertilizer. They sell their product. They're all capitalists. And that's exactly right. You just don't get a guy off the street. He's got a reason to where he's really working for cash, supporting himself. JC: Well, let me ask you a couple of questions back about Norwich. What was your favorite part of going to Norwich? RC: Well, if you're talking socially, I'd say membership in a fraternity. If you're talking academically, it's those three professors I mentioned. JC: What was the – is the most important thing that Norwich taught you? RC: I wrote that out somewhere, because I gave that some thought. And I – JC: I think it's on the back. RC: Respect for authority and responsibility. JC: What did the school's motto, "I Will Try," mean to you when you were a student? RC: Say that again. JC: The school's motto, "I Will Try." What did that mean to you as a student? RC: Basically, I'm in college and I will try to finish this course, I will try – and it's been my motto all my life. On my tombstone. JC: I was going to ask you, has it changed any since you were in college? RC: No. JC: No. What about the idea about citizen soldier? RC: I think it's an excellent education. JC: And why is that? RC: Because it teaches you responsibility, authority, respect. You have to – in order to be able to lead, you have to know how to follow. And Norwich teaches you that. I had a classmate whose sons went to the Citadel. Three boys and they all went to Citadel. Because of his experience at Norwich. JC: You think they regretted going to the Citadel instead of going to Norwich? RC: I have no idea why he picked it. 15 JC: (Laughs) How do you think your professional life would have been different had you not been a Norwich graduate? Or had not gone to Norwich? RC: Not as disciplined. JC: It seems like discipline was a very major part. RC: Yes. If you take, in my day and my era and my location, kids went to the University of New Hampshire. First of all, a large percent of them flunked out after the first semester. Another big chunk flunked out after the first year. So, those that really got in to graduate was a lot smaller than those that got accepted to go there. Reason why, they weren't prepared for it. In my era, they came from these little towns throughout New Hampshire down into the more metropolitan area, Portsmouth area, New Market area and open campus and open lifestyle that they weren't used to. And, if affected them. Very few percentage of them really ended up graduating from college, at that time. JC: Do you think going to Norwich has opened some doors for you that might not have been opened otherwise? RC: Oh, yes, I think so. But, particularly in my later line of work. I can remember having a meeting up in Woodsville, New Hampshire. And, I was working on locating a company, it was Bass Shoe as a matter of fact. And, Bass Shoe was a Maine company and I knew that I couldn't deal with the management of Bass Shoe, because they were favored to Maine. Bass Shoe, and I forgot the name, but the parent company was in Greenwich, Connecticut, so I just, on my own, drove down to Greenwich, Connecticut. No appointment. I had a name and an address. And I knocked on the door, and went in and they listened to me. They're located in Haverill, New Hampshire. While I was doing that, talking with local people in the Woodsville/Haverill area, and a ___(?) [1:04:47] sat and he says, "I knew there was a reason why I liked you." So, I said, "Well, yes, you went to Norwich." JC: (Chuckles) RC: And he had gone to Norwich. JC: Do you think Norwich folks have a special bond that other military and civilian institutions lack? RC: Oh, yes. A great deal. The corps of cadets brought that about. And, from my day to this day, wherever we meet, we always, always get together. Homecoming is an uplift, particularly now at my age because all my roommates are gone. All my closest friends are gone. My brothers are gone. My cousins are gone. But, we go up there and Eddie Barrow's (?) [1:05:51] there, always a joke from him. And Louie Swift, all my cousins, great bunch. 16 JC: Have you continued to be involved with Norwich since you left? RC: I have been very interested in the museum. And I contribute to it. Not much, but I do every year. Because I think they're doing a tremendous job of carrying the history of the institution, from when it was almost nothing, on. And I can remember being involved with Todd's wife because she really worked hard on that. And she used to come down to affairs in the town of Norwich, over here, and I'd meet them over there. They dedicated a stone plaque over there in the town of Norwich a few years ago, and she was there. And I think you've all done a wonderful job up there with that. And the improvement on that library was very interesting. By the way, I have it here somewhere and if I can't find it, I was on the committee that resurrected bricks from the barracks in Norwich. JC: Oh, okay. RC: And clean them up. I got a picture here somewhere and I'll mail it to you when I find it. It's a group of us in Hanover, by the field house. What's the name of the field house? (inaudible) [1:07:47] The great big field house there. And we dumped the bricks in there. And literally we cleaned them up, put them on pallets and took them – they all ended up at Norwich. And some when out to national headquarters of Theta Chi and some you have there in the vestibule of the library. I was in that group that worked on that. JC: And the rest of them are downstairs in the museum. RC: Yes. JC: Did you stay in touch with a lot of your classmates? RC: Yes. As much as possible. JC: What advice would you give a rook today on how survive through that first year? RC: Well, it was a hell of a lot tougher my first year than it is today, I'm sure. If you can't survive it, you don't belong there. That's just as simple as that. JC: Was there anything else you'd like to add that we didn't talk about that we should? RC: To run it all up together, the best thing about Norwich was that it was an institution with traditions, small in size, closeness to faculty and classmates. And we acted together, lived together, worked together and played together. That would be Norwich. In my day. JC: Anything else you want to add? 17 RC: No. JC: Well, thank you very much. (end of audio)

10/28/2020 University Journal - March 2014 www.fresnostatejournal.com/vol17no6/index.html 1/8 March 2014 Vol. 17 No. 6 Arts | FYI | Newsmakers | Service | Sports FEATURE STORY: Diversity Forum addresses race relations A day-long forum to address the challenges in exploring the importance of diversity on campus was hosted Feb. 19 byPresident Castro and the President's Commission on Human Relations and Equity. See the full story with video here. Dr. Frank Lamas is new vice president for Student Affairs President Joseph I. Castro has appointed Frank R. Lamas as the new vice president forStudent Affairs effective July 1, 2014. Lamas, who has more than 30 years of administrativeexperience in higher education, has been vice president for Student Affairs and dean ofstudents at the University of Texas at Arlington for nearly nine years. A native of Havana, Cuba,and raised in Syracuse, N.Y., he is a first-generation college student. Read the full story. Provost search nets three finalists Fresno State's nationwide search for a provost and vice president for Academic Affairs hasresulted in three finalists who will visit the campus to meet with faculty, staff and students. The new provost will succeedDr. William A. Covino, who became president of California State University, Los Angeles in September. The candidates are: Dr. Christopher Ingersoll, dean of the College of Health Professions – Central Michigan University Dr. Scott Ryan, dean of the School of Social Work – The University of Texas at Arlington Dr. Lynnette Zelezny, associate provost – California State University, Fresno Construction begins on Campus Pointe retail phase, 'The Squ are' Construction of Fresno's newest retail center was formally launchedon Feb. 10 with groundbreaking for "The Square at Campus Pointe."The first 12 business tenants were announced for the project onChestnut north of Shaw, near the Save Mart Center and Highway168.10/28/2020 University Journal - March 2014 www.fresnostatejournal.com/vol17no6/index.html 2/8 The Square is the next phase of the 45-acre mixed-use developmentCampus Pointe project, a public/private partnership between theCalifornia State University, Fresno Association, Inc. and KashianEnterprises, the master developer of the project. Read the full story . President Castro, Chancellor White speak at African-American churches Chancellor Timothy P.White and PresidentJoseph I. Castro spoke atAfrican-American churchesSunday, Feb. 16, as part of CSU Super Sunday — the flagship event of the CSU African-American Initiative that focuses on closing the collegeachievement gap for African-American students. Throughout California, CSU campus presidents, trustees, the chancellor andother higher education officials spoke from the pulpit about college readinessand the possibilities for obtaining financial aid. Launched in 2005, CSU SuperSunday is an annual event where leaders throughout the 23 CSU campuseswork together in a united effort to give underrepresented students the toolsneeded to successfully enter college. To date, almost 500,000 churchgoershave received information about financial aid, been introduced to the 23 CSUcampuses and learned how to achieve academic success at the university. Read the full story and view photo gallery . FACULTY / STAFF SPOTLIGHT Madhusudan Katti's international research team uncovers urban biodive Can thriving urban areas support biodiversity in plants and birds?Surprisingly, yes, according to worldwide research findings ofFresno State Associate Professor Madhusudan Katti and aninternational team. The findings were published in the biologicalresearch journal Proceedings of the Royal Society B. Contrary toconventional wisdom that cities are a wasteland for biodiversity, thestudy found that overall the mix of species in cities reflects theunique biotic heritage of their geographic location. See the fullstory . Benjamin Boone takes music education to the masses Music Professor Benjamin Boone, a composer and accomplished jazzmusician, has been drawing headlines for his "Inside the Music" pre-concertlectures with the Fresno Philharmonic. The lecture series was recentlyfeatured in the Fresno Bee . See the full story . John Capitman appointed to air quality board Dr. John Capitman, executive director for the Central Valley HealthPolicy Institute, was appointed by California Governor Jerry Brown to theSan Joaquin Valley Unified Air Pollution Control District GoverningBoard. See the full story . FYI 10/28/2020 University Journal - March 2014 www.fresnostatejournal.com/vol17no6/index.html 3/8 First Jensen Pistachio professor joins plant science faculty A $1.5 million pledge last year from the California Pistachio Research Board to the Jordan Collegeof Agricultural Sciences and Technology brings Dr. Timothy Spann to Fresno State conductadvanced research and education for the pistachio industry. Read the full story. Inventory of keys is coming; watch for email A campus-wide inventory of keys will be conducted in coming weeks. All administrators, staff andfaculty will receive an email from Bob Boyd, associate vice president of Facilities Management, asking you to logon to awebpage to report the physical keys you have. This information will be reconciled against the Lockshop records.Thisinventory process will also provide you a convenient opportunity to return any keys no longer needed. If you have anyquestions about this process, contact the Lockshop at 278.2172. View a short video on this project. On-site Employee Assistance Program counselor taking appointments Fresno State has selected an on-site, part-time Employee Assistance Program counselor, David Crabtree, throughEmpathia our current provider of EAP services. Appointment times are available 9 a.m. to 2 p.m. on Monday , Tuesday , Thursday and Friday . A licensed clinical social worker, Crabtree is available to provide counseling services to all activefaculty, staff and their family members. His direct phone is 278.1655 and email address is dcrabtree@csufresno.edu . Hisoffice is Lab School Room 185 (confidential side door entry for scheduled appointments). Advancement team wins four communications awards The Council for Advancement and Support of Education (CASE) Western district awarded four honors for excellence toFresno State's Division of Advancement. The university earned a silver award for a magazine insert on former universityPresident John D. Welty. Bronze awards were earned by the Fresno State Alumni Association for the "What Day Is It? It'sHump Day!" video, University Communications editor Eddie Hughes for a Fresno State Magazine story introducing newuniversity President Joseph I. Castro and photographer Cary Edmondson for a water image of Fresno State footballplayer Davante Adams . The awards were presented by the CASE District VII, which represents universities in Arizona,California, Guam, Hawaii, Nevada, Northern Mariana Islands and Utah. Provost's Awards nominations due April 4 Nominations are being accepted through April 4 for the Provost's Awards for the 2013-2014 academic year. Students,faculty, and staff are encouraged to submit nominations of full-time tenured and tenure-track faculty, or an academicprogram for the Assessment of Learning award. Nominations may be submitted in the following categories: Excellence in Teaching Technology in Education Graduate Teaching and Mentoring Faculty Service Distinguished Achievement in Research, Scholarship, or Creative Accomplishment Promising New Faculty Award Distinguished Achievement in Assessment of Learning (Department award) Nomination forms and instructions are available online and in the Office of the Provost, Haak Administration CenterRoom 4116, Henry Madden Library, 4th floor. Peach Blossom Festival is March 13-14 The 56th annual Peach Blossom Festival of Oral Interpretation will be March 13-14 at various locations on campus withapproximately 6,000 children representing nearly 200 San Joaquin Valley elementary schools. The event is hosted by theDepartment of Communication. For more information call 8-4419 or go to www.peachblossomfestival.com . Secret Garden party and Leo Politi Garden rededication, April 13 The Arne Nixon Center Advocates (ANCA) invites you to attend the annual Secret Garden party and Leo Politi Gardenrededicationon April 13, from 3 to 5 p.m. at the Politi Garden on the east side of the Madden Library. The party is ANCA'smajor annual fundraising event, with all profits going to the Arne Nixon Center. Leo Politi was the Caldecott Award-winning illustrator and/or author of over three dozen books. A Fresno native whorelocated to Los Angeles, he was a good friend of Professor Arne Nixon often returned to Fresno to participate in Nixon'schildren's literature classes and festivals. The Politi Garden was created with funds raised by ANCA to honor the specialfriendship between the two men. Paul Politi and Suzanne Bischof, the son and daughter of the late Leo Politi, will attendthe rededication. For more information or to make reservations, please send email to jsanford@csufresno.edu . CLEAR launches a new peer-reviewed journal The Center for Leadership, Equity and Research (CLEAR) has launched " The CLEARvoz Journal ," a quarterly peer-reviewed journal focused on equity issues in education. The online, scholarly journal seeks to promote research in10/28/2020 University Journal - March 2014 www.fresnostatejournal.com/vol17no6/index.html 4/8 elementary, secondary and postsecondary schools with articles that address a range of topics including advocacy, equity,mentoring, diversity and engagement. Read the full story . STAR Day is May 29 The annual Staff Training And Recognition – STAR – Day will be held May 29 . STAR Day is designed to commemoratethe end of a successful year, promote staff development and recognize the accomplishments of our campus staff. Theevent will include a guest speaker, professional development workshops, a service recognition awards ceremony, staffluncheon and a vendor fair. Watch for upcoming email announcements about the event and visit the website for updates. Grants offer new opportunities for nurse practitioner students The College of Health and Human Services was awarded nearly $300,000 ingrants to help fill a regional void of primary health care providers. The grantswere awarded by the Song-Brown Commission, which encourages universitiesand health care professionals to provide quality health care in underservedareas. Read the full story . BRAND BULLETIN Social media and branding elements By Susan Hawksworth Continuing and Global Education Many departments and programs are activelycommunicating by using social media, such asFacebook, Twitter or LinkedIn. According to Dr. TamyraPierce, director of Social Media and IntegratedMarketing, there are nearly 100 Facebook pages andapproximately 50 Twitter accounts associated withFresno State. However, having a good social media presence is morethan just "having" a site. It's important to buildconnectionsand engagement. In addition, any site associated withFresno State should also include the correct use ofbranding elements. Pierce conducted an analysis of the known sites affiliatedwith Fresno State and found that some still feature the old Fresno State and no longer approved sunburst logo orthe university seal. Some sites are using the correct new logo, but it has been improperly condensed to fit theexisting space or cropped. The University Communications office has digital versions of the new logo, sized for use on the various socialmedia sites. They are available by emailing brand@csufresno.edu. "We encourage anyone who is theadministrator of a social media site to help promote our branding efforts by using the appropriate logo and thecorrect name of the university," Pierce says. The content analysis of various social media sites found that many of them are using the university nameincorrectly (CSUF, CSU Fresno, Fresno State University, FSU, for example). We encourage everyone to useFresno State in social media to increase search results. FS is permitted on Twitter and Instagram due to characterrestrictions. CSUF is now affiliated with Fullerton and should not be used (FYI, @CSUF is Fullerton's twitterhandle). "Through our Integrated Marketing Communications work over the past two years, we have designated the use ofeither Fresno State or California State University, Fresno for our name," Pierce said. "Consistency with our logoand name help strengthen our brand." It's a good idea to review your department's or unit's Facebook page(s) and website(s) to ensure the properbranding is used. If you're not sure whether the branding is correct, review the brand guidelines( www.fresnostate.edu/brand ) or contact Dr. Pierce at tpierce@csufresno.edu . S􀵾􇸍􀶋􈬍􀶏􈼍􀶂􈈍􀵼􇰍􀵾􇸀10/28/2020 University Journal - March 2014 www.fresnostatejournal.com/vol17no6/index.html 5/8 Spring into Service, March 22 The campus community is encouraged to participate in a Fresno State morning of service on Saturday, March 22 from 8-12:30 p.m. As part of the campus-wide "Spring into Service" event, volunteers are needed to complete service projectsincluding tree and shrub planting, and installation of a water wise demonstration garden. Families are encouraged tovolunteeer. Please fill out the Spring into Service 2014-Volunteer Registration Form . Volunteer space is limited and filledon a first come, first serve basis. For questions please contact Renee Delport at rdelport@csufresno.edu or 278.7063. STUDENT ACHIEVEMENT Lopez named campus first-ever Gates Cambridge Scholar Senior Stephanie Gabriela Lopez was awarded the Gates Cambridge Scholarship, afull-ride graduate scholarship to Cambridge University, making her the first FresnoState student to receive the prestigious academic honor. The scholarship is awardedto 95 students worldwide each year. Lopez is one of 40 United States studentsrepresenting 35 institutions. Read the full story. Student wins College Entrepeneur of the Year Award Student Roe Borunda, will receive the College Entrepreneur of the Year Award fromthe Greater Fresno Area Chamber of Commerce for her hatchery-assisted business,Roetography. Borunda is a senior, double major (Art and Mass Communication andJournalism) from Fresno whose company was one of four selected to be recognized atthe chamber's Valley Business Awards Luncheon in March. "If it wasn't for programs like the Lyles Center Student Hatchery and faculty and staffmembers at Fresno State to help push me in the direction of my dreams, I probablywould have never known the sky can be the limit," Borunda said. A􀶋􈬍􀶍􈴍􀶌􈱁 Absurd Masterworks , March 14-22 The Theatre Arts Department presents three pieces by the masters of Absurdist theatre, Samuel Beckett and Eugene Ionesco, March 14-22 at the Dennis & Cheryl Woods Theatre. The style of theplays ranges from tragic to comic--from meditations on an adulterous affair to asatire of modern suburban living that morphs into a living puppet show. Other University Theatre productions: Experimental Theatre Company, April 4-6 For Young Audiences - The Velveteen Rabbit, April 5 University Dance Theatre, April 24-26 Othello, by William Shakespeare , directed by Brad Myers , May 2-10. All performances begin at 8 p.m., except for Sunday matinees, which begin at 2p.m. ID must be presented to claim discounted tickets. Tickets can be purchasednoon-4 p.m. Monday-Friday at the University Theatre Box Office at the northentrance of the Speech Arts Building, 278.2216. View ticket information . Other Music events in March: Wind Orchestra Concert, March 6 Keyboard Concerts -Sergei Babayan & Danil Trifonov, March 7 Jazz Bands, March 13 Orpheus Chamber Music Ensemble and El Cimarrón Ensemble present NOTHING and more, March 15 Saxes at Stage, March 18 The Frenso State Guitarists, March 28 Guitar Festival, March 28 Fresno State Symphonic Band Concert, April 210/28/2020 University Journal - March 2014 www.fresnostatejournal.com/vol17no6/index.html 6/8 See ticket information. 'Turning Pages: Intersections of Books and Technology' is March 24-May 30 The Arne Nixon Center for the Study of Children's Literature and the Special Collections Research Center will host"Turning Pages: Intersections of Books and Technology." The exhibition will be held in the Leon S. Peters Ellipse Gallery,March 24 - May 30. The Special Collections division has teamed up with the Center for Creativity and the Arts tocollaborate with this year's chosen theme of Data and Technology. Technologies new, old and reinterpreted have altered the paradigm of the book since its inception. From creation andcontent to format itself, the collective notion of the book, a benign object, is continually changing. "Turning Pages" willprovide a glimpse into some of the ways in which technology has radicalized books and bookmaking. Exhibition artistsinclude Thomas Allen, Su Blackwell, Brian Dettmer, Pamela Paulsrud, and Mike Stilkey. A reception to celebrate the exhibition's opening will be held on Friday, March 28, at 6:00 p.m. at the Madden Library2206. A presentation by book artist Mike Stilkey will begin at 7 p.m. The event is free and open to the public. Relaxedparking for the event in Lots P30 and P31. To RSVP email jsanford@csufresno.edu or call the Arne Nixon Center at278.8116. N􀵾􇸍􀶐􉀍􀶌􈰍􀶆􈘍􀵺􇨍􀶄􈐍􀵾􇸍􀶋􈬍􀶌􈱗 Wade Gilbert (Kinesiology) will co-present on "Athletic Talent Development: Current Status and FutureDirections" at the U.S. Olympic Academy on April 15 in Los Angeles. The academy will togetherscholars and students, athletes and administrators, business experts and leading mediaauthorities to discuss important Olympic issues. Nitaigour "Prem" Mahalik (Industrial Technology) received a $500,000 grant from the Department of Defense to acquireequipment and instrumentation to further the university's ability to teach and research emphasizingsensing and control. Blain Roberts (History) and Ethan J. Kytle (History) were askedby the New York Times to write about the Central Valley drought. Withinhours of publication online, it was the third most-emailed, the ninth most-viewed and the 10th most-tweeted story. Read the column. A new book by Roberts (History)," Pageants, Parlors, andPretty Women: Race and Beauty in the Twentieth-Century South," was published by the University of NorthCarolina Press. Read more . Asao Inoue (English) won a 2014 Outstanding Book Award in the Edited Collection category for his book,"Race and Writing Assessment" from the Conference on College Composition andCommunication, a constituent organization within the National Council of Teachers of English(NCTE). The award honors books within the field of composition and rhetoric. 10/28/2020 University Journal - March 2014 www.fresnostatejournal.com/vol17no6/index.html 7/8 Nancy Akhavan (Kremen School) is the editor of the inaugural issue of CLEARVoz, the peer reviewed journal ofFresno State's Center for Leadership, Equity, and Research (CLEAR). Read the Journal. Steve Spriggs (University Development) challenged a $165 fine for using his cellphone map application whilestuck in traffic and has won an appellate court ruling that Californians can use cellpohnes to look atmap applications while driving. He does not encourage cellphone usage while driving, but hopesthat California legislators will now revisit the issue and fix it. Spriggs story has been widely carried inthe media. Read the USA Today story . S􀶉􈤍􀶈􈠍􀶋􈬍􀶍􈴍􀶌􈱂 Baseball, softball, basketball and lacrosse are in store thisMarch Don't miss out on the Bulldog action as it offers plenty of opportunities forour veterans, faculty and staff, and your family. Baseball Tuesday, March 11 at 6:35 p.m. vs. Penn State - Season ticket holderappreciation. Wednesday, March 12 at 6:35 p.m. vs. Penn State - Season ticket holderappreciation Friday, March 14 at 6:35 p.m. vs. New Mexico - Alumni Night . Saturday, March 15 at 2:05 p.m. vs. New Mexico - Youth Jersey Saturday . Youth wearing jerseys receive free admission Sunday, March 16 at 1:05 p.m. vs. New Mexico - St. Patty's Kick Off/ Saluteto Sundays . Free admission for all active military and veterans . Kids runbases. Tuesday, March 18 at 6:35 p.m. vs. California - Staff and Facultyappreciation night. Free admission for all staff and faculty. Honor professors. Wednesday, March 19 at 6:35 p.m. vs. BYU Tuesday, March 25 at 6:35 p.m. vs. UC Santa Barbara - Greek night, Tankgiveaway. Softball Thursday, March 13 at 5 p.m. vs. Pacific. Social Media Madness - 2-1 Ticketdeal for fans following Fresno Athletics. Friday, March 14 at 6 p.m. vs. Ohio State - Dog Pound Night/Youth JerseyFriday - Youths wearing jersey receive free admission . Meet the Team post-game. Saturday, March 15 at 3:45 p.m. vs. Cal Poly - Throwback Night/AlumnaeNight Saturday, March 15 at 8:15 p.m. vs. New Mexico State - ThrowbackNight/Alumnae Night Sunday, March 16 at 3:45 p.m. vs. Saint Mary's College - Free Admissionfor all Veterans and active military. Kids run the bases . Friday, March 28 at 6 p.m. vs. Utah State . Strike Out Cancer/Youth JerseyFriday -Youth Wearing Jersey get free admission. First 5 Fresno Countybook drive. Saturday, March 29 at 6 p.m. vs. Utah State. Strike Out Cancer . Blood Drive - First 5 Fresno County Book Drive. Sunday, March 30 at 1 p.m. vs. Utah State - Strike Out Cancer. Freeadmission for all veterans and active military. First 5 Fresno County bookdrive . Kids run bases post-game. Freshman autograph signing post-game. Women's Basketball Friday, March 7 at 7 p.m. vs. San Jose State - Free Admission by Redeeming Voucher (Found at gobulldogs.com) to10/28/2020 University Journal - March 2014 www.fresnostatejournal.com/vol17no6/index.html 8/8 Ticket Office . T-Shirt In-Game Giveaway. Kids Fun Activity Zone-bounce house, face painting, and more . Mutts in Motionhalftime Performance. Lacrosse Wednesday, March 5 at 5 p.m. vs. Stanford - Dog Pound/Greek Night . Sunglasses giveaway. Saturday, March 8 at 12 p.m. vs. Colorado - Youth Day : Kids fun activity zone- bounce, face painting, and more . Autograph card giveaway . Team autograph session post-game Wednesday, March 19 at 2 p.m. vs. Columbia - Staff and Faculty appreciation day . Tote bag giveaway . HonoringProfessors. Friday, March 28 at 5 p.m. vs. USC - Alumnae Night. The Journal is published online by the Office of University Communications the first day of each month – or the weekday closest to the first – fromSeptember through May. The deadline for submissions to Journal is 10 days prior to the first of each month. Please e-mail submissions to journal@csufresno.edu . You may include digital photos, video clips or audio clips that are publishable online. Phone messages, PDFs, faxes, andprinted hard copies will not be accepted. President , Joseph I. Castro Vice President for University Advancement , Peter N. Smits Associate Vice President for University Communications , Shirley Melikian Armbruster Director of University Web Communications and Publications , Bruce Whitworth Editorial Coordinator , Margarita Adona • Photographer , Cary Edmondson • Videographer , Randy Haar • Contributor , April Schulthies Web Coordinator , Kevin Medeiros • Editorial Adviser , Angel Langridge Production Assistant , Leilani Esqueda Archives | Academic Calendar | FresnoStateNews | Journal Deadlines | University Communications Print this Page

20 años las naciones ricas pensando el Desarrollo; 20 años las naciones pobres defendiendo los recursos; 20 años, sin recursos y sin Desarrollo. 4. Movimientos sociales se resisten a la minería a gran escala en América LatinaAsí como se evidencia la relación entre conflictos mineros y violaciones a los derechos de las personas que cohabitan en zonas con recursos, podemos afirmar que existe una capacidad de organización social, que denuncia y defiende derechos con base en la universalidad (para todos), la inviolabilidad, en la no negociabilidad, en la imprescriptibilidad, en la indivisibilidad y en la irreversibilidad. Sin embargo esta protesta y resistencia por parte de los ciudadanos que están directamente involucrados en conflictos mineros en América Latina, presentan problemas de todo tipo que van desde la criminalización de la protesta hasta la expulsión de sus territorios (1) (Gráfico 6). El cuadro 3 demuestra los casos de criminalización, siendo esta la práctica más reiterada en los países con mayores recursos y también en donde sus poblaciones en buen porcentaje son comunidades étnicas (indígenas). Cuadro 3.PaísCasos de criminalizaciónMéxico1Nicaragua1Colombia1Brasil1El Salvador2Guatemala3Perú7Ecuador10Es importante resaltar que no se trata de una serie de protestas sociales de tipo reaccionario al sistema económico, como fueron los discursos anti-imperialistas de los años 70. Se trata de justas reclamaciones por la defensa de la Vida y la exigencia a las multinacionales a la extracción responsable; no solo con la naturaleza sino con las comunidades que conviven en ambientes llenos de recursos. En este sentido la organización social latinoamericana, se ha ido cuantificando y cualificado especialmente en aquellas regiones / países en donde se presentan más conflictos y a su vez mayor inversión externa al sector minero. (Cuadro 4) Cuadro 4. Matriz de organizaciones involucradas asuntos mineros según el Observatorio de conflictos Mineros de América Latina y el I Encuentro Nacional Minero, Colombia, 2012 (2) PaísOrganizacionesColombia (3)Censat Agua Viva / AICO Pueblo de los Pastos, AIDA, Asentamiento indígena wayuú de Tamaquito II, Asociaciones de Zonas de Reserva Campesina, ASOCOMUNAL (Caldono), Asociación Minga, ASAPAZ, ASOCAMPO, BIOSIGNO, FEDERACIÓN DE MINEROS DEL CHOCO (AFROS), Colectivo de Abogados José Alvear Restrepo, CAMAWARI Pueblo (Awá de Ricaurte Nariño), CEAT (UN) UNIVALLE, Cimarrón, CIMA, Cinep, CODHES, Colectivo C.A.M.P.O, Colectivo S.E.A.T., Comisión de Seguimiento a sentencia 072, CSJ, Consejos Comunitarios del Chocó, Corporación Arco iris, Corporación Compromiso – Bucaramanga, CRIHU (Huila), CRIR (Risaralda), Espacio Regional de Paz del Cauca, Fundación Natura, Gidca, Instituto de Estudios para el Desarrollo y la Paz – INDEPAZ, Informe de desarrollo humano PNUD, International Alert, Mesa joven minería, Mesa de Unidad Agraria – MUA, OIA (Antioquia), ONIC, PCN, Pensamiento y Acción Social, PAS, Planeta Paz, Pueblo PASTOS (Nariño), Pueblo Wayuú (GUAJIRA), Pueblo Piaroa de Vichada, Pueblo Nasa de Caquetá, Suippcol, Red de justicia ambiental, Resguardo indígena Wayuú de Provincial.EcuadorAcción Ecológica, Pastoral Shuar, Pueblo Shuar Arutam, FICSH, Coordinadora de mujeres Intag, CDNV, Fundación Vientos de VidaPerúGrufides, Cooperación, Vima, ConacamiBoliviaCEPA, CEDIB, Centro Vicente Cañas, SOPE, EcomujeresArgentinaAsamblea Patagónica por la vida y el territorio contra el saqueo y la contaminaciónChileOlca, Conferre, Justicia paz e integralidad de la creación de St Columbano, Defensa del Valle Chalinga, Pastoral Salvaguarda de la creación, OCAS, Consejo Ciudadano Salamanca, Grupo Atacama LimpiaFuente: Elaboración propia con base en información del Observatorio de Conflictos mineros de América Latina, disponible en http://www.conflictosmineros.net/quienessomos, mayo 2012 El trabajo que adelanta el Observatorio de Conflicto mineros es importante. Sin embargo existe otro cúmulo de organizaciones que realizan un trabajo similar y no hacen parte de él como por ejemplo la Asamblea Popular por el Agua en Argentina y en Colombia, el Consejo Nacional Indígena del Cauca, CRIC.En Argentina, La Asamblea Popular por el Agua es una iniciativa ciudadana que surgió en el año 2006 como una expresión de rechazo a los proyectos de la mega minería y por la defensa del agua. La Asamblea que reúne diferentes sectores sociales de la provincia de Mendoza, logro en junio de 2007 que se sancionara la ley 7722 la cual prohíbe la minería contaminante. Desde entonces, esta asamblea conformada por un cúmulo de organizaciones sociales y comunitarias de la provincia, trabaja por defender el ambiente libre de minería contaminante por medio de la movilización social, la pedagogía ciudadana entre otras (4). En Colombia existen muchos más colectivos y asambleas populares y sociales que de a poco se han ido organizando para debatir y hacer propuestas sobre el impacto y los costos de la mega minería. El ejemplo más reciente, fue el Primer Encuentro Nacional Territorio, productividad, ambiente y minería, La María- Piendamó, Cauca- Colombia, 27 de abril de 2012, convocado principalmente por el Consejo Regional Indígena del Cauca- CRIC. Este primer encuentro denotó la necesidad apremiante de las comunidades que se resisten a salir de sus territorios o permitir el uso indiscriminado de los recursos, dando paso a la contaminación del ambiente, la desigualdad económica, la ausencia de transparencia institucional entre otras.Conclusiones del Primer Encuentro Nacional Territorio, productividad, ambiente y mineríaa) que la política se orienta en beneficio de favorecer la privatización de empresas públicas mineras y el manejo exclusivo de las transnacionales; siendo declarada como actividad de utilidad pública e interés social lo que habilita un proceso de reforma y transformación del Estado por medio de una locomotora legislativa que facilita la expropiación de tierra e irrespeta el derecho fundamental a la consulta previa. Informando que se han protocolizado 156 procesos de consulta previa en el 2012 referidos a proyectos de inversión donde ha sido característico que su realización se hace desconociendo la participación de las organizaciones regionales.b) que hay especulación por parte de las compañías en las fases previas a la explotación, y que los recursos que pagan las compañías por concepto de regalías e impuestos sobre la renta, les son devueltos luego en exenciones fiscales y subsidios; facilitados por la corrupción de las instituciones locales, departamentales y nacionales.c) que se han ejecutado desalojos de comunidades, desplazamientos masivos y pérdida de territorios ancestralesd) que hay contaminación del aire por las explosiones para extraer el carbón, derrame de sustancias tóxicas, muerte de peces, contaminación de fuentes hídricas, deforestación y erosión de suelos, destrucción de las redes de acueductos comunitarios Se presentan fenómenos de transformación de las culturas, ruptura del tejido social, pérdida de usos y costumbres, afectación a las economías locales (trueques), invasión de tecnología que afecta a la población joven de los resguardos, llegada de programas asistenciales gubernamentales que afectan la cohesión de los pueblos indígenas, pérdida de medicina tradicional y de sabios indígenas cuidadores del territorio.f) que la amenaza minera se extiende en la mayoría de los territorios, utilizando nueva tecnología para adelantar las actividades de prospección y exploración en especial sobre territorios ocupados ancestralmente por comunidades indígenas, campesinas y afro descendientes; lo cual produce alteración de usos del suelo y de la productividad de la tierra, y que las empresas transnacionales, por medio de actos de corrupción estatal diseñan planes de ordenamiento territorial de los municipios. También que las zonas entregadas en concesión en territorios indígenas coinciden con sitios sagrados o con sus áreas circundantes. Se denuncia que muchos proyectos de infraestructura vial están al servicio de megaproyectos mineros.g) Que los conflictos mineros acrecientan la presencia de actores armados, fuerza pública, guerrilla, paramilitares, en particular la creación de unidades militares minero-energéticas especializadas en la custodia y protección de los proyectos y batallones de alta montaña en territorios indígenas; se intensifican los enfrentamientos entre grupos armados que afectan a la población civil con situaciones generadas por explosivos abandonados o minas anti persona.Fuente: apartes de las conclusiones Generales del Encuentro Nacional de Territorio, Productividad, Ambiente y Minería La María, Piendamó, Cauca, abril 27 de 20125. Desarrollo y sustentabilidadLa creciente complejidad de los distintos sistemas sociales y políticos contemporáneos, nos hacen reflexionar nuevamente sobre aquello que parecía claro y resuelto hace 20 años. Estuvimos en Rio 1992, debatimos ideas rectoras e imaginamos las recetas para conseguir el desarrollo sostenible. En el papel todo parecía quedar claro y de fácil consecución (4). 20 años después nos encontramos de nuevo en Rio (junio, 2012), con algunos deberes inconclusos y en muchos casos con problemas de desarrollo y sostenibilidad agravados. Entonces, la primera pregunta que se formula, es ¿qué paso en estos 20 años para no haber logrado los objetivos planteados en 1992? En estos 20 años, se ratifica que la especie humana no es una especie que actúa exclusivamente por intereses económicos; comprobamos lo anterior, porque algunas sociedades humanas conservan su componente espiritual y luchan por ello, lo cual las hace trascender para valorar otra realidad, que se desconoce al momento de trazar políticas de alcance social y político para el desarrollo sostenible. Todos los pueblos quieren alcanzar este desarrollo sostenible: el problema que sugiere esta premisa, es qué significa estos dos conceptos para ellos y como se realiza una construcción colectiva para lograrlo. Un ejemplo claro de lo anterior, es la explotación minera en América Latina. Sin entender esta relación, jamás podrá existir un proyecto minero sin conflictos sociales o políticos. O se realizará dicho proyecto sin que impliquen violaciones a derechos, si esa comunidad tiene antecedentes mineros, es decir, si históricamente tiene vínculos de ese tipo con su tierra. Al respecto, es importante trabajar y demostrar que los recursos son necesarios para el crecimiento económico de las naciones, pero que deben existir consensos sociales para el uso de estos y su relación con quienes auténticamente han cuidado de ellos. Presentamos algunas ideas que sirven para abrir un debate, que seguramente se dará y seguirá después de Rio +20. Primer asunto relevante: Confianza en el Estado. Una de las mayores razones por las cuales las comunidades locales se resisten a convivir con proyectos de mega minería, es por ausencia de confianza que existe hacia las instituciones del Estado; este es el caso de países como Bolivia o Argentina. Los indicadores de Percepción de Corrupción (Transparency International, 2011) señalan que la mayoría de países de América Latina registran una percepción media-alta de corrupción en sus instituciones (5). El país en donde los ciudadanos confían y tienen la mejor percepción es Nueva Zelanda que ocupa el primer lugar; el último lugar a nivel mundial lo tiene Somalia. Gráfico 8. Fuente: Corruption Perceptions, Index 2011. Disponible en:http://cpi.transparency.org/cpi2011/results/ Existen vacios jurídicos y políticos para confiar en que las instituciones pueden controlar acciones de la mega minería y obrar con transparencia. Los Estados están en la obligación, dado sus mandatos constitucionales, de generar confianza a las comunidades y bienestar a las naciones. Esta situación se complejiza aún más, cuando en países como Colombia o Perú, sus gobiernos son llamados de manera informal por las empresas trasnacionales y el sector privado como 'gobiernos pro-mineros'. El discurso del presidente Santos en el primer congreso de Minería a Gran escala, que se realizó en Cartagena en febrero de 2012, así lo refleja: " Aquí hay todavía espacio –de sobra– para recibir a las grandes casas mineras –y a las junior, por supuesto– que estén dispuestas a trabajar en armonía con el desarrollo de Colombia". Segundo asunto relevante: la Generación y distribución de la riqueza, no de la pobreza. Los informes de la Consejo Económico para América Latina- CEPAL- 2011, señalan que los índices de pobreza en América Latina han disminuido, como lo presenta el gráfico 9. Sin embargo estos porcentajes no logran estar por debajo del diez por mil (10%), cifra que no es comparable con las obtenidas por economías de los países del báltico, la cual está por debajo del 5%. Con lo anterior, se mantiene premisa, que América Latina es el segundo subcontinente más pobre del planeta, con mayor diversidad y más conflictos sociales. Gráfico 9. Fuente: CEPAL, 2010. Recurso Disponible en:http://www.oecd.org/dataoecd/37/60/48157176.pdf La actividad minera requiere de grandes inversiones; a pesar de la generación de empleo informal (mano de obra no calificada en su mayoría) y la actividad económica que esta deja, es cortoplacista: se produce riqueza en forma rápida y fugaz; sin embargo, se plantea como problema, de un lado el retiro o la falta de garantías para la reinversión en países en dónde se han generado los beneficios para las empresas mineras; y de otro, la percepción social que el boom de la minería no va más allá del mediano plazo, acentúa la inestabilidad económica de las comunidades en dónde se desarrolla la industria extractiva a gran escala. Los complejos contenidos sobre la maximización de las rentas y la consolidación de las inversiones, es un asunto de la política macroeconómica de las naciones, que excede a la minería y en algunos casos no se plantea. Sería un error tener la visión que la minería es tan solo un negocio ilimitado en el tiempo, pues se estaría desconociendo la matriz productiva de muchos pueblos tradicionalmente agrícolas, ganaderos o industriales. Si el asunto de la mega minería no se percibe como una política de estado, la confianza y la estabilidad nunca hará parte de las bondades de las naciones. Tercer asunto: Viabilidad Social y Ambiental. En la división de Desarrollo Sustentable, del Departamento de Asuntos Económicos y Sociales de Naciones Unidas, 6 países -Colombia, Argentina, Chile, Guatemala, México y Costa Rica- presentan informe 'especifico' sobre las regulaciones jurídicas y socio ambientales de la minería. Mientras que países con altos índices de inversión minera como Perú, El Salvador, Bolivia y Brasil la actividad minera 'hace parte de los informes anuales' por país que archiva la organización (6). Podría inducir lo anterior, que la necesidad de socializar a nivel regional la legislación y regulación para esta industria es apenas incipiente y que se hace necesario compartir estudios y experiencias para trabajar de manera conjunta sobre este asunto específico. Es posible afirmar que los proyectos mineros en América Latina carecen de viabilidad social y ambiental; viabilidad que no se consigue por diversos intereses de tipo económico, sociales, políticos, pero principalmente porque la minería, altera las relaciones del hombre con la tierra. Recordemos que las poblaciones rurales la valoran mucho más allá de lo meramente económico. Al respeto surge uno de los debates cruciales y controvertidos como el uso de la energía o el uso del Agua. El agua es tal vez es la cuestión más conflictiva cuando se proponen o imponen proyectos mineros de gran envergadura. Creemos que es imposible que cuando se demanda un recurso vital como este y se pone el peligro el derecho adquirido, no surjan (7) conflictos. Entonces se replantean cuestiones como, el valor en el mercado del agua, sus usos, su propiedad, etc. Pero volvemos al punto de partida, la relación del hombre con su tierra, en gran parte depende del agua, de su calidad, cantidad y de su disponibilidad en el tiempo. En este sentido, nadie está dispuesto a poner en juego esta relación sin tener claro y garantizado que sus derechos, no serán vulnerados. Los estados que pretendan tener proyectos mineros en sus territorios, deben sin lugar a duda tener claridad social, política y jurídica sobre este balance: abastecimiento hídrico pertinente y garantía al derecho fundamental a este. ¿Qué esperamos de Rio +20? Una reconocida periodista Colombiana Marta Ruiz- afirmó en una columna de opinión lo siguiente: "Como si fuera poco, la "buena" noticia que trajo Santos de Asia es que los chinos están interesados en nuestro oro. Y uno no sabe si reír, llorar o salir a incendiar las dragas (…) Anuncio y premonición de los conflictos que va a desatar la minería" (8). Y no es insolencia. Como sugerimos en este escrito, es indudable que las sociedades contemporáneas necesitan los recursos naturales para mantener la forma de vida que desde la modernidad se ha encausado; sin embargo se hace urgente, necesario y justificable, en el marco de la exigibilidad de los derechos universales de las comunidades que han sostenido relaciones naturales, espirituales y económicas con la tierra llena de recursos, que el uso sea racional y sostenible. Son muchas las organizaciones sociales que trabajan por la defensa a la vida y el medio ambiente según lo reporta el Observatorio de Conflictos Mineros de América Latina; en ese sentido es posible hacer algunas sugerencias, de cara a la reunión de Rio+20 durante el mes de junio de 2012 y con el ánimo de visibilizar el debate, eliminar las tasas de violaciones a derechos fundamentales por causas relacionadas a la mega minería y de cara a disminuir las tasas de pobreza e inequidad que manifiestan las comunidades afectadas. Una cumbre que reafirme y reconozca los derechos individuales y los derechos de las naciones a hacer uso de sus recursos, buscando un desarrollo sostenible en el marco de las realidades culturales, sociales, políticas y económicas propias. Un espacio en donde se reflexione y se tomen decisiones sobre la promoción de políticas que prioricen la solución de problemas locales o micro regionales, en donde cada comunidad local pueda decidir qué tipo de desarrollo sostenible quiere y le conviene, en el marco del respeto a la soberanía y los derechos fundamentales. Un lugar de apoyo y financiamiento a los acuerdos transversales entre países en vía de desarrollo. Especialmente en lo concerniente a políticas públicas que atiendan problemáticas comunes como debería ser, el impacto de proyectos de mega minería en territorios étnicos y campesinos. Un espacio que abogue por la consulta previa, libre y transparente a los pueblos que tradicionalmente han cultivado y cosechado en estas tierras. Otra cumbre para la tierra y para quienes habitan en ella.Referencias: Conclusiones al Primer Encuentro Nacional Territorio, Producción, Ambiente y Minería, La María, Cauca, Colombia, 27 de abril de 2012. Disponible En: http://www.indepaz.org.co/?p=2028Corruption Perceptions, Index 2011. Disponible En: http://cpi.transparency.org/cpi2011/results/Cumbre para la tierra, programa 21, 14 de junio de 1992, Rio de Janeiro. Disponible En: http://www.unep.org/Documents.Multilingual/Default.asp?DocumentID=52&ArticleID=49&l=en Dayton-Johnson, Jeff (2011). Perspectivas económicas para América Latina, 2011. Banco Central de la Reserva del Perú, Organización para la Cooperación y el Desarrollo Económicos –OCDE-, México D.C. Declaración de Rió sobre el Medio Ambiente y el Desarrollo, del 14 de junio de 1992. Disponible En:http://www.pnuma.org/docamb/dr1992.php Escobar, Arturo (1996). La invención de tercer mundo. Construcción y deconstrucción del desarrollo, Ed. Norma, Bogotá González Posso, Camilo (2011). Renta minera, petróleo y comunidades. Ed. Indepaz, Bogotá Memorias al I Congreso de Minería a Gran escala, Cartagena de Indias, febrero de 2012. Disponible En: http://www.mineriaagranescala.org/smge/ Mingin Intelligence Series (2012). Business News Americas, En: http://www.bnamericas.com/news/mining Observatorio Latinoamericana de Conflictos Ambientales (2012). Observatorio de conflictos mineros de América Latina, En http://www.olca.cl/oca/index.htm Division for Sustainable Development, UN department of economic and social affair, En:http://www.un.org/esa/dsd/dsd_aofw_ni/ni_natiinfo_costarica.shtml (1) Todos los casos que registra el Observatorio sobre desplazamiento forzado están en Colombia.(2) Las organizaciones políticas, sociales, ambientales y comunitarias que hacen parte de este Observatorio, no representan la totalidad de acciones colectivas que existen y que realizan un seguimiento y denuncia a las actividades mineras en América Latina.(3) Censat Agua Viva es la única organización colombiana que hace parte del Observatorio; sin embargo existen otras muchas organizaciones que participan en este proceso, las cuales se hicieron presentes en el Primer Encuentro Nacional Territorio, productividad, ambiente y minería, La María- Piendamó, Cauca- Colombia, 27 de abril de 2012(4) Más información disponible en: http://quienessomosasamblea.blogspot.com/ (5) La Declaración de Rio/92 fue una declaración de principios a los cuales los estados firmantes se comprometían a mejorar las condiciones de vida de todos los habitantes del planeta. Por ejemplo el principio 11 "Los Estados deberán promulgar leyes eficaces sobre el medio ambiente. Las normas, los objetivos de ordenación y las prioridades ambientales deberían reflejar el contexto ambiental y de desarrollo al que se aplican. Las normas aplicadas por algunos países pueden resultar inadecuadas y representar un costo social y económico injustificado para otros países, en particular los países en desarrollo". Según varios estudios, se ha demostrado que los países latinoamericanos con gran cantidad de recuros naturales como Colombia o Perú, la legislación es inoportuna.(6) Percepciones de Corrupción de 182 países de todos los continentes, Index 2011 de Transparencia Internacional(7) Los reportes nacionales que cada país entrega a división de Desarrollo Sustentable, del departamento de asuntos económicos y sociales de Naciones Unidas (búsqueda en Internet, junio 2012) solo los 6 países mencionados presentan un informe. No son informes estandarizados pero tienen características comunes como información sobre las políticas y regulaciones internas, situación actual de la minería en cada país, mecanismos de seguimiento y monitoreo, buenas prácticas en el sector. Fuente: http://www.un.org/esa/dsd/dsd_aofw_ni/ni_natiinfo_costarica.shtml(8) Romeo el Agresivo, En: Revista Arcadia, 25 de mayo de 2012. *Tathiana Montaña es Colombiana, asesora académica del Instituto de Estudios para el Desarrollo y la paz (Colombia); profesora universitaria licenciada en Relaciones Internacionales, con estudios de perfeccionamiento en Desarrollo; Magister en Ciencia Política. Actualmente es candidata a Doctor en Política y Gobierno, mención en Relaciones Internacionales. Ha publicado libros y artículos en medios nacionales y latinoamericanos sobre asuntos de paz y postconflicto. José Carlos Pozzoli es Argentino, politólogo, especialista en Políticas Públicas; ha sido consultor para el BID y trabajó como asesor de la Comisión de Ambiente de la Honorable Cámara de Diputados de Mendoza; Coordinador General Tercera Conferencia ICID +19 Clima, Sostenibilidad y Desarrollo en Regiones Semi Aridas; Asesor de Gabinete, Secretaría de Ambiente y Desarrollo Sustentable de la Provincia de Mendoza.